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Abstract 
 
The dynamics of T cell responses have been extensively studied during 
single virus infection of naïve mice. During a viral infection, viral antigen is 
presented in the context of MHC class I molecules on the surface of infected 
cells. Activated CD8 T cells that recognized viral antigens mediate clearance of 
virus through lysis of these infected cells. We hypothesize that the balance 
between the replicating speed of the virus and the efficiency at which the T cell 
response clears the virus is key in determining the disease outcome of the host. 
Lower T cell efficiency and delayed viral clearance can lead to extensive T cell-
mediated immunopathology and death in some circumstances. To examine how 
the efficiency of the immune response would impact immunopathology we 
studied several viral infection models where T cell responses were predicted to 
be less than optimal: 1. a model of co-infection with two viruses that contain a 
crossreactive epitope, 2. a viral infection model where a high dose infection is 
known to induce clonal exhaustion of the CD8 T cell response, 3. a neonatal 
virus infection model where the immune system is immature and 4. A model of 
beneficial heterologous immunity and T cell crossreactivity where mice are 
immunized as neonates when the T cell pool is still developing.   
Model 1. Simultaneous co-infections are common and can occur from 
mosquito bites, contaminated needle sticks, combination vaccines and the 
simultaneous administration of multiple vaccines. Using two distantly related 
arenaviruses, lymphocytic choriomeningitis virus (LCMV) and Pichinde virus 
vii
(PICV), we questioned if immunological T cell memory and subsequent 
protection would be altered following a simultaneous co-infection, where two 
immune responses are generated within the same host at the same time. Co-
infection with these two viruses, which require CD8 T cell responses to clear, 
resulted in decreased immune protection and enhanced immunopathology after 
challenge with either virus. After primary co-infection, each virus-specific immune 
response impacted the other as they competed within the same host and 
resulted in several significant differences in the CD8 T cell responses compared 
to mice infected with a single virus. Co-infected mice had a dramatic decrease in 
the overall size of the LCMV-specific CD8 T cell response and variability in which 
virus-specific response dominated, along with skewing in the immunodominance 
hierarchies from the normal responses found in single virus infected mice. The 
reduction in the number of LCMV-specific CD8 memory T cells, specifically cells 
with an effector memory-like phenotype, was associated with higher viral loads 
and increased liver pathology in co-infected mice upon LCMV challenge. The 
variability in the immunodominance hierarchies of co-infected mice resulted in an 
enhanced cross-reactive response in some mice that mediated enhanced 
immune-mediated fat pad pathology during PICV challenge. In both viral 
challenge models, an ineffective memory T cell response in co-infected mice 
facilitated increased viral replication, possibly leading to enhanced and prolonged 
accumulation of secondary effector T cells in the tissues, thereby leading to 
increased immune pathology. Thus, the magnitude and character of memory 
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CD8 T cell responses in simultaneous co-infections differed substantially from 
those induced by single immunization. This has implications for the design of 
combination vaccines and scheduling of simultaneous immunizations.  
Model 2. The balance between protective immunity and immunopathology 
often determines the fate of the virus-infected host. Several human viruses have 
been shown to induce a wide range of severity of disease. Patients with hepatitis 
B virus (HBV), for example, show disease progression ranging from acute 
resolving infection to a persistent infection and fulminant hepatitis. Certain rapidly 
replicating viruses have the ability to clonally exhaust the T cell response, such 
as HBV and hepatitis C virus (HCV) in humans and the clone 13 strain of LCMV 
in mice. How rapidly virus is cleared is a function of initial viral load, viral 
replication rate, and efficiency of antigen-specific T cells. By infecting mice with 
three different inocula of LCMV clone 13, we questioned how the race between 
virus replication and T cell responses could result in different disease outcomes. 
A low dose of LCMV generated efficient CD8 T effector cells, which cleared the 
virus with minimal lung and liver pathology. A high dose of LCMV resulted in 
clonal exhaustion of T cell responses, viral persistence and little 
immunopathology. An intermediate dose only partially exhausted the CD8 T cell 
responses and was associated with significant mortality, and the surviving mice 
developed viral persistence and massive immunopathology, including necrosis of 
the lungs and liver. This was a T cell-mediated disease as T cell-deficient mice 
had no pathology and became persistently infected like mice infected with a high 
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dose of LCMV clone 13. This suggests that for non-cytopathic viruses like LCMV, 
HCV and HBV, clonal exhaustion may be a protective mechanism preventing 
severe immunopathology and death. 
Model 3. Newborns are more susceptible to infections due to their lack of 
immunological memory and under-developed immune systems. Passive 
maternal immunity helps protect neonates until their immune systems have 
matured. We questioned if a noncytolytic virus that produces strong T cell 
responses in adult mice would also induce an equally effective response in 
neonatal mice. Neonates were infected with very low doses of LCMV Armstrong 
and surprisingly the majority succumbed to infection between days 7-11, which is 
the peak of the T cell response in adult mice infected with LCMV. Death was 
caused by T cell-dependent pathology and not viral load as 100% of T cell 
deficient neonates survived with minimal lung and liver pathology. This is similar 
to the adult model of medium dose LCMV clone 13, but T cell responses in 
neonates were not partially clonal exhausted. Furthermore, surviving neonates 
were not persistently infected, clearing virus by day 14 post infection. In adult 
mice direct intracranial infection leads to LCMV replication and CD8 T cell 
infiltration in the central nervous system (CNS), causing CD8 T cell-mediated 
death. However, this does not occur in adults during LCMV intraperitoneal (ip) 
infections. We questioned if unlike adults LCMV could be gaining access to the 
CNS in neonates following ip infection. Replicating LCMV was found in the brain 
of neonates after day 5 post infection along with virus-specific CD8 T cells 
xproducing IFNγ at day 9 post infection. Neonates lacking perforin had complete 
survival when followed until day 14 post infection, suggesting perforin-mediated T 
cell-dependent immunopathology within the CNS of neonates was causing death 
after LCMV infection. Passive immunity from LCMV-immune mothers also 
protected 100% of pups from death by helping control viral load early in infection. 
We believe that the maternal antibody compensates for the immature innate 
immune response of neonates and controls viral replication early so the neonatal 
T cell response induced less immunopathology. Neonates are commonly thought 
to have less functional immune systems, but these results show that neonates 
are capable of producing strong T cell responses that contribute to increased 
mortality. 
Model 4. Due to their enhanced susceptibility to infection neonatal and 
infant humans receive multiple vaccines. Several non-specific effects from 
immunizations have been observed, for example, measles or Bacillus Calmette-
Guerin (BCG) vaccines have been linked to decreased death of children from 
infections other than measles virus or tuberculosis. These studies mirror the 
concepts of beneficial heterologous immunity, where previous immunization with 
an unrelated pathogen can result in faster viral clearance. LCMV-immune mice 
challenged with vaccinia virus (VV) have lower viral loads then naïve mice and 
survive lethal infections, but some mice do develop fat pad immunopathology in 
the form of panniculitis or acute fatty necrosis (AFN). We questioned how 
immunological T cell memory formed during the immature neonatal period would 
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compare to memory generated in fully mature adults during a heterologous viral 
challenge. Mice immunized as neonates had comparable reduction in VV load 
and induction of AFN, indicating that heterologous immunity is established during 
viral infections early in life. Interestingly, the LCMV-specific memory populations 
that expanded in mice immunized as neonates differed from that of mice 
immunized as adults. In adult mice 50% of the mice have an expansion of LCMV-
NP205-specific CD8 T cells while the majority of neonates expanded the LCMV-
GP34-specific CD8 T cell pool. This alteration in dominant crossreactivities may 
be due to the limited T cell receptor repertoire of neonatal mice. In naïve 
neonatal mice we found altered Vβ repertoires within the whole CD8 T cell pool. 
Furthermore, there was altered Vβ usage within virus-specific responses 
compared to adult mice and a wide degree of variability between individual 
neonates, suggesting enhanced private specificity of the TCR repertoire. 
Beneficial heterologous immunity is maintained in neonates, but there was 
altered usage of crossreactive responses.  
 As neonatal mice were found to be so sensitive to LCMV infection we 
questioned if neonates could control another arenavirus that did not replicate as 
efficiently in mice, PICV. Unlike LCMV infection, neonatal mice survived infection 
with PICV even with adult-like doses. However, viral clearance was protracted in 
neonates compared to adults, but was cleared from fat pad and kidney by day 11 
post infection. The peak of the CD8 T cell response was similarly delayed. PICV-
infected neonates showed dose-dependent PICV-specific CD8 T cell responses, 
xii
which were similar to adult responses by frequency, but not total number. As with 
LCMV infection there were changes in immunodominance hierarchies in 
neonates. Examination of the immunodominance hierarchies of PICV-infected 
neonates showed that there were adult-like responses to the dominant NP38-
specific response, but a loss of the NP122-specific response. Six weeks post 
neonatal infection mice were challenged with LCMV Armstrong and there was a 
strong skewing of the PICV immunodominance hierarchy to the crossreactive 
NP205-specific response. These data further support the hypothesis that 
heterologous immunity and crossreactivity develop following neonatal 
immunization, much as occurs in adults, although TCR repertoire and 
crossreactive patterns may differ.  
 Changing the balance between T cell efficiency and viral load was found 
to altered the severity of the developing immunopathology after viral infection.  
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1Chapter 1: Introduction 
 
 The dynamics of the CD8 T cell response during viral infection has been 
extensively studied during single virus infections in mouse models. Specifically, 
the lymphocytic choriomeningitis virus (LCMV) model of mouse infection has 
been a cornerstone in our current understanding of the activation, effector 
function and memory formation of CD8 T cells. During a viral infection the 
immune system generates CD8 T cell responses specific to viral antigens. T cells 
require specific signals to become properly activated and undergo clonal 
expansion and differentiate into effector cells (Kaech and Cui, 2012; Russ et al., 
2012). Activated CD8 T cells recognize peptide presented by MHC class I 
complexes on infected cells and lyse these cells to clear virus, after which virus-
specific T cells undergo contraction and form a heterogeneous memory 
population that protects individuals against a reinfection (Kaech and Cui, 2012; 
Russ et al., 2012). Under normal circumstances, reinfection results in the 
reactivation of memory CD8 T cells. Memory cells are at a higher frequency and 
require only reexposure to antigen to become reactivated causing faster viral 
clearance and less pathology compared to a primary infection (Arens and 
Schoenberger, 2010; Pihlgren et al., 1996). Understanding how to generate a 
protective memory response that rapidly clears virus without causing pathology is 
important, specifically in terms of vaccine development. 
2 Memory CD8 T cells can also recognize and be reactivated against 
antigens from unrelated pathogens and significantly alter disease outcome. This 
is known as heterologous immunity and may more closely mimic what occurs in 
humans as they are sequentially infected with unrelated pathogens. Compared to 
single virus infections, heterologous infections change the dynamics of viral load 
and the CD8 T cell responses depending on the sequence of infections and 
characteristics of the crossreactive responses involved. Heterologous immunity 
can be beneficial or detrimental depending on the circumstances. For example, 
LCMV-immune mice infected with VV clear virus faster than naïve mice, but not 
as fast as VV-immune mice (Chen et al., 2003; Cornberg et al., 2010; 2007; Selin 
et al., 1998). In this circumstance even though virus is cleared faster some mice 
developed immunopathology in the form of acute fatty necrosis (AFN) (Nie et al., 
2010; Selin et al., 1998; Yang et al., 1985). However, these mice are protected 
from lethal vaccinia virus (VV) infection (Chen et al., 2001). This is beneficial 
heterologous immunity. However, influenza A virus (IAV)-immune mice given 
LCMV clear virus more slowly than naïve mice and develop severe lung 
pathology (Chen et al., 2003; Wlodarczyk et al., 2013). The severity of lung 
pathology directly correlates with the size of the memory crossreactive CD8 T 
cell responses. Ablation of these crossreactive memory responses, by use of 
mutant viruses lacking these epitopes or peptide tolerization, leads to reduced 
pathology (Wlodarczyk et al., 2013). This is an example of detrimental 
heterologous immunity. 
3 The goal of this thesis is to build on these findings and further examine 
how the context of viral infection, such as co-infection, antigen load or the 
maturity of the immune system could effect the dynamics of the CD8 T cell 
response, viral clearance and the induction of immunopathology. These are all 
common major variables that may play a role in the outcome to any human viral 
infection. It is important that we understand how these variables may modify 
outcome in order to appropriately design vaccines or therapies that prevent viral 
immunopathology. These studies will focus on the well-developed LCMV 
infection model in mice, along with virus infections such as Pichinde virus (PICV) 
and VV, which have been well defined in single virus and heterologous virus 
models.  
 The subsequent introduction is divided into separate sections that give 
more detail on topics directly related to this thesis.  
 
Antigen processing and presentation is required for CD8 T cell 
priming 
 
 CD8 T cells sample their environment by interacting with peptides loaded 
in MHC class I molecules on the surfaces of cells. Under homeostatic situations 
the normal turnover of proteins results in degradation through the proteasome 
and trimming by peptidases (Rock et al., 1994b). The proteasome is vital for 
peptide presentation as blocking the major peptidase subunits of the proteasome 
with inhibitors blocked expression of MHC-peptide complexes on the surface of 
4cells (Rock et al., 1994b). Degraded peptides are shuttled from the cytoplasm 
into the endoplasmic reticulum (ER) by transporter associated with antigen 
processing (TAP) 1 and 2 where they undergo further trimming by 
aminopeptidases to 8-10 amino acids in length and are loaded into MHC class I 
molecules and transported to the surface (Neefjes and Sadaka, 2012). During 
infection, IFNγ signaling induces the immunoproteasome, which leads to 
increased presentation of viral antigens on the surface of cells (Groettrup et al., 
1996; Hisamatsu et al., 1996; Nandi et al., 1996).  
Antigen can be loaded into MHC class I molecules through direct 
presentation, which occurs in all cells when peptides are transported into the ER 
and loaded into MHC molecules. Dendritic cells (DC) can also present antigen 
through cross presentation or cross dressing (Joffre et al., 2012; Wakim and 
Bevan, 2011). During cross presentation peptides from necrotic cells are taken 
up by endocytosis, pinocytosis or phagocytosis into the cytoplasm (Rock and 
Shen, 2005). Peptides can then enter the direct presentation pathway by 
transport into the ER or be degraded by enodosomal proteases, such as 
cathepsins, and loaded in the MHC class I molecules in the endosome (Rock and 
Shen, 2005). Cross presentation has been found to occur only in CD8+ DC (Jung 
et al., 2002). DC can also present antigen by cross dressing through the transfer 
of membrane between cells, or trogocytosis (Wakim and Bevan, 2011). Peptide 
pulsed DC were found to share or pass on peptide-MHC class I complexes to a 
5population of unpulsed DC, which were able to activate CD8 T cells in culture 
(Wakim and Bevan, 2011).  
 
CD8 T cell activation  
  
 Naïve CD8 T cells require three signals to become properly activated. 
Signal 1 is the interaction with cognate antigen in the context of MHC class I 
molecules on the surface of mature antigen presenting cells (APC). APC that 
encounter antigen through uptake of foreign antigen or infection must undergo 
maturation and migration to the draining lymph node to interact with naïve CD8 T 
cells. Maturation of APC occurs through innate receptor signaling, such as toll-
like receptors (TLR) or intracellular receptors, such as RIGI or MDA5 (Russ et al., 
2012). Upon activation, APC upregulate MHC molecules and costimulatory 
molecules, such as CD80 and CD86 (Acuto and Michel, 2003). Interaction of the 
co-receptor, CD8, on the surface of the T cell with the MHC class I molecule on 
the APC stabilizes this interaction and allows for proper signaling (Laugel et al., 
2011). CD8 T cells also require costimulation, or signal 2, from the APC to 
become properly activated. CD80 and CD86 interact with CD28 on the surface of 
the CD8 T cells and induce signaling cascades that synergize with T cell receptor 
(TCR) signaling and lead to calcium flux (Acuto and Michel, 2003; Belz et al., 
2007). Most notably, CD28 signaling in T cells causes activation of the 
transcription factor, nuclear factor kappa B (NFkB), and induction of IL-2 (Acuto 
and Michel, 2003; Narayan et al., 2006; Qiao et al., 2008). Proinflammatory 
6cytokine signaling is the third signal required for proper CD8 T cell activation 
(Curtsinger and Mescher, 2010). Numerous papers have been published on type 
I IFN and IL-12 signaling providing the 3rd signal for CD8 T cells during activation 
(Curtsinger and Mescher, 2010; Curtsinger et al., 2005; Keppler and Aichele, 
2011; Keppler et al., 2012; Pham et al., 2011; Xiao et al., 2009). For instance, 
type I IFN receptor deficient CD8 T cells have decreased survival and limited 
effector functions after LCMV infection (Aichele et al., 2006; Kolumam et al., 
2005). CD8 T cell responses to other intracellular pathogens, such as Listeria, 
require both of these proinflammatory cytokines, IL-12 and type I IFN, for their 
3rd signal in activation (Xiao et al., 2009). It is the integration of signals 1, 2 and 
3 that drives the differentiation of a naïve cell into an effector cell (Kaech and Cui, 
2012; Russ et al., 2012).       
 
Functional phenotypes of activated CD8 T cells 
 
 After receiving the three signals required for activation CD8 T cells 
undergo rapid division, which is correlated with differentiation and the acquisition 
of effector functions (Jenkins et al., 2008). Effector CD8 T cells produce 
proinflammatory cytokines, such as IFNγ and TNFα (La Gruta et al., 2004), and 
can induce apoptosis of infected cells through release of perforin (Kägi et al., 
1994) and granzymes (Jenkins et al., 2007; Moffat et al., 2009; Peixoto et al., 
2007) and Fas-FasL interactions (Kägi et al., 1994; Suda et al., 1995). The 
7effector CD8 T cell population is heterogeneous forming a continuum between 
terminally differentiated effectors, that make up the majority of the population and 
die during contraction, and a smaller pool of memory precursors that will survive 
into memory (Figure 1.1) (Kaech and Cui, 2012). Several studies have 
characterized the differences between a cell with high potential to become a 
memory cell versus one that has a greater probability of dying during contraction 
(Joshi et al., 2007; Kaech et al., 2003; Sarkar et al., 2008; Schluns et al., 2000). 
Memory-precursor effector cells (MPEC) have high expression of the IL-7 
receptor (IL-7R), which provides survival signals and low expression of killer cell 
lectin-like receptor G1 (KLRG1), a marker of terminal differentiation (Joshi et al., 
2007; Kaech et al., 2003; Sarkar et al., 2008; Schluns et al., 2000). MPEC also 
have increased proliferative potential in response to secondary antigen exposure, 
and have the ability to produce IL-2 and self-renew (Kaech et al., 2003). These 
characteristics allow for MPEC to be reactivated upon reinfection and produce a 
secondary round of effector cells to quickly clear infection. IL-7R high cells also 
have a greater potential to produce central memory cells (Tcm), which will be 
discussed below (Kaech and Cui, 2012). Terminally differentiated effectors, or 
short-lived effector cells (SLEC), express low levels of the IL-7R and high levels 
of KLRG1 (Hand et al., 2007). These cells have been shown to have decreased 
longevity (Kaech et al., 2003). After a simultaneous transfer of equal numbers of 
IL7R high or low CD8 T cells from mice at day 15 of LCMV infection into the 
same host reveals that IL7R low cells are not maintained over time  
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Figure 1.1
Figure 1.1. Effector CD8 T cell differentiation forms a continuum. A.
Naïve CD8 T cells respond to the integration of TCR stimulation, costimula-­
tion and cytokine signaling and differentiate to form a heterogeneous effector
CD8 T cell pool. Cells range from less differentiated, with increased memory
cell potential, longevity, self-­renewal and proliferation potential, to terminally
differentiated cells that have a reduction in these properties. B. Less differen-­
tiated cells have increased expression of IL7R and CD62L, with decreased
expression of KLRG1 and CXCR3, these cells are known as memory-­
precursor effector cells (MPEC). As cells differentiate these markers change
and terminally differentiated cells have high expression of KLRG1 and
CXCR3 with low expression of IL7R and CD62L and are called short-­lived
effector cells (SLEC). C. Differentiation is also linked with graded expression
of transcription factor pairs, such as Eomes and Tbet and BCL-­6 and
BLIMP1. Less differentiated cells have high expression of Eomes and BCL-­6,
while terminally differentiated cells express high Tbet and BLIMP1. Modified
from Kaech SM and W Cui. Transcriptional control of effector and memory
CD8+ T cell differentiation. Nature Reviews Immunology 12: 749-­761 (2012).
Copyright license number 3196031411599.
9(Kaech et al., 2003). More recently, the chemokine receptor CXCR3 has been 
associated with terminally differentiated effector CD8 T cells (Hu et al., 2011; 
Kohlmeier et al., 2011; Kurachi et al., 2011). CXCR3 is responsible for recruiting 
CD8 T cells to the site of infection. It is thought that CXCR3-expressing cells are 
more likely to undergo terminal differentiation due to their enhanced exposure to 
proinflammatory cytokines and antigen at the site of infection (Hu et al., 2011; 
Kohlmeier et al., 2011; Kurachi et al., 2011). 
 The fate of an individual cell is not preprogramed, but dependent on the 
integration of several factors including strength and duration of TCR stimulation, 
inflammatory cytokine environment, transcriptional regulation, metabolic switches 
and the segregation of factors during cell division (Kaech and Cui, 2012). For 
some pathogens, larger doses of antigen cause greater CD8 T cell expansion 
and lead to a bigger memory population (Badovinac et al., 2002; Kaech and 
Ahmed, 2001). One study controlled the length of time T cells could interact with 
antigen by transferring transgenic CD8 T cells and peptide-pulsed DC, which 
carried the transgene for diphtheria toxin, while at the same time infecting with 
Listeria (Prlic et al., 2006). The injection of diphtheria toxin would induce 
apoptosis of antigen presenting DC and stop T cell exposure to antigen. If DC 
were only allowed to interact with T cells for shorter periods of time mice 
developed smaller CD8 T cell populations indicating a role for length of exposure 
to antigen in influencing the size of the CD8 T cell response (Prlic et al., 2006). 
Inflammatory cytokines, such as IL-12 and type I IFN, also play a major role in 
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the differentiation of CD8 T cells during infection (Curtsinger and Mescher, 2010). 
Direct effects of type I IFN are required for CD8 T cell expansion during LCMV 
infection as IFNα receptor deficient CD8 T cells had decreased survival and 
limited effector functions (Curtsinger et al., 2005). Timing of signal 3 plays a 
major role on effector CD8 T cell proliferation and development of effector 
functions. Exposure of naive CD8 T cells to type I IFN prior to interaction with 
cognate peptide caused a transient inhibition of proliferation and 
unresponsiveness to inflammatory cytokines due to decreased IFNα receptor 
expression and upregulation of the protein known as suppressor of cytokine 
signaling (SOCS) 1 (Marshall et al., 2011); Stina Urban, unpublished data). 
SOCS1 is a cytokine-inducible protein that acts in a negative feedback loop to 
attenuate cytokine signaling (Yoshimura et al., 2007). It is the integration of 
several signals that ultimately shapes the CD8 T cell response through the 
expression of different transcription factors.  
 Multiple transcription factors are induced in response to CD8 T cell 
activation (Figure 1.1). Two T-box transcription factors, Tbet and Eomesodermin 
(Eomes) are coupled in CD8 T cell differentiation (Kaech and Cui, 2012). Tbet is 
induced by high levels of IL-12 signaling and promotes terminal differentiation 
(Joshi et al., 2007). Tbet induces the expression of IFNγ (Szabo et al., 2000) and 
granzyme B (Cruz-Guilloty et al., 2009). Eomes is induced in CD8 T cells 
subsequent to Tbet and stimulates MPEC development (Banerjee et al., 2010; 
Intlekofer et al., 2005). Eomes mediates memory formation by the upregulation of 
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CD122, which is required for IL-2 and IL-15 signaling, and memory formation and 
maintenance (Intlekofer et al., 2005). Blimp1 and Bcl-6 are two other transcription 
factors that are coupled and determinants in T cell differentiation (Kaech and Cui, 
2012). Blimp1 is induced by IL-2, IL-12 and IL-21 signaling and is a 
transcriptional repressor of Bcl-6 and IL7R (Pipkin et al., 2010). Blimp1 
expression in CD8 T cells declines with transition into the memory phase 
(Rutishauser et al., 2009), while Bcl-6 progressively accumulates in the memory 
population (Cui et al., 2011). These pairs of transcription factors are co-
expressed in activated CD8 T cells and the balance between them determines 
where an individual cell will appear in the continuum between terminally 
differentiated cells and memory precursor cells (Kaech and Cui, 2012). 
 
CD8 T cell memory: friend or foe? 
 After viral clearance, the effector T cell response contracts to form a 
memory pool. Memory cells provide an advantage to the host during secondary 
infection with the same pathogen. Compared to naïve T cells, antigen-specific 
memory cells are at a higher frequency due to the clonal expansion that 
occurred during the primary infection. Memory cells also have a lower activation 
threshold (Pihlgren et al., 1996) and do not require signal 2 or 3 to become 
reactivated (Arens and Schoenberger, 2010). Naïve cells are restricted to the 
blood and secondary lymphoid organs, while memory cells can enter peripheral 
sites allowing them to detect reinfection earlier (Arens and Schoenberger, 2010). 
12
Collectively these attributes make memory cells superior to naïve cells during a 
reinfection. These are also important features for heterologous immunity, for viral 
clearance, but also make them a lethal weapon when not used appropriately. 
Similar to the effector phase, the memory pool is also a heterogeneous 
population. Two major subsets that make up the memory pool are central and 
effector memory cells (Sallusto et al., 2004).  
 Effector memory (Tem) cells are characterized by their low levels of CD62L 
and CCR7, receptors that allow trafficking through high endothelial venules into 
secondary lymphoid organs (Kohlmeier et al., 2011; Sallusto et al., 2004; Wakim 
et al., 2008). Tem cells express CCR5, which allows them to patrol the peripheral 
tissues for reinfection (Kohlmeier et al., 2011; Wakim et al., 2008). Upon 
reinfection Tem cells can rapidly exert effector functions, such as cytokine 
production and cytolytic activity, but the proliferation potential of this population is 
low, making this population unsustainable during infection (Masopust et al., 2001; 
Sallusto et al., 2004). Tissue resident Tem cells are more recently identified cells 
that are retained in the original site of infection (Gebhardt et al., 2009; Mackay et 
al., 2012). On the other hand, Tcm, which express high levels of CD62L and 
CCR7, play a supportive role during reinfection. Tcm cells reside within the 
secondary lymphoid tissues and during reinfection quickly divide to produce a 
large population of effectors cells (Masopust et al., 2001).  
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CD8 T cell immunodominance hierarchies 
 
 During a viral infection all viral peptides are processed, but only a small 
percentage are presented to T cells. Epitope-specific T cell populations can be 
arranged into a hierarchy based upon the size of each epitope-specific response, 
also known as an immunodominance hierarchy (Yewdell, 2006). The 
immunodominance of an epitope-specific population is influenced by multiple 
factors, including processing and presentation of viral antigen and the 
characteristics of the TCR repertoire. Altering antigen processing by studying 
mice that lack aminopeptidases (York et al., 2006) or components of the 
immunoproteasome (Kincaid et al., 2012) results in altered immunodominance 
hierarchies after LCMV infection. Mice lacking the endoplasmic reticulum 
aminopeptidase (ERAP) 1 develop reduced CD8 T cell responses to several 
LCMV epitopes, including NP396, GP33, NP205 and GP118 (York et al., 2006). 
Interestingly, there is an increase in the CD8 T cell response to the longer 11mer 
epitope, GP276 (York et al., 2006). This same increase in the GP276-specific 
CD8 T cell response was also found in mice that lacked the three main 
components of the immunoproteasome (Kincaid et al., 2012), indicating the 
major role that antigen processing and presentation plays in determining the 
immunodominance of an epitope. The kinetics of antigen presentation also alters 
immunodominance, as the LCMV nucleoprotein is processed and presented 
earlier during infection then the glycoprotein and results in earlier T cell 
responses to nucleoprotein derived epitopes (Probst et al., 2003). The TCR 
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repertoire (Brehm et al., 2002; Chen et al., 2001; Haeryfar et al., 2008; Kim et al., 
2002; La Gruta et al., 2006), recruitment of T cells to the site of infection (Khanna 
and Lefrançois, 2008), and affinity of the TCR to the peptide-MHC complex 
(Khanna and Lefrançois, 2008) also affect how dominant an epitope-specific T 
cell population will be. Crossreactive memory responses that mediate 
heterologous immunity have been found to skew immunodominance hierarchies 
during sequential infections (Brehm et al., 2002; Chen et al., 2001; Kim et al., 
2002). For example, infection with either LCMV or PICV alone induced a 
subdominant NP205-specific response, but a subsequent heterologous challenge 
with the other virus (either LCMV+PICV or PICV+LCMV) caused the NP205-
specific response to increase and become dominant in most mice (Brehm et al., 
2002; Chen et al., 2012). During a LCMV+PICV infection the memory LCMV-
NP205-specific CD8 T cells were at a higher precursor frequency and had a 
lower activation threshold, which allowed them to outcompete the naïve PICV-
specific CD8 T cell response after PICV challenge. 
 
T cell clonal exhaustion 
 
 T cell clonal exhaustion is the stepwise loss of effector function that occurs 
during chronic infections (Figure 1.2). In the early stages of clonal exhaustion 
cells lose cytotoxicity and the ability to proliferate and produce IL-2           
 
15
 
Figure 1.2
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Figure 1.2. T cell exhaustion is a stepwise loss of function that occurs
during persistent high viral load or loss of CD4 T cell help. Naive CD8 T
cells are activated by antigen, costimulation and inflammatory cytokines. Top.
During an acute infection CD8 T cells are fully functional, wherein they have high
proliferation potential, are cytotoxic and can produce several cytokines. Bottom.
However, during a chronic infection, where cells are exposed to persistent
antigen, there is a stepwise loss of function as cells become exhausted. Cells
first lose proliferation potential and cytotoxicity, followed by the loss of production
of IL-­2, TNF and finally IFN . Cells that have only lost part of their function are
considered partially exhausted. Exhausted cells express several markers,
including PD-­1, LAG-­3, CD244(2B4) and CD160. In additional to high viral load,
exhaustion is also induced by the loss of CD4 T cell help. Modified from Wherry
EJ. T cell Exhaustion. Nature Immunology 12: 492-­499 (2011). Copyright license
number 3196040142324.
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(Freeman et al., 2006; Wherry, 2011). As clonal exhaustion progresses cells lose 
the ability to produce TNFα then IFNγ (Freeman et al., 2006; Wherry, 2011). The 
final stage of clonal exhaustion is deletion of virus-specific cells through 
apoptosis (Freeman et al., 2006; Wherry, 2011). The extent of clonal exhaustion 
has been linked to high viral load, high epitope presentation and the lack of CD4 
help (Battegay et al., 1994; Matloubian et al., 1994). More recently clonal 
exhaustion has been correlated with NK cell killing of activated CD4 T cells 
(Waggoner et al., 2012). 
 During an acute viral infection the CD8 T cell activation phase is followed 
by a negative regulation phase where activation signals are dampened to prevent 
over activation. Cytotoxic T lymphocyte associated protein 4 (CTLA-4) is 
upregulated on the surface of the activated T cells and binds to the costimulatory 
molecules CD80 and CD86 with higher affinity then CD28 (Chambers, 2001). 
This blocks the costimulation through CD28 and dampens downstream signaling 
through blocking AKT activation, the sernine threonine kinase downstream of 
phosphatidylinositol 3 kinase (PI3K), which is activated during costimulation (Keir 
et al., 2008). Another member of the CD28 family, programmed death (PD) 1 is 
also expressed on activated T cells and has been extensively studied within the 
LCMV system (Riley, 2009; Wherry, 2011). PD1 interacts with programmed 
death ligand (PDL) 1 or 2 and decreases CD28 costimulation through inhibiting 
PI3K activity, thereby preventing downstream signaling (Keir et al., 2008). 
Soluble inhibitory factors, such as IL-10, are expressed after the activation phase 
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and suppress the over activation of the T cell response in LCMV infection 
(Brooks et al., 2010; Ng and Oldstone, 2012). After an acute LCMV infection 
there is a burst of IL-10 at day 1 post infection, but during a persistent LCMV 
clone 13 infection, which induces clonal exhaustion, this transient burst is 
following by persistent IL-10 production (Brooks et al., 2010). Similarly, PD-1 
expression of virus-specific CD8 T cells peaks at day 6 of an acute LCMV 
infection, but remains high on these cells during a persistent LCMV clone 13 
infection (Barber et al., 2006). Therefore, during clonal exhaustion negative 
regulatory cell surface markers are used to identify cells that are at some stage 
of clonal exhaustion prior to apoptosis (Figure 1.2) (Wherry, 2011). Blocking one 
or more of these negative regulators after exhaustion has been shown to lead to 
recovery of function (Blackburn et al., 2009; Brooks et al., 2008a; 2008b; 
Nakamoto et al., 2009). For example one study blocked PD-1 signaling by 
administering a blocking antibody for PD-L1 into mice persistently infected with 
LCMV clone 13 and found an increase in both the cytokine production and 
proliferation of exhausted virus-specific CD8 T cells leading decreased viral load 
in several organs (Barber et al., 2006). Interestingly, when mice are deficient in 
PD-L1 they have a more functional CD8 T cell response after high dose LCMV 
clone 13 infection, as measured by IFNγ production on a per cell basis, but die 
between day 6-8 post infection (Barber et al., 2006). These studies suggest that 
clonal exhaustion is a mechanism of survival. This reversal of the clonal 
exhaustion phenotype could be further enhanced if anti-PD-L1 treatment was 
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given concurrently with a blocking antibody for lymphocyte activation gene-3 
(LAG3), another inhibitory maker associated with clonal exhaustion (Blackburn et 
al., 2009). Recently two studies found that the blockade of type I IFN would also 
result in viral clearance of mice persistently infected with LCMV clone 13 (Teijaro 
et al., 2013; Wilson et al., 2013). Type I IFN signaling caused the negative 
regulatory environment as blocking type I IFN receptor signaling reduced IL-10 
production and the expression of PD-L1 (Teijaro et al., 2013; Wilson et al., 2013). 
 In addition to signaling molecules, depletion of some cell types has also 
been found to induce clonal exhaustion or restore function to CD8 T cells 
(Battegay et al., 1994; Matloubian et al., 1994; Waggoner et al., 2012). Transient 
depletion of CD4 T cells at the time of infection with LCMV clone 13 resulted in 
life long infection, while non-depleted mice cleared virus after three months 
(Matloubian et al., 1994). Furthermore, the rapidly replicating WE strain of LCMV 
induced persistent infection at a 100-fold lower infecting dose in mice deficient of 
CD4 T cells compared to wildtype controls (Battegay et al., 1994), indicating a 
clear role for CD4 help in virus-specific CD8 T cell response during infection with 
viruses that can induce clonal exhaustion. More recently the depletion of NK cells 
was found to prevent clonal exhaustion of CD8 T cells during high dose LCMV 
clone 13 infection (Lang et al., 2012; Waggoner et al., 2012). This discovery led 
to the conclusion that NK cells can control the developing T cell response, both 
through the lysis of antigen presenting cells and the killing of activated CD4 T 
cells that are required to provide help to CD8 T cells (Waggoner et al., 2012).  
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T cell receptor repertoire and crossreactivity 
 
 One of the hallmarks of the immune system as a whole, but also the T cell 
pool, is an ability to respond to a wide range of pathogens. For T cells this ability 
to recognize a range of pathogens is dependent on the diversity of the TCR 
repertoire. The TCR interacts with short peptides, both pathogen and self-derived, 
presented on the cell surface in the context of MHC molecules. In the thymus 
imprecise somatic recombination of germline variable (V), diversity (D) and 
junctional (J) segments of the tcrβ locus and VJ recombination of tcrα locus, 
along with random pairing of the α and β subunits of the TCR significantly 
enhances diversity (Figure 1.3) (Nikolich-Zugich et al., 2004). The 
complementarity-determining regions  (CDR) of the TCR account for the majority 
of the diversity, as these regions interact with antigen (Rock et al., 1994a). CDR 
1 and 2 are located in the V segments of the TCR α and β subunits (Pannetier et 
al., 1993). The CDR3 is the most diverse as it overlaps the N terminal of the V 
segment and the C terminal of the J segment. In addition to the germline VDJ 
segments there is lack of precise joining between segments and non-template-
encoded nucleotides (N) that are inserted in between these segments, highly 
diversifying the TCR and the CDR3 region (Figure 1.3) (Cabaniols et al., 2001).  
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Figure 1.3
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Figure 1.3. Generation of T cell receptor (TCR) diversity during VDJ rearrange-­
ment and non-­template-­encoding nucleotide insertions. A. During T cell develop-­
???? ??? ??? ?? ??? ???????? ??????? ??????? ????????????? ?? ??? ?? ???????? ??
??? ??????? ??? ??? ???????? ?? ??? ???????? B. ????? ??? ????? ???????????????-­
??????????? ??????? ?????? ?? ????????????? ??????? ?? ???? ??? ??? ?? ???
????????? ??? ???? ??? ???? ??????? ??? ??????? ?????? ??? ? ???????? ???
???? ??????? ?? ???????? ?? ??? ????????????? ?? ??? ?? ???????? ?? ??? ???????
??? ??? ???????? ?? ??? ???????? ?????? ??? ????? ????????? ?? ????????????-­
???????? ??????????? ??????? ????? ???????? ??????? ????????? ??? ??????????
?????? ???????? ???? ?????? ?? ?? ??? ????? ?????????? ???????????? ?? ? ???? ????????
???? ?? ? ??????? ?????? ??????? ??????????? ?? ??????? ??????? ????????? ???????
?????? ??????????????
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The number of antigens that the TCR repertoire of a single individual can 
recognize is further increased by crossreactivity of the TCR, or the ability to 
recognize multiple antigens. The TCR can interact with different peptides  
presented in MHC molecules. The number of antigens a single TCR can 
recognize has been estimated up to 106 (Mason, 1998). TCR-peptide interactions 
are usually dependent on a few key amino acids (Figure 1.4). A TCR may be 
able to recognize multiple antigens containing these same key amino acids. This 
is known as molecular mimicry and is dependent on sequence similarity (Figure 
1.4) (Wilson et al., 2004). Crossreactivity is not always dependent on 
homologous peptide sequences and can be due to the 3-dimensional structure of 
the peptide this is known as alternative recognition (Figure 1.4).  One major 
limitation to the diversity of the TCR repertoire is the spatial capacity of individual 
humans and mice. Even after thymic selection the theoretical estimate of 
possible TCR rearrangements results in diversity being 1013 different TCR, but 
the realistic estimates are 106-107 in mice and 107-108 in humans (Arstila et al., 
1999; Casrouge et al., 2000; Nikolich-Zugich et al., 2004).  
 
T cell responses and Heterologous immunity 
 
 Memory T cells can be crossreactive and recognize peptides derived from 
unrelated pathogens or cancers (Nilges et al., 2003; Urbani et al., 2005). 
Crossreactive immune responses can alter heterologous infection a phenomenon  
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Figure 1.4
A. B. C.
Figure 1.4. Possible mechanisms for T cell receptor crossreactivity. A. TCR
interacts with peptide in the context of MHC class I. B. Crossreactivity occurs
when peptide epitopes that share amino acids make contacts with the same TCR.
C. However, alternative recognition is when other parts of the TCR interact with a
different epitope and are not dependent of sequence similarity. Image taken from
Welsh RM and Selin LK. No one is naïve: Significance of heterologous T cell
immunity. 2002. Nature Reviews Immunology. 6:417-­426 (2002). Copyright
license number 3196040973332.
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termed heterologous immunity (Welsh and Selin, 2002; Welsh et al., 2010). 
Heterologous immunity can be either beneficial or detrimental to the host (Chen 
et al., 2012; 2001; 2003; Cornberg et al., 2010; Nie et al., 2010; Selin et al., 
1998; Wlodarczyk et al., 2013). For example, LCMV-immune mice have lower VV 
loads after challenge than naïve mice, although not as low as VV-immune mice. 
Unlike naïve mice, some LCMV-immune mice develop fat pad pathology or AFN 
during VV challenge (Selin et al., 1998), but since they are protected from a 
lethal VV challenge (Chen et al., 2001) this is considered beneficial heterologous 
immunity. On the other hand, detrimental heterologous immunity can occur if the 
crossreactive T cell response is not efficient at clearing the unrelated pathogen 
infection (Chen et al., 2003; Wlodarczyk et al., 2013). IAV-immune mice had 
higher viral loads than naïve mice after challenge with either LCMV or murine 
cytomegalovirus (MCMV) and developed more severe lung pathology (Chen et 
al., 2003; Wlodarczyk et al., 2013). In this case the virus lingered in the 
peripheral tissues allowing for increased infiltration of activated crossreactive T 
cells, thus causing immunopathology. This enhanced severity of pathology and 
protracted viral clearance is collectively known as detrimental heterologous 
immunity (Chen et al., 2003; Wlodarczyk et al., 2013).  
 Both beneficial and detrimental forms of heterologous immunity have been 
found between pathogens in both humans and mice. For example, IAV-specific 
CD8 T cells were found to recognize and be reactivated in response to HCV and 
Epstein-Barr virus (EBV) infections (Clute et al., 2005; Urbani et al., 2005). HLA-
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A2 patients with EBV-induced acute infectious mononucleosis (AIM) have 
enhanced crossreactive IAV-M1-specific CD8 T cell responses compared to 
healthy donors (Clute et al., 2005).  This suggests that IAV-specific memory cells 
can be reactivated upon EBV infection and induce an inappropriate CD8 T cell 
response that mediated severe pathology. Indeed the severity of disease in AIM 
patients correlated with the frequency of cells that were crossreactive between 
IAV-M1 and EBV-BMLF1 (Nuray Aslan, unpublished data). Interestingly, this 
same epitope crossreactivity between IAV and EBV was also found to be 
protective against EBV-infection in EBV-seronegative middle-aged adults (Levi 
Watkin, unpublished data). IAV M1-specific CD8 T cells isolated from EBV-
seronegative donors expanded and produced cytokine in response to EBV 
peptides. These crossreactive IAV M1-specific cells could also kill EBV-infected 
targets suggesting that they could protect from EBV infection. These 
crossreactive IAV-M1-specific memory cells in EBV-seronegative donors differed 
from similar cells in EBV-seropositive individuals in the characteristics of their 
TCR repertoire. CDR3 region sequences from the crossreactive cells isolated 
from EBV-seronegative donors were highly oligoclonal, with a limited number of 
unique clones compared to EBV-seropositive donors (Levi Watkin, unpublished 
data). Crossreactive responses have also been found between different 
serotypes of Dengue virus (Beaumier and Rothman, 2009; Friberg et al., 2011a; 
2011b; Kurane et al., 1989) and may be a factor in the increased severity of 
25
disease, including dengue hemorrhagic fever, upon reinfection with a different 
serotype.  
 In mice cross-reactive responses have been identified between several 
pathogens including, LCMV and PICV, LCMV and VV, PICV and VV, IAV and 
LCMV, West Nile virus and Japanese Encephalitis virus and Bacillus Calmette-
Guerin (BCG) and VV (Brehm et al., 2002; Chen et al., 2012; 2003; Cornberg et 
al., 2007; 2006; Kim et al., 2002; Mathurin et al., 2009; Trobaugh et al., 2010). 
The crossreactive epitopes and sequences of LCMV, PICV, VV and IAV are 
summarized in Figure 1.5. The LCMV and PICV and LCMV and VV models will 
be explained in more detail below, but both are models of beneficial heterologous 
immunity and are utilized in this thesis.    
 
Private Specificity and heterologous immunity 
 
 Genetically identical naïve mice will all have the same, highly predictable 
virus-specific T cell immunodominance hierarchy to the different virus epitopes, a 
phenomenon known as public specificity (Cibotti et al., 1994). LCMV-immune 
mice all develop the same CD8 T cell immunodominance hierarchies, but within 
these polyclonal epitope-specific populations of individual mice there are different 
TCR, the Vβ repertoire and the CDR3 sequences of the epitope-specific 
responses are unique to individual hosts, which is known as private specificity 
(Cibotti et al., 1994). These differences in the TCR repertoire between genetically 
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identical mice arise during T cell development due to VDJ recombination, TCR α 
and β chain pairing and the insertion of noncoding nucleotides into the junctions 
between the VDJ segments (Nikolich-Zugich et al., 2004). This TCR variability, 
along with the stochastic events that occur during positive thymic selection and 
randomness of which T cell interacts with antigen first during an infection, control 
the private specificity of the TCR repertoire. The private specificity of an 
individual’s TCR repertoire mediates crossreactive expansion during 
heterologous challenge (Figure 1.5) (Kim et al., 2005). In LCMV-immune mice 
challenged with VV there are multiple LCMV-specific memory responses that can 
be crossreactive and expand to skew the LCMV-specific immunodominance 
hierarchy (Kim et al., 2005). To elucidate the role of TCR repertoire in the unique 
expansion of different crossreactive responses in individual LCMV-immune mice 
challenged with VV one study transferred LCMV-immune splenocytes from a 
single donor into three naïve recipients, which were all subsequently challenged 
with VV (Kim et al., 2005).  The donor populations in all three recipients showed 
expansion of the same crossreactive LCMV memory response, but differed 
depending on the donor, indicating that the private specificity of an individual’s 
TCR repertoire controls crossreactivity (Kim et al., 2005). Private specificity was 
also found to control immunopathology in this model of heterologous immunity 
(Nie et al., 2010). Using a similar transfer model, this study examined the 
development of AFN, or fat pad immunopathology, after VV challenge  
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Figure 1.5. Crossreactivity patterns show a dynamic network of crossreactive 
responses in mice. A. A diagram of crossreactive CD8 T cell responses in LCMV, 
PICV, VV and IAV infection. Arrows indicate which memory epitope-specific CD8 T 
cells can be activated by which crossreactive epitopes. PICV NP205-, LCMV 
GP118-, GP34- and NP205-specific CD8 T cells can be activated by VV A11R. VV 
A11R can also crossreact with VV E7R in a reciprocal manner. LCMV NP205 can 
activate PICV NP205-specific CD8 T cells and vice versa. LCMV GP34 can be 
activated by IAV PB1 and LCMV GP276 can be activated by IAV PA224. B. 
Alignment of amino acid sequences of VVA11R and LCMV NP205 with their known 
crossreactive epitopes and the percentage of their sequence similarity.  
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(Nie et al., 2010). The level of severity of AFN between two recipients who 
received adoptive transfer of LCMV memory cells from one donor was found to 
be similar and controlled by the private specificity of the donor LCMV-immune 
splenocytes (Nie et al., 2010).  
 
Neonatal Immune System 
 
 Neonates are highly susceptible to death from infection. Neonates lack 
protective memory and are still developing and undergoing a process of 
colonization of their skin and gut with microbial flora. Disparities in the innate, 
cellular and humoral arms of the immune system all play a role in the reduced 
immune responses of neonates to infection. To combat the susceptibility of 
neonates, three vaccines have been administered world-wide to newborns, 
including the HBV vaccine, BCG and the oral polio vaccines, in an effort to 
further protect this highly susceptible group (Sanchez-Schmitz and Levy, 2011). 
The immune system of a neonate is significantly different than that of an adult 
(Figure 1.6) making understanding how the neonatal immune system responds 
to vaccination or infection necessary to improve vaccines and treatment. 
 As their exposure to antigen in utero is limited neonates lack 
immunological memory and are more reliant on their innate immune responses 
(Krishnan et al., 2003). However, the innate immune system of the neonate is 
functionally distinct from that of an adult. For example, blood derived monocytes  
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Figure 1.6. The immune system of neonates is immature. Neonates have 
decreased frequencies and total numbers of CD4 and CD8 T cells that are more 
Th2 prone compared with adults. The T cell receptor (TCR) diversity of neonates is 
limited in neonates and grows with age. Neonates have increased proportions of 
FoxP3+ T regulatory (Treg) cells and decreased B cell responses. Neonates have a 
less mature innate immune response, for example dendritic cells (DC) produce less 
type I IFN and IL-12 than adult DC. Neonates also have the unique feature of the 
presence of maternal antibody.  
Figure 1.6 
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from human infants have reduced IFNα, IFNγ and IL-12 production upon TLR 
stimulation, but have an increase in IL-10 and Th17 inducing cytokines IL-6 and 
IL-23 (Kollmann et al., 2009). Compared to adults neonates were also found to 
have altered adaptive responses. Antibody responses are reduced, of shorter 
persistence with decreased affinity maturation and altered IgG isotype skewing 
(Siegrist and Aspinall, 2009). The T cell responses in neonates differ from that of 
adults by decreased number of T cells in the spleen (Ridge et al., 1996) 
frequencies of T cell subsets (Tang et al., 2008), and responsiveness to 
stimulation and TCR diversity (Rudd et al., 2011) resulting in altered T cell 
responses after infection. Additionally, neonatal T cells proliferate less, produce 
altered cytokine responses and have decreased cytotoxic activity under certain 
situations (Garcia et al., 2000). Neonatal T cells were thought to be unresponsive 
until 1996, when three seminal papers showed that neonatal T cells were more 
prone to Th2-skewing (Forsthuber et al., 1996; Ridge et al., 1996; Sarzotti et al., 
1996). However, it is still not completely understood why this happens during 
some infections, but not others. For example, high doses of murine leukemia 
virus induced a Th2 response in neonatal mice, while low doses allowed for the 
induction of adult-like cytotoxic CD8 T cell and Th1-skewed CD4 T cell 
responses (Sarzotti et al., 1996). This may be partially due to the defectiveness 
of recent thymic emigrants (RTE) to develop Th1 responses (Haines et al., 2009; 
Opiela et al., 2009) and as RTE make up the majority of the peripheral T cells in 
neonates this may explain this Th2 bias. In utero FoxP3+ regulatory T cells 
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(Treg) are a dominating cell type suppressing immune responses to non-
inherited maternal antigens (Tang et al., 2008). After birth this large proportion of 
Tregs may play a role suppressing a Th1 immune response.  
 Neonatal T cells also differ in the diversity of their TCR. During T cell 
development diversity is accrued in the TCR repertoire by VDJ recombination, αβ 
pairing of the TCR and noncoding nucleotide insertions and deletions in the 
CDR3 region of the TCR. These CDR3 insertions and deletions are mediated by 
the enzyme terminal deoxynucleotyl transferase (TdT), which is responsible for 
up to 90% of the TCR diversity (Cabaniols et al., 2001). In humans this enzyme 
is expressed in the thymus during the third trimester, but in mice it turned on 
between days 4-5 of age with increased CDR3 lengths not detected in single 
positive thymocytes until day 8 of age (Bogue et al., 1991). As mice age the 
CDR3 length of their TCR increases (Rudd et al., 2011). Shorter CDR3 regions 
have been associated with increased crossreactivity (Gavin and Bevan, 1995). T 
cell clones specific to IAV-NP366 were isolated from wildtype and TdT ko adult 
mice and assessed for their ability to lyse targets coated with a library of peptides. 
TdT ko clones were able to recognize a greater number of peptides, indicating 
that they are more crossreactive (Gavin and Bevan, 1995). This goes against 
what is found in adult studies with IAV M1-specific responses in HLA-A2 
individuals, where increased alanine/glycine representation within the CDR3 loop 
is associated with increased flexibility and increased crossreactivity (Naumov et 
al., 2008). TdT ko T cells, with shorter CDR3 regions, can respond to more 
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antigens and this may be attributed to a greater interaction with the alpha chain 
of MHC class I instead of the peptide (Gavin and Bevan, 1995). The increased 
crossreactivity of the neonatal T cell repertoire may allow for smaller populations 
of T cells to protect against a wide range of pathogens (Gavin and Bevan, 1995). 
The limited TCR repertoire in mice lacking TdT also alters immunodominance 
hierarchies. TdT ko mice infected with the P8R strain of IAV or VV showed a shift 
in the immunodominance hierarchies (Haeryfar et al., 2008). Wildtype Balb/c 
mice infected with IAV have a dominant response to the epitope NP147, but in 
TdT ko mice NP147-specific cells are a subdominant response and HA518 
becomes the dominant epitope (Haeryfar et al., 2008).  
In the LCMV model the age of infection has been shown to alter disease 
outcome. Neonatal mice infected at day 1 of age become persistently infected for 
life due to the deletion of LCMV-specific CD8 T cells (Hotchin and Cinits, 1958; 
Volkert and Larsen, 1964). Only one LCMV study has examined the development 
of T cell responses in more mature infant mice (day 14 of age) (Belnoue et al., 
2007). This study found that infant Balb/c mice cleared LCMV WE by 3 weeks 
post infection in the spleen and 4 weeks in the kidney and brain. Interestingly, 
viral clearance was found to be B cell-dependent as µMT ko mice, which lack B 
cells were persistently infected (Belnoue et al., 2007) 
 
LCMV and Immune response to LCMV  
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 LCMV is an old world arenavirus.  All arenaviruses are enveloped with a 
bisegmented RNA ambisense genome. The natural host of LCMV is the house 
mouse (Mus domesticus, Mus musculus), but ~5% of humans are seropostitive 
for LCMV and is known to cause severe meningoencephalitis in humans 
(Armstrong and Lillie, 1934; Jahrling et al. 1992). Over a 17 year span, from 1941 
to 1958, LCMV was thought to contribute to ~10% of patients with aseptic 
meningitis (Meyer et al., 1960), showing that LCMV is a relevant human 
pathogen. LCMV uses the α-dystroglycan receptor to gain entry into cells (2010). 
There are several research strains of LCMV. The ones used in this thesis include 
LCMV Armstrong and clone 13. LCMV Armstrong is a polyclonal virus isolated 
from a monkey infected with an isolate from a woman who was thought to have 
St. Louis encephalitis in 1933  (Armstrong and Lillie, 1934; Welsh and Seedhom, 
2008). LCMV clone 13 is a clonal strain isolated from a mouse persistently 
infected with LCMV Armstrong (Ahmed et al., 1984) and has three amino acids 
distinct from the Armstrong strain (Matloubian et al., 1990; Salvato et al., 1991). 
Two of these mutations enhance the affinity of the LCMV clone 13 for the α-
distroglycan receptor allowing it to systemically infect mice and the other 
mutation is in the RNA polymerase and allows for faster viral replication 
(Matloubian et al., 1990; Salvato et al., 1991).  
 When B6 mice are infected with LCMV intraperitoneally (ip) there is a 
strong induction of type I IFN that peaks day 2-3, which correlates with NK cell 
activation (Biron et al., 2002). In mice infected with the Armstrong strain of LCMV,  
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Table 1. Mouse T cell epitopes 
LCMV CD8 T cell epitopes PICV CD8 T cell epitopes 
GP33-41 KAVYNFATC Db NP38-45 SALDFHKV Kb 
GP34-41 AVYNFATC Kb NP122-132 VYEGNLTNTQL Db 
GP92-101 CSANNSHHYI Db NP205-212 YTVKFPNM Kb 
GP118-125 ISHNFCNL Kb 
GP276-286 SGVENPGGYCL Db VV CD8 T cell epitopes 
NP205-212 YTVKYPNL Kb A11r198-206 AIVNYANL Kb 
NP396-404 FQPQNGQFI Db B8R20-27 TSYKFESV Kb 
E7r130-137 STLNFNNL Kb 
LCMV CD4 T cell epitopes A47L138-146 AAFEFINSL Kb 
GP61-80 GLKGPDIYKGVYQFKSVEFD IAb 
NP309-328 SGEGWPYIACRTSIVGRAWE IAb 
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virus is cleared from all organs by day 8 and the CD8 T cell response peaks 
between day 8 and 9 followed by the peak of the CD4 T cell response between 
day 9 and 11 (De Boer et al., 2003; Varga and Welsh, 1998; Wherry et al., 
2003a). The LCMV-specific CD8 T cell response in naïve adult B6 mice is 
predictable among individuals and maintained throughout the life span of the 
mouse (Ahmed and Gray, 1996; Homann et al., 2001; Tough and Sprent, 1994; 
Zimmerman et al., 1996). There are two co-dominant responses against the 
LCMV epitopes NP396 and GP33/34. The epitope GP276 induces an 
intermediate dominance and there are 24 subdominant responses (Kotturi et al., 
2007). In this thesis I am only interested in the subdominant responses to NP205, 
GP118 and GP92, which have been shown to be crossreactive with VV A11R 
(table 1; Figure 1.5) (Cornberg et al., 2007; Kim et al., 2005). There is no 
difference in the kinetics of viral clearance in mice deficient of B cells, suggesting 
that antibodies play little role in a primary infection (Cerny et al., 1988). The 
neutralizing antibody response for LCMV is generated later in infection between 
1 and 3 months and mediates faster viral clearance during a secondary 
challenge (Battegay et al., 1993).  
 LCMV contains epitopes that are known to be crossreactive with PICV, VV 
and IAV (Figure 1.5) (Brehm et al., 2002; Chen et al., 2001; 2003; Cornberg et 
al., 2006; 2007; Kim et al., 2002; Wlodarczyk et al., 2013). In this thesis LCMV is 
used in every model of infection to study how the balance of viral load and the 
efficiency of the immune response determines immunopathology.  
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PICV and PICV immune response 
 
 Pichinde virus (PICV) is also an arenavirus, but as a new world arenavirus 
it is distantly related to LCMV with only 48% homology (calculated using William 
Pearson’s Lalign program, see materials and methods). It was isolated from the 
Tomes’s rice rat (Oryomys albigularis) and is not associated with human disease, 
but seroconversion has occurred in humans. New world arenaviruses are divided 
into three clades: A, B and C (Bowen et al., 1997). Clade C is similar to old world 
arenaviruses in that it also uses the alpha-dystroglycan receptor to enter cells 
(Spiropoulou et al., 2002). Clade B, which contains numerous hemorrhagic 
viruses, uses the transferrin receptor to enter cells (Flanagan et al., 2008). 
However, at this time the receptor for Clade A new world arenaviruses, including 
PICV, is unknown. The AN3739 strain of PICV was utilized for this thesis. This 
strain of PICV does not cause mortality in B6 mice even at high doses. Similar to 
LCMV, PICV is a strong type I IFN inducer (Marshall et al., 2010). The CD8 T cell 
immunodominance hierarchy consists of one dominant response NP38, and two 
subdominant responses NP122 and NP205 (Brehm et al., 2002) (Table 1). 
Typically PICV needs to be administered at a dose 400-fold higher than LCMV 
(107 PFU) to induce a cytolytic CD8 T cell response (Selin et al., 1994). There 
are no neutralizing antibodies to PICV and no known CD4 T cell epitopes. 
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 PICV is known to be crossreactive with LCMV and VV (Chen et al., 2012; 
Cornberg et al., 2006; Kim et al., 2005; Selin et al., 1994; 1996) (Figure 1.5). 
PICV is used with LCMV in this thesis to study the immunoprotection mediated 
by co-infection in the presence of a crossreactive response and to study neonatal 
immune responses and heterologous immunity. 
 
VV and the immune response to VV 
 
VV is a large DNA virus from the poxvirus family. The original host for VV 
is unknown. The receptor(s) for VV are also unknown, but due to its ability to 
infect multiple cell types and species it is thought that VV has multiple receptors. 
The work done in this thesis used the WR strain of VV. Unlike LCMV and PICV, 
VV is not an inducer of type I IFN. VV employs multiple mechanisms to block the 
ability of cells to produce IFN. For example the C6 protein of VV has been found 
to block type I IFN production by inhibiting the activation of the transcription 
factors IRF3 and IRF7 (Unterholzner et al., 2011). Typically VV is cleared by day 
7 post infection and the T cell response peak at day 6 post infection. VV has 
several documented CD4 and CD8 T cell epitopes (Sette et al., 2009) (table 1). 
The major immunodominant CD8 T cell epitope is B8R20-27 with several 
subdominant epitopes including A47L138-146, E7R130-137 and A11R198-206, which will 
be examined in this thesis (table 1). VV induces a strong antibody response 
leading to a potent neutralizing antibody response. 
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 Previous immunization with several different pathogens provides 
protection against VV challenge including LCMV, PICV, IAV, MCMV and BCG 
(Figure 1.5) (Chen et al., 2001; Cornberg et al., 2007; Mathurin et al., 2009; 
Selin et al., 1998). In this thesis VV is used to challenge LCMV-immune mice and 
examine how this model of beneficial heterologous immunity can be altered if 
mice are immunized as neonates.    
 
LCMV and VV model of heterologous immunity 
 
  Previous immunization with LCMV protects mice from lethal VV 
challenge (Chen et al., 2001) and mediates a 10-300-fold reduction in VV load 
(Selin et al., 1998). Both LCMV memory CD4 and CD8 T cells are required in 
adoptive transfer studies to mediate protection from VV infection (Selin et al., 
1998). LCMV-specific memory cells are reactivated and proliferate after VV 
infection (Kim et al., 2002; Selin et al., 1994). After VV infection there are several 
LCMV-specific memory responses that expand. The most common 
crossreactivities include NP205, GP34 and GP118 (Figure 1.5) (Chen et al., 
2001; Cornberg et al., 2007; Kim et al., 2002; 2005). By using NP205 in a blast 
search against the genome with H2-kb binding motifs the crossreactive VV-A11R 
epitope was identified (Cornberg et al., 2007). T cell lines from LCMV-immune 
splenocytes stimulated with VV-A11R peptide were found to be crossreactive 
with LCMV NP205, GP118 and GP34 (Cornberg et al., 2007). The most common 
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crossreactivities in the cell lines were to GP118 and GP34 (Cornberg et al., 
2007). Which crossreactive memory LCMV-specific response is reactivated upon 
VV infection is determined by the unique TCR repertoire, or private specificity of 
the individual mouse. After VV challenge, hosts that received LCMV-immune 
splenocytes from the same donor had an expansion of the same epitope-specific 
crossreactive response (Kim et al., 2005).  
 In addition to the immunoprotection mediated by this crossreactivity, some 
LCMV+VV mice develop enhanced immunopathology compared to naïve mice 
infected with VV. After an intraperitoneal VV challenge LCMV-immune mice 
develop AFN of the abdominal/epididymal fat pads, similar to the human 
panniculitis condition erythema nodosum (Figure 1.7) (Selin et al., 1998). In an 
analogous fashion, if VV is given intranasally LCMV-immune mice develop 
bronchus-associated lymphoid tissue (BALT) and bronchiolitis obliterans (Chen 
et al., 2003). Both erythema nodosum and bronchiolitis obliterans occur in 
humans of unknown etiology, but have been associated with viral infections and 
vaccinations. For example, erythema nodosum has been associated with HBV 
infection (Rogerson and Nye, 1990).      
LCMV memory T cells that mediate protective immunity after VV challenge 
are also responsible for the enhanced immunopathology. Transfer of T cells from 
LCMV-immune donors into naive hosts resulted in lower viral titers, but also 
increased AFN compared to naive hosts that received naive donor cells (Selin et 
al., 1998). Furthermore, there was no correlation between the VV load in a  
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Figure 1.7
Figure 1.7. Fat pathology comparison in both humans and mice. A.
Epididymal fat pads from (a.) LCMV-­immune mice on day 5 post VV challenge
show acute fatty necrosis (AFN). Fat pads from (b.) naïve mice on day 5 post VV
infection and (c.) LCMV-­immune mice are healthy showing no necrosis. B.
Histology of epididymal fat pad from an LCMV-­immune mice challenged with VV
with large areas of necrosis and mononuclear infiltrates, or panniculitis. C.
Histology of human skin samples of patients with erythema nodosum, a form of
panniculitis, with similar histological features (Courtesy of Bruce Smoller).
Image taken from Welsh RM and Selin LK. No one is naïve: Significance of
heterologous T cell immunity. 2002. Nature Reviews Immunology. 6:417-­426
(2002). Copyright license number 3196040973332.
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mouse and the level of AFN (Nie et al., 2010). AFN was found to be mediated by 
IFNγ- and TNFα-dependent upregulation of Fas on adipose cells, which 
interacted with FasL on the surface of activated crossreactive CD8 T cells and 
caused necrosis of the fat pads (Siwei Nie, unpublished data). The severity of 
AFN in an individual LCMV-immune mouse challenged with VV was found to be 
dependent on the crossreactive TCR repertoire of that individual due to private 
specificity (Nie et al., 2010). LCMV-immune splenocytes from a single donor 
transferred into two naive hosts resulted in a similar severity of AFN in both hosts 
after VV challenge (Nie et al., 2010). This model of heterologous immunity was 
used to examine if immunization with LCMV as a neonate would induce the same 
protective crossreactive responses after VV challenge as mice immunized as 
adults. 
 
LCMV and PICV model of heterologous immunity 
 
 LCMV-immune adult mice challenged with PICV had immunoprotection 
compared to naive mice challenged with PICV with a 1-log reduction in splenic 
viral titer (Selin et al., 1998). This was also true for the reverse, PICV-immune 
mice challenged with LCMV, but there was a more modest reduction of only 0.5 
logs PICV in the spleen (Selin et al., 1998). In this model of heterologous 
immunity there is only one cross-reactive epitope, NP205 (Figure 1.5) (Brehm et 
al., 2002; Chen et al., 2012). LCMV and PICV share six out of the eight amino 
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acids in this epitope (Figure 1.5) (Brehm et al., 2002). After a primary infection of 
either LCMV or PICV, NP205 was a subdominant response, but after the 
heterologous viral challenge the NP205-specific response expanded and became 
the immunodominant CD8 T cell response in some mice (Brehm et al., 2002). 
Similar to the LCMV+VV model, transfer of LCMV-immune splenocytes into naïve 
hosts mediates a reduction of PICV viral load in the spleen and fat pad (Selin et 
al., 1998). However, depletion of CD4 or CD8 T cells before transfer ablates any 
protection (Selin et al., 1998). Using a mutant strain of LCMV Armstrong, which 
has a leucine to alanine mutation at position 212 that prevents the presentation 
of the NP205 epitope (L212A variant), there is no longer immunoprotection after 
PICV challenge in either the fat pad or the spleen (Chen et al., 2012). 
 The expansion of the crossreactive NP205-specific response during 
sequential infection skewed the immunodominance hierarchies for both LCMV 
and PICV, with NP205-specific T cells dominating in most mice (Brehm et al., 
2002). Within the NP205-specific CD8 T cell population in sequentially infected 
mice there was also narrowing of the Vβ repertoire (Cornberg et al., 2006). In 
LCMV-immune mice the majority of NP205-specific cells use Vβ 16. While Vβ 16 
is also present in the NP205-specific population after PICV infection, it is co-
dominant with Vβ 5.1/5.2 (Cornberg et al., 2006). After a homologous challenge, 
there is a slight narrowing of the repertoire, but after a heterologous challenge 
there is significant narrowing of the repertoire and alteration of Vβ usage. For 
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example, PICV-immune mice challenged with LCMV can skew to Vβ 5.1/5.2, 16, 
7 or 12 (Cornberg et al., 2006). 
 This skewing of the NP205 Vβ repertoire in PICV+LCMV-immune mice 
permanently alters the memory repertoire and has detrimental effects during a 
subsequent PICV rechallenge (PICV+LCMV+PICV) (Chen et al., 2012). 
PICV+LCMV-immune mice challenged with PICV have a higher probability of 
developing AFN (Chen et al., 2012). During an acute PICV infection 0 out of 25 
mice developed AFN and only 2 out of 10 PICV-immune mice developed AFN 
during PICV rechallenge. However, 74% (17/23) of PICV+LCMV-immune mice 
got AFN when they were re-exposed to PICV (Chen et al., 2012). This enhanced 
disease severity is attributed to the crossreactivity of the NP205 epitope between 
LCMV and PICV (Chen et al., 2012). If PICV-immune mice are challenged with 
the L212A mutant virus, which lacks the NP205 response, and then rechallenged 
with PICV (PICV+L212A+PICV)  the incidence of AFN drops significantly to 34% 
(9/24). This suggests that beneficial crossreactivities can become detrimental 
depending on the context of the infection.  
 A variation of this model was used to study the effects of simultaneous co-
infection rather than sequential infection with these two viruses containing a 
crossreactive epitope on immunoprotection during a homologous rechallenge. 
Also, neonates were immunized with PICV and challenged with LCMV as adults 
to study the effect of the maturity of the immune response during infection on 
crossreactivity.  
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Thesis Objectives 
 
 After viral infection CD8 T cell responses are induced to clear the virus 
and maintained in memory to protect against reinfection. CD8 T cells employ 
many functions to decrease viral load including proinflammatory anti-viral 
cytokines, such as IFNγ and TNFα. They also employ several cytotoxic functions 
to kill virus-infected cells, such as FasL expression and the release of perforin 
and granzymes. Their ability to produce chemokines to recruit many types of 
immune cells and to make proinflammatory cytokines, as well as lyse infected 
cells makes CD8 T cells, if not controlled, capable of inducing severe 
immunopathology and death. Therefore, my hypothesis is that a balance exists 
between viral load and efficiency of the immune response, specifically the T cell 
response, which determines the disease outcome of the host after infection. If 
there is an inefficient immune response it would allow for virus to linger in 
peripheral tissues, which would recruit increased numbers of activated cytotoxic 
CD8 T cells, which would recruit other immune cells, such as neutrophils and 
monocytes and lead to increased immunopathology. In this thesis 4 models were 
examined where the efficiency of the immune response was predicted to be less 
than optimum: 1. mice were co-infected with two viruses containing a 
crossreactive epitope, 2. the inoculating dose of a virus that can induce clonal 
exhaustion was administered at different doses, 3. neonatal mice, which have 
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immature immune systems, were immunized with arenaviruses and 4. a 
beneficial model of heterologous immunity was examined in neonatal mice. My 
thesis is presented in five parts: 
 
Chapter III:  Co-infection alters CD8 T cell immunity and immunopathology 
This chapter tests the hypothesis if the competition between the immune 
responses to two viruses, LCMV and PICV, which contain a crossreactive 
epitope, administered simultaneously will lead to alterations in the CD8 T cell 
response, and if these alterations can affect the disease outcome in viral 
clearance or immunopathology upon homologous challenged with either virus. 
 
Chapter IV:  Clonal exhaustion as a mechanism to protect against severe 
immunopathology and death from an overwhelming CD8 T cell response 
In this chapter mice were infected with 3 different doses (low, intermediate and 
high) of LCMV clone 13, a virus that is known to induce clonal exhaustion when 
administered at a high dose. We will test the hypothesis whether decreasing the 
inoculating dose would change the clonal exhaustion or functional capacity of the 
CD8 T cells and impact the severity of immunopathology. In other words does 
clonal exhaustion act as a mechanism to prevent death from T cell-mediated 
immunopathology, with some rapidly replicating viruses. 
 
Chapter V:  T cell mediated mortality in neonatal mice infected with LCMV  
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This chapter tests the hypothesis whether an immature, Th2-skewed neonatal 
immune system can control infection with the arenavirus LCMV and by what 
mechanism.  
 
Chapter VI:  Heterologous immunity is a mechanism for protection in 
neonatal mice: LCMV+VV 
This chapter tests the hypothesis that neonatal mice develop equivalent CD8 T 
cell crossreactivity and T cell-mediated immunoprotection in the LCMV+VV 
model of heterologous immunity as adult mice.  
 
Chapter VII:  Neonates control PICV infection and show CD8 T cell 
immunodominance hierarchy skewing after LCMV challenge 
This chapter tests the hypothesis whether the immature immune system of 
neonatal mice can control infection with a less virulent arenavirus, PICV. Along 
wit the hypothesis that the immaturity of the neonatal immune system at the time 
of PICV infection may alter crossreactive responses in mice challenged with 
LCMV as adults.  
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Chapter 2: Methods 
 
Mice 
Male C57BL/6J (B6, H-2b) mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME) at 5-6 weeks of age. For neonatal studies females at 8-10 
weeks of age were used for breeding. Neonates were used at the indicated ages. 
All mice were maintained under specific pathogen free conditions at the 
Department of Animal Medicine, University of Massachusetts Medical School.  
This study was done in compliance within the guidelines of our Institutional 
Animal Care and Use Committee. 
 
Viruses 
LCMV (Armstrong strain and clone 13 strain) and PICV (AN3739 strain) stocks 
were propagated in BHK21 baby hamster kidney cells (Selin et al., 1994). The 
L212A LCMV Armstrong variant was made using reverse genetics by Juan 
Carlos de la Torre (Chen et al., 2012). This alanine mutation at position 212 of 
the nucleoprotein disrupts MHC class I binding for the NP205 epitope and results 
in ablation of this CD8 T cell response. Vaccinia virus (WR stain) was propagated 
on NCTC-L929 or Hela cells (Selin et al., 1994). To control for culture 
contaminants supernatants from PICV-infected BHK or VV-infected NCTC-L929 
were purified through a sucrose gradient and diluted in Hank’s balanced salt 
solution (HBSS), and LCMV was diluted >40-fold in HBSS. 
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Infections  
Adult mice 6-8 weeks old were immunized intraperitoneally (ip) with 5x104 
plaque-forming units (PFU) of LCMV Armstrong (wildtype or L212A variant) 
and/or 2x107 PFU of PICV. At 6 weeks post-immunization mice were considered 
immune. Control mice were left uninoculated or inoculated with HBSS. Control 
mice were always age and sex matched to the experimental group and kept in 
the same specific pathogen free housing. Immune mice were challenged with 
either 2x106 PFU LCMV clone 13 intravenously (iv), 2x107 PFU of PICV ip or 
1x106 PFU of VV ip. For LCMV clone 13 infections mice were inoculated iv with 
low dose, 2x104 PFU; medium dose, 2x105 PFU; and high dose, 2x106 PFU of 
LCMV clone 13. Neonatal mice were infected with 5, 50 or 500 PFU of LCMV 
Armstrong ip or 4x104, 4x105 or 4x106 PFU of PICV ip.   
 
Peptides  
LCMV-specific peptides: NP396-404 (FQPQNGQFI; Db), GP33-41 
(KAVYNFATC; Db), GP34-41 (AVYNFATC; Kb), GP276-286 (SGVENPGGYCL; 
Db), NP205-212 (YTVKYPNL; Kb) and GP118-125 (ISHNFCNL; Kb)  
PICV-specific peptides NP38-45 (SALKFHKV; Kb) NP122-132 (VYEGNLTNTQL; 
Db) NP205-212 (YTVKFPNM; Kb) 
VV-specific peptides: B8R20-27 (TSYKFESV; Kb), E7R130-137 
(STLNFNNL; Kb), A47L138-146(AAFEFINSL; Kb) and A11R198-205 
(AIVNYANL; Kb) (Table 1.1) 
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Peptides were at 90% purity by reverse phase-HPLC from 21st Century 
Biochemicals (Marlboro, MA). 
 
CD4 and CD8 T cell depletion  
Adult mice were injected ip on days -1 and 7 of LCMV clone 13 infection with 
100µg of anti-CD8 antibody (clone 2.43). Neonates were injected with 50µg in 
50µl of anti-CD4 (clone GK1.5) anti-CD8 (clone 2.43) antibodies or IgG control 
LFT2 on days 0, 4 and 8 of LCMV infection.  
 
  
Viral titer 
LCMV, PICV and VV viral titers were determined by plaque assay. Spleens, fat 
pads, kidneys, brains or lungs were homogenized in 1mL and livers were 
homogenized in 2mL in adult mice. In neonates liver, kidney and brain were 
homogenized in 0.5mL of complete RPMI media containing 10% heat-inactivated 
fetal bovine serum (FBS), 50units/mL penicillin and 50µg/mL streptomycin. 
Homogenized samples were spun at 2,000 rpm for 20 minutes and then 
supernatants were frozen down at -80°C. On the day of the plaque assay 
samples were thawed and serially diluted 1:10 in complete MEM containing 10% 
heat-inactivated FBS, 50units/mL penicillin and 50µg/mL streptomycin and 100µl 
of diluted sample was used to infect a monolayer of vero cells in 1mL of complete 
MEM in 6-well plates. Plates were incubated for 1.5 hours at 37°C and overlayed 
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with 4mL of 1:1 EMEM containing 10mL of heat-inactivated FBS, 25 units/mL 
penicillin and 50ug/mL streptomycin :1% agarose in water. Samples were stained 
at 48 hours for VV, 3 days for PICV and 4 days for LCMV with 2ml of 1:1 EMEM: 
1% agarose in water and 0.015mg/ml of 1% Neutral red in PBS. Plaques were 
counted at 72 hours for VV, day 4 and 5 for PICV and day 5 and 6 for LCMV. To 
determine LCMV viral load in the co-infected mice, a plaque assay was 
performed as above for LCMV but stained with 1ml of 1% iodonitrotetrazolium 
chloride (INT) in PBS on day 4 after plaque assay. The chemical stains 
uninfected and PICV-infected cells, thereby allowing for specific identification and 
enumeration of LCMV plaques alone (Cooper, 1959; Logan et al., 1975). Viral 
loads are shown as log10 PFU/mL. 
 
ALT assay  
Alanine transferase (ALT) assay was purchased from D-Tek LLC (Bensalem, PA). 
15µl of frozen serum was thawed and mixed with 150µl of reconstituted substrate 
and absorbance was read at 340nm at 0, 1, 2 and 3 minutes immediately 
afterwards. ALT concentration was calculated as the average change in 
absorbance/minute *1768. Data are shown in international units/liter.  
 
Leukocyte Preparation 
Peripheral blood (100-300µl) was treated with 3mL of 0.84% NH4Cl and 
incubated for 10 minutes at 37°C. Blood was then washed with complete RPMI.  
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Spleens from mice were ground spleens between two pieces of fine mesh with 
the back of a syringe and strained through fine mesh. Samples were then treated 
with 2mL 0.84% NH4Cl to lyse red blood cells. Mice were profused with 10mL of 
HBSS prior to isolation of brains to remove peripheral blood that may 
contaminate samples. Brains of mice were processed through mesh similar to 
spleens, spun down and resuspended in 30% percoll in RPMI. Samples were 
then underplayed with a 70% percoll in RPMI and spun at 500 g for 30 minutes at 
18°C with no deceleration brake. Lymphocytes were collected from the 30/70 
interface.  
 
Intracellular cytokine staining 
Single cell suspensions were prepared from peripheral blood, spleens or PEC 
from mice, counted, plated at 2x106 cells/well and stimulated with 1µM of peptide 
along with golgi plug (brefeldin A) and recombinant human IL-2 for 4.5 hours at 
37°C in complete RPMI. Cell were treated with Fc receptor blocking antibody (BD 
Pharmigen clone 24.G2) and stained for CD8 (BD Pharmigen clone 53-6.7), 
CD44 (biolegend clone IM7 and ebioscience clone IM7) and PD-1 (BD 
Pharmigen clone J43) in FACS buffer consisting of HBSS with 2% heat-
inactivated FBS. Samples were then treated with cytofix/cytoperm and stained 
with IFNγ (BD Pharmigen clone XMG1.2) and TNFα (BD Pharmigen clone MP6-
XT22) in PermWash (BD Pharmigen) diluted 1:10 in water. Samples were 
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collected on a LSRII (BD Pharmigen) and analyzed with FlowJo software (Tree 
Star Inc.).  
 
Vβ staining 
Vβ staining was done on both unstimulated cells or peptide stimulated cells after 
4.5 hour incubation. After treatment with 24.G2 to block Fc receptors Vβ 
monoclonal antibodies were added to the panel of surface stains. In separate 
wells cells were stained for Vβ 2- PE (clone B20.6), Vβ 3-PE (clone KF25) and 
Vβ 5.1/2-FitC (clone MR9-4), Vβ 4-PE (KT4) and Vβ 9-FitC (MR1O-2), Vβ 6-PE 
(clone RR4-7) and Vβ 12-FitC (clone MR11-1), Vβ 7-PE (clone TR310) and Vβ 
8.1/2-FitC (clone MR5-2), Vβ 8.3-PE (clone 1B3.3) and Vβ 13-FitC (clone MR12-
3), Vβ 10b-PE (clone B21.5) and Vβ 14-FitC (clone 14-2), Vβ 11-PE (clone RR3-
15) and Vβ 17a (clone KJ23). All Vβ antibodies were purchased through BD 
Biosciences.  
 
Surface and tetramer staining 
Single cell suspensions were prepared from peripheral blood or spleens from 
mice. Samples were then treated with 0.84% NH4Cl to lyse red blood cells. 
Samples were treated with Fc receptor blocking antibody (BD pharmigen clone 
24.G2) and then stained with PE labeled tetramers in 100µl of FACs buffer. 
Surface stains including KLRG1 (eBioscience clone 2F1), IL7R (eBioscience 
clone A7R34), CD62L (BD pharmigen and clone mel-14), CD44 (biolegend clone 
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IM7 and ebioscience clone IM7) and CD8 (BD Pharmigen clone 53-6.7) were 
then added. Samples were then treated with cytofix and samples were collected 
on a LSRII (BD Pharmigen) and analyzed with FlowJo software (Tree Star Inc.). 
 
Cytometric bead array 
Mouse inflammation cytometric bead array was purchased from BD Pharmingen. 
Briefly, 10µl of thawed serum was incubated with 10µl of capture bead mixture 
and 10µl of PE-detection reagent and incubated for 2 hours at room temperature. 
Samples were collected on a LSRII (BD Pharmigen) and analyzed with FCAP 
Array software (BD Pharmigen). 
 
Type I IFN Bioassay 
Serum was isolated from mice at 24, 48 and 72 hours post-infection. Serum was 
serially diluted and added to NCTC-L929 cells in a 96-well flat bottom plate. The 
following day 2x104 PFU of VSV was added to each well. Two days after the 
addition of virus, the dilution of serum at which 50% of the cells were protected 
was determined.  
 
AFN scoring 
The level of acute fatty necrosis (AFN) was scored visually to assess disease 
severity on a scale from 0 to 8. Level 1 and 2 represent very mild to mild AFN 
with a few small necrotic spots on one or both abdominal fatpads; level 3 and 4 
54
denote mildly moderate to moderate AFN with larger necrotic spots on one or 
both abdominal fatpads; levels 5 and 6 represent moderately severe to severe 
necrosis with very large patches; level 7 represents very severe AFN with 
extensive necrosis of the majority of the fat pads; level 8 represents moribund 
necrosis to which the animal can not survive.  
 
Histology 
Lungs, livers and fat pads from mice were collected, fixed in 10% neutral 
buffered formaldehyde and paraffin-embedded. Tissue sections (5 µm) were 
stained with hematoxylin and eosin (H&E) and analyzed microscopically by a 
pathologist.  
 
Lung histology scoring 
Scoring of lung pathology was graded based on a scale outlined below and 
based on previously published studies (Chen et al., 2003; Wlodarczyk et al., 
2013). Scoring of lung pathology was graded by one pathologist, who was 
blinded in regards to treatments the mice had received. Lungs were scored on a 
scale of 0-5 (0, within normal limits; 1, mild interstitial mononuclear infiltrates, 
disorganized BALT, perivascular edema; 2, moderate interstitial mononuclear 
infiltrates, small amount of organized BALT, pulmonary edema; 3, moderate 
interstitial mononuclear infiltrates, pulmonary edema, enhanced organized BALT, 
mild consolidation; 4, severe interstitial mononuclear infiltrates, greatly enhanced 
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pulmonary edema, enhanced organized BALT, moderate consolidation and 
moderate necrotizing bronchiolitis; 5, severe interstitial mononuclear infiltrates, 
greatly enhanced pulmonary edema, enhanced organized BALT, severe 
consolidation, severe necrotizing bronchiolitis and vasculitis involving more than 
half of the lung.) 
 
Fat pad histology scoring 
Abdominal fat pads were fixed in 10% neutral buffered formaldehyde and paraffin 
embedded. Tissue sections were stained with H&E and analyzed microscopically. 
Fat pad pathology was blindly graded by a pathologist based on the distribution 
and severity of disease from 0 to 6 (0, within normal limit; 1, mononuclear 
infiltrate; 2, mononuclear infiltrate with small areas of necrosis; 3, greater than 10 
areas of necrosis less than 1/25 of visual field; 4, areas of necrosis that are 1/10 
of visual field; 5, areas of necrosis that are ½ of visual field; 6, areas of necrosis 
that are greater than ½ of visual field.)  
 
Analysis of sequence similarity between viruses  
The sequence similarity between measles and mumps viruses and LCMV and 
PICV were determined using the William Pearson’s Lalign program 
(ch.EMBnet.org). Global alignments were done on the L and S segments for 
LCMV (L segment NC_004291 and S segment NC_004291) and PICV (L 
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segment NC_006439 and S segment NC_006447). Whole genome alignments 
were done for measles virus (NC_001498) and mumps virus (AB744048).  
 
Statistics 
Descriptive statistics are expressed as mean +/- standard error of the mean. 
Standard error of the mean is displayed in all figures where relevant unless 
stated differently in figure legends. Statistical analysis was done using the 
Student’s T test when comparing two groups and ANOVA when comparing three 
or more. Mortality curves were analyzed with log rank test using Prism software 
(Graphpad software, La Jolla Ca). *p<0.05, **p<0.01,***p<0.001 ****p<0.0001 
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Chapter 3: Viral Co-infection alters CD8 T cell immunity 
and Immunopathology 
 
Antiviral immunity is predominately studied in the context of infection with 
a single pathogen, although simultaneous infection with two or more 
microorganisms is a common occurrence. Simultaneous co-infections occur 
when pathogens share the same route of transmission, such as insect vectors or 
contaminated blood products. Multiple bites from virus-infected insect vectors 
(e.g. mosquitoes) can transmit a simultaneous co-infection. Additionally, 
mosquitoes can be co-infected and transmit multiple viruses (Chamberlain and 
Sudia, 1957; Lam and Marshall, 1968). During a 2006 Dengue virus outbreak in 
India, 19% of patients were co-infected with multiple serotypes of Dengue virus 
and a higher percentage of the patients with Dengue hemorrhagic fever were co-
infected with multiple dengue virus strains (Bharaj et al., 2008). Another study 
found that 13% of patients admitted to the hospital during the 2009 H1N1 IAV 
pandemic were co-infected with at least one other respiratory virus (Esper et al., 
2011). Interestingly, patients co-infected with IAV and coronavirus or respiratory 
syncytial virus had enhanced severity of symptoms over patients infected with 
only IAV (Esper et al., 2011; Palacios et al., 2009).  Used hypodermic needles 
and contaminated blood products may also trigger co-infections when they 
harbor more than one virus. 90-95% of intravenous drug users infected with 
human immunodeficiency virus (HIV) are also infected with HCV (Maier and Wu, 
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2002), with some of these patients possibly contracting both viruses at the same 
time. HIV/HCV co-infection is associated with faster progression to HCV-
mediated liver disease and increased risk of cirrhosis compared to patients 
infected with only HCV (Singal and Anand, 2009). Simultaneous co-infection with 
hepatitis B and D viruses, which is more common in intravenous drug users, is 
also more frequently associated with fulminant hepatitis compared to sequential 
infection (Grabowski and Wedemeyer, 2010). These studies indicate that co-
infections can cause increased severity of disease and show the importance of 
understanding how co-infections differ from single virus infections. 
Despite the apparent detriments afforded by co-infection with multiple pathogens, 
children are routinely exposed to multiple antigens simultaneously through 
combination vaccines and simultaneous administration of multiple vaccines. 
Typically, physicians and parents do not condone more than three injections 
within a single doctor’s visit (Meyerhoff et al., 2003; Woodin et al., 1995). 
However, CDC protocols allow for children to receive up to 9 vaccine injections 
containing 13 different vaccines at their 12-15 month doctor’s visit (Kroger et al., 
2011). One major disadvantage of simultaneous vaccination is the possible 
occurrence of vaccine interference, where one vaccine dampens the response to 
a second vaccine (Vidor, 2007). For example, in Nigerian children the 
simultaneous administration of the measles vaccine with the smallpox, yellow 
fever and the combination diphtheria, pertussis and tetanus vaccines resulted in 
a 89% to 70% decrease in measles seroconversion rates (Ruben et al., 1973). 
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Due to the paucity of identified human T cell epitopes in the majority of vaccines 
it is not clear how concurrent administration of multiple vaccines may affect T cell 
immunity in humans. It is unknown if cellular immunity is reduced by vaccine 
interference or if there are other qualitative changes caused by co-infection, 
where two distinct immune responses are competing within the same host. Using 
a mouse model, where virus-derived T cell epitopes are better defined, we 
questioned how simultaneous co-infection would alter the developing virus-
specific T cell responses.  
In the current study, mice were co-infected with two distantly related non-
cytolytic arenaviruses: LCMV and PICV. Protective immunity to LCMV and PICV 
is predominantly mediated by virus-specific T cell responses with limited 
contributions from neutralizing antibodies (Cerny et al., 1988; Walker et al., 1984). 
During sequential infections with LCMV and PICV there is protective 
heterologous immunity. (Brehm et al., 2002; Chen et al., 2012; Cornberg et al., 
2006; Selin et al., 1998). This alteration in disease outcome is dependent on a 
cross-reactive CD8 T cell epitope, NP205-212, which differs in only 2 of 8 amino 
acids between the two viruses. Naïve mice immunized with PICV generate a low 
frequency of memory CD8 T cells specific for NP205 and these T cells are 
reactivated during subsequent LCMV challenge, resulting in an altered 
immunodominance hierarchy and faster viral clearance than that seen in naïve 
mice challenged with LCMV (Brehm et al., 2002; Cornberg et al., 2006; Selin et 
al., 1998). A similar event occurs in LCMV-immune mice challenged with PICV.  
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During a heterologous viral challenge, only the crossreactive cells are re-
activated and expand, skewing the population and causing a narrowing of the 
TCR repertoire. This narrow TCR repertoire may be more efficient at clearing 
virus early, but during persistent viral infections this may allow for viral immune 
escape (Cornberg et al., 2006).  
This study investigated whether co-infection with two live viruses would 
alter the characteristics of the CD8 T cell response to each virus and 
subsequently alter immune protection and severity of disease compared to  
single virus-immune mice during homologous challenge. Because these two 
viruses contain a cross-reactive epitope this model was also useful for directly 
examining the influence of T cell crossreactivity on disease outcome upon 
challenge following co-infection.  
 
A. Co-immunized mice showed reduced protective immunity 
compared to single virus-immune mice after challenge. 
 
To determine immune protection after co-immunization, naïve mice were 
immunized with the Armstrong strain of LCMV, PICV or both simultaneously. 
After six weeks mice had cleared both viruses and were considered immune and 
challenged with the clone 13 strain of LCMV or PICV. The clone 13 strain of 
LCMV was used because it replicates more extensively due to the attachment 
protein binding more avidly to its receptor (Ahmed et al., 1984).  
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As expected, LCMV-immune mice were protected after LCMV clone 13 
challenge compared to naïve mice, as evidenced by the significant reduction in 
serum viral load at day 2-3 post challenge (Figure 3.1A). Compared to LCMV-
immune mice where 60% (6/10) of the mice had completely cleared virus, virus 
was cleared in only 23% (3/16) of the co-immunized mice. (p<0.05 by Fischer’s 
exact test) (Figure 3.1A). However, both LCMV- and co-immunized mice were 
able to clear LCMV clone 13 from the serum by day 5 post challenge (data not 
shown). In a similar fashion, after PICV challenge 92% (11/12) of PICV-immune 
mice cleared virus by day 3 post challenge while only 20% (3/15) of co-
immunized mice could clear virus (p<0.0004 by Fischer’s exact test). However, 
by day 5 post challenge virus could not be detected in either PICV- or co-
immunized mice (data not shown). Collectively, these results demonstrated that 
co-immunized mice were not as efficient at clearing virus compared to LCMV or 
PICV single-immune mice, suggesting that the memory responses in co-infected 
mice were not as efficient at clearing a secondary challenge. 
  
B. Co-immunized mice had increased immunopathology during 
challenge compared to single virus-immune mice.  
 
Increased and prolonged virus replication, even by a few days, may lead 
to enhanced recruitment and expansion of activated memory T cells and cause 
collateral cellular damage or immunopathology (Selin et al., 2011).  
  
62
  
!"#$%& ()*
!" $%&'( !!" $%&'()*+,-
!!!"*+,-)*+,- !'".,/-0*+,-)*+,-
+)
,)
$%!'( .,/-.,/-0*+,-
1"2
1"3
4"2
4"3
5"2
6104 .,/- 78%99($:(
9;
:
*<
=
0>
.
2 ? 1 4 5 3 @ A
B1
B5
B@
BC
?22
?21
D%E F;GH *+,-
78%99($:(
I(
9%
H!'
(
J
(!
:8
H
$%!'()*+,-
*+,-)*+,-
.,/-0*+,-)*+,-
2 ? 1 4 5 3 @ A
C3
B2
B3
?22
D%EG F;GH .,/-
78%99($:(
I(
9%
H!'
(
J
(!
:8
H
$%!'()79?4
.,/-)79?4
.,/-0*+,-)79?4
$%!'( *+,- .,/-0*+,-
2
1
5
@
C
K
<L
G7
;I
(
6A *+,- 78%99($:(
$%!'( .,/- .,/-0*+,-
2
12
52
@2
?22
?32
122
6A .,/- 78%99($:(
K
.M
9(
'(
9G
+=
0.
$%!'( *+,- .,/-0*+,-
2
1
5
@
C
N%
HF
%D
8!
GH
;9
;:
E
G7
;I
(
6A *+,- 78%99($:(
-) .)
/) 0) !)
***
** ***
************ *
***
***
***
*
*
* *
*
*
*
*
<!:OI( 4"?" ,;P!>>O$!Q(D >!7( 8%D G!:$!N!7%$H9E !$7I(%G(D '!I%9 9;%DG %$D !>>O$;F%H8;9;:E %NH(I 78%99($:("
K"P," 1234&5 6.789 2:; 6.78<=>.8 ?@9"AA$:"B&; A"?& C&%& ?D2EE&:#&; C"FD GH*I =!K 6.78 ?E@:& *( ")4) K"
8"%2E E@2;L C&%& ;&F&%A":&; ": L&%$A 2F ;2ML G9( N@LF9?D2EE&:#&) /2F2 C2L N@@E&; O%@A FD%&& L"A"E2% &PN&%"A&:FL) R"
7"?& C&%& C&"#D&; ;2"EM5 2:; %&E2F"4& C&"#DF C2L ?2E?$E2F&; O%@A ;2M I) :Q(9R A"?&<#%@$N) /2F2 2%& %&N%&L&:F2F"4& @O
FD%&& L"A"E2% &PN&%"A&:FL) SF2F"LF"?L ?@AN2%& 6.789 2:; ?@9"AA$:"B&; A"?&) ," ,6T E&4&EL C&%& ;&F&%A":&; @: ;2M U
N@LF 6.78 ?E@:& *( ?D2EE&:#& ": FD& L&%$A) : Q V A"?&<#%@$N) /2F2 C&%& N@@E&; O%@A FC@ L"A"E2% &PN&%"A&:FL) 6"PS"
1234&5 =>.89 2:; ?@9"AA$:"B&; A"?& C&%& ?D2EE&:#&; C"FD GH*IU =!K @O =>.8 ")N) 6" 7"?& C&%& C&"#D&; ;2"EM 2:;
%&E2F"4& C&"#DF C2L ?2E?$E2F&; O%@A ;2M I) :QU9*G A"?&<#%@$N) SF2F"LF"?L LD@C ;"OO&%&:?&L W&FC&&: =>.89 2:;
?@9"AA$:"B&; A"?&) /2F2 2%& N@@E&; O%@A FC@ L"A"E2% &PN&%"A&:FL) T" ,?$F& O2FFM :&?%@L"L X,!1Y L?@%& @O
2W;@A":2E<&N";";MA2E O2F N2; 2:; <" O2F N2; D"LF@N2FD@E@#M L?@%&L C&%& ;&F&%A":&; @: ;2M U N@LF =>.89?D2EE&:#&)
:QR9*G A"?&<#%@$N) /2F2 2%& N@@E&; O%@A FC@ L"A"E2% &PN&%"A&:FL) Z"LF@N2FD@E@#M 2:; ,!1 L?@%":# LMLF&A @$FE":&; ":
72F&%"2EL 2:; 7&FD@;L) S" !2F N2; L&?F"@:L O%@A :234& XS"!"Y5 :234&[=>.8 XS"!!"Y5 =>.8[=>.8 XS"!!!"Y 2:;
?@9":O&?F&;[=>.8 XS"!'"Y C&%& LF2":&; C"FD Z\0 2F ;2M U @O =>.89?D2EE&:#&) S"!" :234& A"?& LD@C&; :@%A2E O2F N2;
LF%$?F$%&) S"!!" :234&[=>.8 A"?& LD@C&; O@?2E N2F?D&L @O A@:@:$?E&2% ":O"EF%2F&L) S"!!!" =>.8[=>.8 A"?& LD@C&; A"E;
A@:@:$?E&2% ":O"EF%2F&L 2%@$:; FD& N&%"ND&%M) S"!'" 6.78<=>.8[=>.8 A"?& LD@C&; L&4&%& :&?%@L"L @O $N F@ VI] @O
FD& O2F N2;) ^N_I)IV5 ^^N_I)I*5^^^N_I)II* ^^^^N_I)III*
63
LCMV challenge. The high dose of LCMV clone 13 used in this study 
induces transient weight loss in naïve mice during the first week of infection. Mice 
will eventually undergo clonal exhaustion of the T cell response and do not 
develop severe immunopathology (Stamm et al., 2012; Waggoner et al., 2012). 
To determine if co-immunized mice were developing enhanced immunopathology 
compared to LCMV-immune mice, weight loss was measured after LCMV 
challenge (Figure 3.1B). Naïve mice infected with LCMV clone 13 progressively 
lost 15% of their body weight by day 7, whereas LCMV-immune mice were 
largely protected from weight loss. Interestingly, co-immunized mice lost 
significantly more weight than LCMV-immune mice. Co-immunized mice lost up 
to 15% of their body weight during the first 4 days of challenge. During this time, 
co-immunized mice were similar to naïve mice challenged with LCMV clone 13, 
with no significant difference in their relative weight. These data suggest that co-
immunized mice were deficient in immunological protection from LCMV clone 13-
induced weight loss during this time period. In contrast to acutely infected naïve 
mice, co-immunized mice began to regain weight after day 4, such that co-
immunized mice had a greater relative weight at day 6 (p<0.004) and day 7 
(p<0.002). 
LCMV clone 13 infection has previously been associated with lung and 
liver pathology (Pellegrini et al., 2011; Waggoner et al., 2012), so to more 
specifically assess immunopathology we measured liver damage by quantifying 
the liver enzyme alanine transaminase (ALT) after LCMV challenge (Figure 
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3.1C). Clinically, elevated ALT levels are diagnostic of hepatocellular injury 
(Sheehan and Haythorn, 1979). After LCMV challenge, naïve mice had the 
highest ALT levels at day 7 compared to either of the immune groups. Co-
immunized mice had higher ALT levels than LCMV-immune mice, indicating 
enhanced liver damage in co-immunized mice during LCMV clone 13 challenge.   
PICV challenge. Co-immunized mice also had enhanced 
immunopathology during challenge with PICV compared to PICV-immune mice 
(Figure 3.1D). Resembling LCMV-immune mice challenged with LCMV clone 13, 
PICV-immune mice had the least relative weight loss during PICV challenge.  
Naïve mice infected with PICV had a substantial drop in relative weight by day 2 
post challenge, but by day 7 were approximately equal to PICV-immune mice 
(Figure 3.1D). Co-immunized mice lost weight gradually until day 4, but unlike 
the naïve group, co-immunized mice did not regain weight by day 7 post 
challenge. Unlike LCMV clone 13 infection, PICV infection was not found to 
induce liver damage as measured by ALT levels. However, in sequential 
heterologous challenge models, mice can develop severe panniculitis (Chen et 
al., 2012; Nie et al., 2010; Selin et al., 1998), a necrosis of the  abdominal fat 
also known as acute fatty necrosis (AFN). The most common form of human 
panniculitis is erythema nodosum, which affects subcutaneous fat and can occur 
following certain acute viral infections or vaccinations (Maggiore et al., 1983; 
Smoller et al., 1990). After PICV challenge we assessed panniculitis of 
abdominal/epididymal fat pads. (Figure 3.1E-G). Naïve mice did not develop 
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AFN, and only 1 out of 9 PICV-immune mice had very mild AFN (AFN score = 1) 
(Figure 3.1E). Co-immunized mice had a range of AFN scores. Two co-
immunized mice had severe AFN (AFN score = 6 and 7), five mice had mild to 
moderate AFN (AFN score = 1-3) and five mice had no AFN. To further assess 
severity of pathology we also scored histological sections of the fat pads (Figure 
3.1F&G). Naïve mice challenged with PICV displayed distinct focal areas of 
mononuclear infiltrates within the fat pads. PICV-immune mice presented with 
mild mononuclear infiltrates located only along the periphery of the fat pad. In 
contrast, co-immunized mice on average demonstrated more severe and variable 
panniculitis (Figure 3.1F) wherein the most affected mice had severe necrosis 
covering more than half of the fat pad (Figure 3.1G). These data show that co-
immunized mice had significantly enhanced immunopathology compared to 
single virus-immune mice during both LCMV and PICV challenges. These data, 
along with the increased viral load in co-immunized mice compared to single 
virus immunized mice, suggest that there was a difference in the memory 
response in co-immunized mice. 
  
C. Co-infected mice had variable and unpredictable epitope-specific 
CD8 T cell responses after primary infection.   
 
During a viral infection, T cells respond to a limited number of viral 
epitopes. The different epitope-specific T cell populations can be arranged into a 
hierarchy based upon the size of the response, also known as an 
66
immunodominance hierarchy. The immunodominance hierarchy is controlled by 
several factors, including precursor frequency, antigen-MHC class I binding 
affinity and stability and the ability of the antigen-presenting cell to effectively 
process and present antigen (Yewdell, 2006). We questioned if co-infection 
would affect the development of two different virus-specific CD8 T cell responses 
within the same host. Specifically, we wondered if co-infection would alter the 
immunodominance hierarchies for the individual viruses. In addition, we 
questioned if there were any changes in the cross-reactive NP205-specific 
response, as both viruses present a variant of this epitope.  
As demonstrated previously, naive mice infected with a single virus 
developed predictable and reproducible CD8 T cell immunodominance 
hierarchies that are stable for the life of the host (Ahmed and Gray, 1996; 
Homann et al., 2001; Tough and Sprent, 1994; Zimmerman et al., 1996) unless 
sequentially infected with another pathogen (Selin et al., 1996; 1999). In 
agreement with those findings, mice immunized with LCMV exhibited the 
strongest CD8 T cell responses to the co-dominant epitopes NP396 and 
GP33/34 (Figure 3.2A) and weaker responses against the subdominant and 
cross-reactive epitope, NP205. PICV immunization of naïve mice produced a 
strong response to the dominant PICV epitope NP38 and a smaller response to 
the subdominant NP205 epitope (Figure 3.2A). In contrast to the single virus-
infected mice, the highly predictable immunodominance hierarchy against each 
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virus was perturbed in co-immunized mice, with significant individual variation 
between mice (Figure 3.2B). In a single experiment examining four co-
immunized mice, the hierarchies of two mice were predominantly directed 
against immunodominant LCMV-specific epitopes (NP396 and GP33/34) 
whereas each of the other mice had a dominant response against either PICV 
NP38 or the cross-reactive NP205 epitope (Figure 3.2B). This latter response 
was unexpected, since immunodominance by NP205-specific CD8 T cells has 
not been observed in mice infected with either LCMV or PICV alone (Brehm et al., 
2002). To see if the CD8 T cell responses in co-infected mice were skewed in 
general to one virus over the other, mice were categorized by which virus 
dominated the CD8 T cell response (Figure 3.2C). For example of the four 
individual co-immunized mice in figure 3.2B, mouse 1 & 3 are skewed to LCMV, 
while mouse 2 skewed to PICV and mouse 4 skewed to NP205. The majority of 
co-infected mice had a dominant response to only one of the viruses. The LCMV-
specific response was the stronger in 37% of co-infected mice, while 40% had a 
dominant PICV-specific response. In 22% of co-infected mice there was a co-
dominant LCMV- and PICV-specific response. These data were from mice co-
infected with two separate virus injections, but similar variance in 
immunodominance hierarchy and dominance was found when LCMV and PICV 
were combined in the same needle before injection (Figure 3.2C). These data 
suggest that there is greatly increased variability between individual co-
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immunized mice and that a normally subdominant cross-reactive T cell response 
can be a dominant response during simultaneous viral infections. 
 To understand how this variability may impact the viral clearance and 
immunopathology of co-infected mice during a challenge, virus-specific 
immunodominance hierarchies were examined (Figure 3.2D&E). Three epitopes 
for LCMV (NP396, GP33 and NP205) and two epitopes for PICV (NP38 and 
NP205) were examined in co-infected mice compared to single virus-infected 
mice in terms of their proportion of the total virus-specific response. Compared to 
PICV-immune mice, co-infection predominantly resulted in a skewed PICV-
specific response (Figure 3.2D). Co-infected mice had a larger fraction of PICV-
specific T cells that responded to the cross-reactive, subdominant NP205 epitope 
rather than NP38. Moreover, there was tremendous variation within the NP205-
specific response between individual co-infected mice. The proportional NP205-
specific response ranged from 0.0-23.8% of the PICV-specific CD8 T cells in 
PICV-immune mice, but in co-infected mice there was a greater range from 0.0-
79.4%. 
The LCMV-specific immunodominance hierarchy was also skewed in co-
immunized mice (Figure 3.2E). Co-infected mice had a higher proportion of 
NP396-specific T cells and a lower proportion of GP33/34-specific T cells 
compared to LCMV-immune mice. In contrast to the PICV-specific response, no 
difference was found in the NP205-specific responses between co-infected and 
LCMV-immune mice. It is important to note that whereas NP396- and GP33/34-
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specific responses are co-dominant in LCMV-immune mice, the proportion of 
NP396-specific cells is significantly (p<0.003) greater than the proportion of 
GP33/34-specific cells among co-infected mice. Collectively, there were 
proportional differences within both the LCMV- and PICV-specific responses of 
co-immunized mice compared to their single-immune counterparts, yet the cross-
reactive NP205 response was only increased within the PICV-specific 
immunodominance hierarchy. 
 
D. NP205-specific memory T cells mediated enhanced 
immunopathology in co-infected mice during PICV challenge.  
 
The cross-reactive NP205-specific response between LCMV and PICV 
mediates immune protection during sequential heterologous infections 
(LCMV+PICV or PICV+LCMV) (Brehm et al., 2002; Chen et al., 2012; Cornberg 
et al., 2006; Selin et al., 1998). However, this same cross-reactive response can 
also mediate immunopathology in PICV-immune mice challenged with PICV 
when there is an intervening LCMV infection (PICV+LCMV+PICV) (Chen et al., 
2012). We questioned if the increased cross-reactive response within the PICV-
specific hierarchy would correlate with enhanced immunopathology in co-infected 
mice during PICV challenge. Weight loss (Figure 3.3A) and severity of 
panniculitis (Figure 3.3C&E) after PICV challenge correlated with the proportion 
of memory NP205-specific CD8 T cells in the peripheral blood of co-immunized 
mice prior to challenge with PICV. By comparison, there was no correlation  
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between the proportion of non-cross-reactive NP38-specific memory cells and 
any measure of PICV-induced immunopathology (Figure 3.3B, D&F). To directly 
test whether the NP205-specific response was involved in induction of 
immunopathology, we utilized a LCMV variant that does not induce a NP205-
specific response. The LCMV variant virus (rL212A) harbors a leucine to alanine 
mutation at position 8, one of the MHC class I binding residues in this peptide 
(Chen et al., 2012). Use of this mutant negates the cross-reactive response 
between LCMV and PICV. Co-infection with the rL212A variant and wildtype 
PICV resulted in a similar variation in the immunodominance hierarchy as found 
with wildtype LCMV co-infection, suggesting that the cross-reactive response is 
not mediating this variability between individuals (Figure 3.2C). After PICV 
challenge, mice co-immunized with PICV and the rL212A variant underwent 
significantly less weight loss than the mice co-infected with PICV and wildtype 
LCMV (Figure 3.4A). Of note, weight loss in rL212A co-infected mice challenged 
with PICV mirrored that of the PICV-challenged, PICV-immune mice. rL212A co-
infection also prevented panniculitis and widespread necrosis of fat pads 
associated with PICV challenge of wildtype co-infected mice (Figure 3.4B-D). 
These results demonstrate that responses to the cross-reactive NP205-specific 
response mediated the increased immunopathology in co-infected mice upon 
PICV challenge. 
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E. Co-infected mice had a decreased number of LCMV virus-specific 
CD8 T cells after primary infection.  
In contrast to PICV challenge, T cell cross-reactivity did not play a major 
role in the enhancement of immunopathology in co-infected mice challenged with 
LCMV clone 13 (data not shown). We questioned whether there was a 
generalized defect in the LCMV-specific memory CD8 T cell response in co-
infected mice after primary infection. At the peak of the CD8 T cell response, the 
magnitude of the entire CD8 T cell response in LCMV-infected mice was 10-fold 
greater than that in PICV-infected mice (Figure 3.5A). The concurrent 
administration of PICV with LCMV caused a 4-fold reduction in the size of the 
LCMV-specific response compared to LCMV-infected mice. In contrast, there 
was no difference in the size of the PICV-specific response between PICV- and 
co-infected mice at day 8 post infection.   
In the memory phase, 8 weeks post infection, LCMV- and PICV-immune 
mice had more LCMV- or PICV-specific cells, respectively, compared to co-
infected mice (Figure 3.5B). These results show that LCMV and PICV co-
infection resulted in smaller memory pools specific to each virus. As the number 
of virus-specific CD8 T cells is known to correlate with protection (Cerwenka et 
al., 1999; Hamada et al., 2009; Zinkernagel and Welsh, 1976), this significant 
reduction in the size of the LCMV-specific memory response may be responsible 
for reduced viral clearance and enhanced immunopathology.  
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F. Co-infected mice had fewer LCMV-specific CD8 T cells with an 
effector phenotype during both the acute and memory phases after 
primary infection. 
 Because co-infected mice had fewer LCMV-specific memory cells (Figure 
3.5A&B), we assessed whether these cells would also have phenotypic 
differences consistent with altered differentiation. At the peak of a primary LCMV 
infection, up to 60% of the LCMV-epitope-specific effector cells became killer cell 
lectin-like receptor subfamily G member 1 (KLRG1)-positive and IL-7 receptor 
(IL7R/CD127)-negative (Figure 3.6A&B). This phenotype is indicative of short-
lived effector cells, which have a greater probability of dying during the 
contraction phase (Hand et al., 2007; Joshi et al., 2007). In co-infected mice, this 
population (KLRG1+IL-7R-) was significantly reduced, 12 and 16% amongst 
NP396- and GP33-tetramer reactive CD8 T cell populations, respectively, 
compared to LCMV-infected mice (Figure 3.6B). The frequency of LCMV-
specific CD8 T cells that were KLRG1-IL7R+ memory precursor effector cells 
was significantly higher in co-infected mice than their LCMV-single infected 
counterparts (Figure 3.6C). Interestingly, there was no difference in the 
differentiation of these two effector populations in PICV NP38-specific CD8 T 
cells between PICV- and co-infected mice (Figure 3.6A-C).  
 Co-immunized mice also had a less effector-like LCMV-specific CD8 T cell 
response in the memory phase. We measured tetramer-reactive LCMV-specific 
CD8 T cells for effector-like memory (CD62L lo KLRG1+IL7R-) and central-like 
memory (CD62L hi KLRG1- IL7R+) phenotypes (Figure 3.6D&E). The normal  
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LCMV-epitope-specific memory response consists of 20-30% effector-like 
memory cells (CD62L lo KLRG1+IL7R-) and ~60% central-like memory cells 
(CD62L hi KLRG1-IL7R+).  However, in the context of a co-infection central-like 
memory cell frequencies were increased by 15% and there was a coincident 6 
and 9% reduction in the frequency LCMV NP396- and GP33-specific effector-like 
memory CD8 T cells, respectively. Similar to the acute time point, in the memory 
phase there was no phenotypic differences in the PICV-NP38-specific cell 
populations between PICV- and co-immunized mice. We calculated the total 
number of CD8 T cells specific to LCMV immunodominant epitopes NP396 and 
GP33 with either a central- or effector-like memory phenotype. Interestingly, 
there was a significant 50% reduction in the number of effector-like memory cells 
(CD62L lo KLRG1+IL7R-) in co-infected mice, but no difference in the number of 
central-like memory cells (CD62L hi KLRG1- IL7R+) between co-immunized and 
LCMV-immune mice (Figure 3.6E&F). These data show that in co-infected mice 
a smaller proportion of LCMV NP396- and GP33-specific CD8 T cells have an 
effector-like phenotype at both the peak of the T cell response and in memory. 
 
G. Infectious LCMV load is similar in LCMV- and co-infected mice 
during primary infection. 
 
Decreased antigen load and shortened durations of antigen presentation 
can lead to a smaller effector T cell response (Badovinac et al., 2002; Kaech and 
Ahmed, 2001; Prlic et al., 2006; Schiemann et al., 2003; van Heijst et al., 2009). 
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Therefore, we examined whether LCMV antigen load was reduced in co-infected 
mice compared to LCMV-infected mice as a possible explanation for the reduced 
size of the LCMV response in co-infected mice. However, there was no 
difference in LCMV viral load in the spleen between LCMV- and co-infected mice 
on days 3, 5 or 7 after primary infection (Figure 3.7A). Viral load was highest in 
both groups on day 3. By day 5 both groups were controlling virus and by day 7 
and at day 15 LCMV was cleared below the limit of detection in both groups. 
These results show that there is no difference in LCMV viral load in the spleen 
where immune responses are being generated. 
 
H. Innate cytokine and chemokine production peaks earlier in PICV- 
and co-infected mice during primary infection. 
 
In addition to viral load, the cytokine milieu early during infection is an 
important factor in the shaping of virus-specific T cell responses (Cui and Kaech, 
2010; Curtsinger and Mescher, 2010; Welsh et al., 2012). Inflammatory cytokines, 
such as type I IFN, have been found to affect proliferation and differentiation of 
effector CD8 T cells during LCMV infection (Curtsinger and Mescher, 2010; 
Marshall et al., 2011; Welsh et al., 2012). We examined whether co-infection 
altered the kinetics or composition of the LCMV-induced cytokine environment.  
LCMV infection induced a strong type I IFN response that peaked 
between days 2 and 3 post-infection (Figure 3.7B) similar to previous studies  
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Figure 3.7. Early cytokine responses in co-­infected mice are significantly
different than in LCMV-­infected mice during primary infection. A. Splenic
viral load was determined by INT stained plaque assay in LCMV-­ and
co-­infected mice after primary infection. n=4-­5 mice/group. Data are representa-­
tive of two similar experiments. B. Functional type I IFN was measured in the
serum of LCMV-­, PICV-­ and co-­infected mice by bioassay. n=3-­14 mice/group.
Data are pooled from 4 similar experiments. C. MCP-­1 and IL-­6 levels were
determined in the serum by cytometric bead array. n=15 mice/group from 3
pooled experiments.
A. B.
C. D.
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(Hinson et al., 2010; Li et al., 2013; Zuniga et al., 2008). PICV triggered a rapid 
type I IFN response, which peaked 24 hours after infection and then rapidly 
tapered off. Interestingly, the kinetics of type I IFN induction in co-infected mice 
mirrored that of PICV-infected mice and was different than that of LCMV-infected 
mice at 24 and 72 hours post infection.  
There were also differences in other inflammatory proteins at 24 hours 
post infection (Figure 3.7C&D). While levels of IL-6 and MCP-1 were low 24 
hours after an LCMV infection, they were greater than 5-fold higher in PICV- and 
co-infected mice, which both had similar levels of cytokines production (Figure 
3.7C&D). At 48 and 72 hours, both MCP-1 and IL-6 were low in all groups with 
no differences. During primary infection within co-infected mice the PICV-induced 
innate response is present, not the LCMV-induced response, suggesting that this 
altered cytokine environment may be altering proliferation and differentiation of 
the LCMV-specific CD8 T cells.  
 
Chapter Summary 
 
In this chapter we show that co-immunization with LCMV and PICV 
resulted in decreased immune protection and enhanced immunopathology after 
challenge with either virus. This data would suggest that during co-infection the 
developing immune responses are less efficient at clearing reinfection. Persisting 
virus lingering in the peripheral tissues may cause recruitment of effector T cells 
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and the development of immunopathology. After primary co-infection there were 
several differences in the CD8 T cell responses compared to mice infected with a 
single virus. Co-infected mice had increased variability in the CD8 T cell 
immunodominance hierarchies and a dramatic decrease in the overall size of the 
LCMV-specific CD8 T cell response. This variability in the immunodominance 
hierarchies of co-infected mice resulted in an enhanced cross-reactive response 
in some mice that mediated enhanced immune-mediated fat pad pathology 
during PICV challenge. During an LCMV challenge, higher viral loads and 
increased liver pathology in co-infected mice was associated with a reduction in 
LCMV-specific CD8 T cells memory cells, specifically cells with an effector 
memory-like phenotype. These data suggest that the magnitude and character of 
memory CD8 T cell responses generated in response to simultaneous co-
infections differed substantially from those induced by single immunization.  
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Chapter 4: Clonal exhaustion as a mechanism to protect 
against severe immunopathology and death from an 
overwhelming CD8 T cell response. 
 
Because of the ability of viruses to infect cells, peptide cleavage products 
from many of their encoded proteins get incorporated into nascent class I MHC 
molecules and get presented at the cell surface to CD8 T cells bearing TCR 
specific for the peptide-MHC complex. As a result, viral infections frequently 
stimulate very potent class I-restricted CD8 T cell responses capable of perforin- 
or FasL-dependent cytotoxicity, as well as IFNγ and TNFα production. Indeed, 
CD8 T cells are essential regulators of viral infection, playing important roles in 
the clearance of virus-infected cells and sometimes causing damaging 
immunopathology (Doherty and Zinkernagel, 1974; Gilden et al., 1972a; 1972b; 
Nathanson and Cole, 1971). The relative balance between protective immunity 
and immunopathology often determines the fate of the virus-infected host (Selin 
et al., 2011). Classic examples are that of LCMV, where the same clone of T 
cells responsible for viral clearance can mediate a severe leptomeningitis if the 
virus is replicating in the brain (Doherty and Zinkernagel, 1974; Gilden et al., 
1972b). The pathology that is induced by T cells during an acute infection most 
likely results from the inflammatory conditions brought about by the presence of 
high numbers of T cells lysing infected tissues via perforin and FasL, producing 
pro-inflammatory cytokines, including TNF, and chemokines which recruit even 
more cells. Important factors in how rapidly virus is cleared include the initial viral 
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load, rate of viral replication and the efficiency of the activated antigen-specific T 
cells.  To understand how these factors mediate immunopathology mice were 
inoculated with three different doses of LCMV clone 13. Due to mutations LCMV 
clone 13 can systemically infect mice and replicate faster than the Armstrong 
strain from which it was isolated (Matloubian et al., 1990; Salvato et al., 1991). 
We hypothesize that infection with lower doses of virus that are easily controlled 
by the T cell response, there will be little immunopathology, but as the viral load 
increases there may be a shift in the balance between antigen load and 
efficiency of the T cell response leading to enhanced pathology until the T cell 
response becomes exhausted.  
 
A. Medium dose LCMV clone 13 led to increased immunopathology 
and mortality.  
 
B6 mice were infected intravenously with low dose (2 X 104 PFU), medium 
dose (2 X 105 PFU) and high dose (2 x 106 PFU) LCMV clone 13 iv There was 
significantly higher mortality in the medium dose group, with only 25% of mice 
surviving at Day 13 (Figure 4.1A). Both the medium and high dose groups 
experienced a rapid and significant weight loss of greater than 20% beginning at 
day 6 after infection, with the high dose group starting to recover after day 10 
while the medium dose group not recovering even by day 13 (Figure 4.1B&C).  
All of the mice that survived the medium dose infection were persistently infected  
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with LCMV, similar to the high dose group. The dramatic immunopathology was 
mediated by the T cell response, as demonstrated by the fact that TCRβ KO 
mice infected with the medium dose did not have any significant weight loss or 
death, in contrast to WT controls (Figure 4.1A&C). The TCRβ KO mice had a 
slightly higher viral load than the WT controls and yet did not have pathology 
(log10 PFU/spleen: B6 5.7±0.13 SEM; TCRβ KO 6.3±0.13; n=5/group; p<.02). 
The CD8 T cells were the major T cell population involved in mediating this effect, 
as demonstrated by depletion of CD8 T cells with mAb. B6 mice depleted of CD8 
T cells prior to infection with the medium dose of LCMV also had significantly 
less weight loss and decreased mortality than the WT controls (Figure 4.1C) 
without a significant difference in viral load in the spleen (log10 PFU/spleen: B6 
4.9±0.5 SEM; anti-CD8 tx 5.3±0.07 n=5-9/group).    
 
B. Medium dose LCMV clone 13 infection caused a partial clonal 
exhaustion of the LCMV-specific CD8 T cell response.  
 
Persistent infection leads to a disruption of the normal immunodominance 
hierarchy and function of CD8 T-cell responses during high dose LCMV clone 13 
infection (Wherry, 2011; Wherry et al., 2003a). CD8 T-cell functional impairment 
occurs in a hierarchical fashion in chronically infected mice. Production of IL-2 
and the ability to lyse target cells in vitro are the first functions compromised, 
followed by the ability to make TNFα, while IFNγ production is most resistant to 
functional exhaustion. Antigen appears to be the driving force for this loss of 
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function, since a strong correlation exists between the viral load and the level of 
exhaustion (Mueller and Ahmed, 2009). Epitopes presented at higher levels in 
vivo result in physical deletion, such as NP396, while those presented at lower 
levels, such as GP33 and NP205, induce functional exhaustion. Data would 
suggest that antigen levels drive the hierarchical loss of different CD8 T cell 
effector functions during chronic infection, leading to distinct stages of functional 
impairment and eventually to physical deletion of virus-specific T cells. Thus, the 
functionality of the epitope–specific CD8 T cells in the three groups of mice was 
determined by intracellular cytokine staining (ICS) for the presence of IFNγ- 
and/or TNFα-producing cells and calculating the ratio of IFNγ+TNFα+/IFNγ+ cells 
at days 7 and 13 post infection. The high dose clone 13-infected mice had 
significant exhaustion of NP396-, GP33 and NP205-specific responses, as 
defined by loss of the double positive IFNγ/TNFα producing cells by day 13 
(Figure 4.2A-C). The medium dose mice had evidence of only partial exhaustion 
of their CD8 T cell response in this same time frame. They had significantly more 
of the double positive IFNγ/TNFα producing T cells by all three epitope-specific 
CD8 T cell responses on day 7 and day 13 than did high dose-infected mice, 
although significantly less than the low dose group. Expression of the prototypic 
cell surface marker of exhaustion, PD-1 (Barber et al., 2006; Sharpe et al., 2007; 
Wherry, 2011) on epitope-specific CD8 T cells at day 10 post infection was 
intermediate in the medium dose as compared to the high and low dose groups, 
consistent with partial exhaustion (Figure 4.2D). These results would suggest  
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Figure 4.2. Partial clonal exhaustion in the LCMV clone 13 medium dose infected mice.
The functionality of the epitope–specific CD8 T cells in the three groups of mice was deter-­
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mice/group). D. CD8 expression of cell surface marker PD-­1 on epitope-­specific cells at day
10 post infection was intermediate in the medium dose as compared to the high and low dose
groups, consistent with partial exhaustion. This is representative of two similar experiments.
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that at the medium dose of virus the viral load is high enough to result in a partial 
exhaustion phenotype (Wherry et al., 2003b) and these sub-optimally functioning 
CD8 T cells are able to mediate the induction of severe immunopathology 
leading to death. 
 
C. Mice infected with medium dose LCMV clone 13 had increased 
lung and liver immunopathology 
  
The lung immunopathology in the surviving medium dose mice as 
assessed by histology demonstrated severe pulmonary edema and interstitial 
infiltrates with consolidation, enhanced bronchus associated tissue (BALT), and 
necrotizing bronchiolitis (Figure 4.3A). Using our established method of scoring 
lung pathology (Chen et al., 2003; Wlodarczyk et al., 2013) the medium dose 
mice had significantly more pathology than either the high and low dose mice or 
the TCRβ KO and the CD8 T cell depleted mice, all of which had minimal 
interstitial infiltrates, consistent with this being CD8 T cell-mediated pathology 
(Figure 4.4A). The livers of the medium dose mice also had significantly 
increased liver pathology (Figure 4.3B) as demonstrated by increased liver 
enzyme, alanine aminotransferase (ALT) (Figure 4.4B), in their serum as 
compared to low dose, TCRβ KO, and CD8 T cell-depleted mice. Histological 
sections of the liver showed serious bridging necrosis in the medium dose mice 
(Figure 4.3B), while the high and low dose mice as well as the TCRβ KO and 
CD8 depleted medium dose mice had only periportal and sinusoidal inflammatory  
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infiltrates. The architecture of lymph nodes of mice infected with LCMV clone 13 
was found to be essentially normal at all three doses. In other words, there was 
recruitment of lymphocytes in T cell zones and increased numbers of germinal 
centers with infection, but there was no overall destruction or necrosis of the 
lymphoid structures as has been reported for high dose LCMV-WE infection 
(Ludewig et al., 1999; Zinkernagel et al., 1999) (data not shown). 
 
Chapter Summary 
 
Using three different inocula of LCMV clone 13 these results showed completely 
different outcomes. Mice given low doses of LCMV clone 13 developed a strong 
effector CD8 T cell response, which cleared the virus. If the viral load becomes 
high very rapidly it can result in clonal exhaustion of the T cell response and viral 
persistence associated with little immunopathology. However, if the mice were 
given an intermediate dose of LCMV clone 13, the immune response was able to 
develop and exhausted more slowly, leaving time for massive collateral damage 
and resulting in increased mortality with severe lung and liver necrosis.  
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Chapter 5: Neonates are highly susceptible to T cell 
mediated immunopathology and mortality after LCMV 
infection 
 
Both neonatal humans and mice are found to be highly susceptible to 
increased mortality after infection. Since, neonates lack any protective 
immunological memory they receive many vaccines. There are numerous 
differences in the innate, humoral and cellular arms of the neonatal immune 
system and these differences understandably result in altered immune responses 
to both vaccination and infections (Figure 1.6).  
 Newborn mice infected at day 1 of age with LCMV undergo central 
tolerance and deletion of their LCMV-specific T cells, which leads to persistent 
live-long infection (Hotchin and Cinits, 1958; Volkert and Larsen, 1964). Only one 
study has been done to examine T cell responses to LCMV infection in older 
neonates (Belnoue et al., 2007). Using day 14 of age Balb/c infants they found 
that LCMV WE strain was cleared with delayed kinetics and little 
immunopathology (Belnoue et al., 2007). To understand how the differences in 
the innate and adaptive arms of the immune system would alter CD8 T cell 
priming we proposed to study the day 7 neonatal mice during infection with the 
nonlytic virus LCMV. This age was chosen as the newborn mouse is 
immunologically much more immature than a human newborn and is at greater 
risk of tolerance induction. In fact at day 7 the mouse immune system is more 
similar to human newborns, including similar IFNγ production to BCG and similar 
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TCR repertoires (Adkins et al., 2004). Throughout the remainder of this thesis the 
term “neonatal mouse” refers to day 7 of age, unless otherwise stated. We 
hypothesized that day 7 B6 neonates will have altered viral clearance and 
pathology as compared to adults upon LCMV (strain Armstrong) infection due to 
there decreased innate and adaptive responses.  
A. Day 7 neonates were susceptible to T cell-mediated 
immunopathology 
 
Adult B6 mice infected with the normal dose of LCMV Armstrong 5x104 
PFU ip clear virus within one week, develop a strong CD8 T cell response and 
have minimal immunopathology. The Belnoue et al. study (Belnoue et al., 2007) 
that infected infant, day 14 of age, Balb/c mice with LCMV WE found a dose-
dependent IFNγ response of LCMV-specific CD8 T cells, with a 30 PFU infection 
inducing a lower response than 100 PFU. As LCMV Armstrong, unlike the WE 
strain, does not cause immunopathology or clonal exhaustion in adult B6 mice 
we began our studies with a slightly higher dose than the previous study. After 
infection with 500 PFU of LCMV Armstrong ip in day 7 of age neonates, 
surprisingly over 80% of pups succumbed to infection (Figure 5.1A). When pups 
were infected with a log less virus, 50 PFU, 80% of pups still died. At 5 PFU of 
LCMV Armstrong there was a significant increase in survival, with only 64% of 
pups dying. However, the kinetics of mortality in pups infected with 500 PFU, 50 
PFU, or 5 PFU were the same with mice succumbing to infection between days  
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Figure 5.1. Neonatal mice developed severe immunopathology and death after LCMV
infection. A. Neonatal mice at day 7 of age were infected with 5, 50 or 500 PFU of LCMV
Armstrong ip. Survival was assessed to day 14 post infection. n=7-­16 mice/group from two
similar experiments. B. Lung (i & ii) and liver (iii & iv) sections were stained with H&E from
naïve day 12 of age neonates (i & iii) and neonates infected with LCMV and harvested at day
9 of infection (ii & iv). Representative organs from 4 similar experiments.
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7-11 post infection (Figure 5.1A). Histology of lungs and livers in surviving 
infected neonates displayed enhanced mononuclear infiltrates at day 9 post 
infection, the time when the majority of the neonates were dying and also the 
peak of the CD8 T cell response in adult LCMV infection  (Figure 5.1B). The 
death rate and immunopathology of vital organs found in neonates infected with 
low doses of LCMV Armstrong resembled that observed in adult male mice 
infected with an intermediate dose of the more virulent LCMV clone 13 when 
given iv (Waggoner et al., 2012) (Chapter 4). An intermediate dose of LCMV 
clone 13 iv resulted in 75% mortality, which appeared to be mediated by T cell 
responses, as TCRβ ko mice and mice depleted of CD8 T cells resulted in 100% 
survival of mice (Figure 4.1A). With this intermediate dose of LCMV clone 13 
there was also severe liver and lung pathology in the surviving mice (Figure 4.3). 
We initially questioned if neonates were dying of a similar mechanism as the 
adult mice receiving an intermediate dose of LCMV clone 13. When TCRβ ko 
neonates were infected with 50 PFU of LCMV Armstrong they had 100% survival 
as compared to wildtype neonates, which had only ~20% survival (Figure 5.2A). 
To further examine which subset of T cells was causing death, pups were 
depleted of either CD4 or CD8 T cells (Figure 5.2B). Pups depleted of CD4 T 
cells showed no difference in either the kinetics or the frequency of mortality 
(Figure 5.2B). Depletion of CD8 T cells significantly reduced mortality to only 
55% (Figure 5.2B). Furthermore, the death found in neonates was not due to 
viral load, as TCRβ ko mice at day 9 post infection had 6 logs of virus in kidney,  
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Figure 5.2. Neonates died from T cell-­mediated immunopathology. A. ?? ??? ????
ko neonates were infected with 50 PFU of LCMV ip and survival was monitored until day
14 post infection. Data are from two similar experiments. wt mice were also shown in
figure 5.1 A. B. ?? ???????? ???????? ???? ? ??? ?? ???? ?? ???? ??????? ???? ???? ??
either anti-­CD8, anti-­CD4 or IgG control on days 0, 4 and 8 post infection. C. Viral load in
???? ???????? ??? ?????????? ?? ??????? ???? ??? ????? ?? ??? ? ???? ????????? ??
plaque assay. Data are from two similar experiments.
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lung and liver, and 100% of these mice survived until the end of the experiment 
at day 14 post infection (Figure 5.2C). We found these results surprising 
because neonates are known to have poor inflammatory responses and smaller 
T and B cell pools compared to adults (Ridge et al., 1996; Siegrist and Aspinall, 
2009). We questioned how much smaller the CD4 and CD8 T cell responses 
were in uninfected day 7 neonates as compared to 6 week old adult mice.  At 1 
week of age uninfected mice had reduced frequencies and total numbers of CD4 
and CD8 T cells compared to 6 week old adults (Figure 5.3 A-D). CD4 T cell 
frequencies are on average 1.8% in 1 week old neonates and expand 12-fold by 
week 6 of age when mice are considered to be adults (Figure 5.3C), similar to 
previous findings (Hassett et al., 1997). The CD8 T cell population consists of 
only 1% of the spleen at day 7 and increases to 13% by week 6 (Figure 5.3A). 
By total number there is a 38-fold reduction in CD8 T cells in spleens of neonatal 
mice (Figure 5.3B). Therefore, it was surprising that after LCMV infection 
neonates could mount a CD8 T cell response strong enough to mediate death.  
B. Neonates developed strong CD8 T cell responses with altered 
immunodominance hierarchies 
 
Immunopathology in the adult mice infected with the intermediate dose of 
LCMV clone 13 iv was found to be due to a partial, rather than complete, clonal 
exhaustion of the CD8 T cell response. Complete exhaustion, as seen in adult 
mice infected with high dose LCMV clone 13 iv, resulted in little pathology and 
persistent infection (Figure 4.1-4.4). At this high dose, high antigen load causes 
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Figure 5.3 Naive neonates had decreased frequencies and total numbers of CD4
and CD8 T cells. At 1, 2, 3, 4, 5 and 6 week(s) of age the frequency (A & C) and total
number (B & D) of splenic CD8 (A & B) and CD4 (C & D) T cells were examined by
surface staining in naïve mice. Data are from 1-­2 similar experiments with at least 3
mice/group.
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overstimulation of the CD8 T cells leading to a stepwise loss of function ending in 
apoptosis. At the intermediate dose antigen load is high enough to induce a 
partial clonal exhaustion with a decrease of the high affinity LCMV-specific 
response NP396 (Figure 4.2). This causes a skewing of the immunodominance 
hierarchy resulting in a dominant GP33-specific response with decreased 
cytotoxicity and TNFα production by these cells, but still strong IFNγ production 
(Figure 5.4A). Due to the similar mortality rates we questioned if neonates were 
also undergoing a partial clonal exhaustion.  
 Examination of the T cell response in neonates at day 14 post infection 
showed a similar change in the immunodominance hierarchy, as intermediate 
LCMV clone 13 in adults, with a loss of NP396-specific CD8 T cells (Figure 
5.4B). To determine functionality of this population we examined cytokine 
production and found that as opposed to the adult model of intermediate LCMV 
clone 13, neonatal CD8 T cells were able to produce both IFNγ and TNFα upon 
restimulation at both day 9 and 14 post infection (Figure 5.4C). Another indicator 
of exhaustion is the prolonged expression of the CD28-family inhibitory molecule, 
PD-1, on the surface of activated CD8 T cells. The peak of PD-1 expression on 
LCMV-specific CD8 T cells in adult mice was prior to day 9, after which PD-1 is 
downregulated during low dose LCMV Armstrong infection, as previously 
reported (Figure 5.4D) (Barber et al., 2006). Similar to adults PD-1 expression 
on activated CD8 T cells was downregulated by day 9 post infection. By day 14 
post infection LCMV-specific CD8 T cells in neonates were PD-1 negative. These  
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Figure 5.4 Neonates had altered CD8 T cell immunodominance hierarchies, but
were not undergoing clonal exhaustion. A. Adult mice were immunized with either
LCMV Armstrong or an intermediate dose of LCMV clone 13 and harvested on day 9 or
day 14 post infection, respectively. Immunodominance hierarchies were determined by
IFNg production by CD44 hi CD8 T cells after peptide stimulation. Data are from 5-­7
mice in 2-­3 similar experiments. B. Neonates were infected with 5, 50 or 500 PFU of
LCMV Armstrong and immunodominance hierarchies were determined on day 14 post
infection. n= 2-­4 mice/group. Data are representative of 1-­3 experiments. C. Represen-­
tative facs plots of IFNg vs TNFa gated on CD8+ CD44hi splenocytes in an adult
infected with LCMV Armstrong at day 9 post infection and a neonate infected with 500
PFU of LCMV Armstrong at day 9 and 14 post infection. Data are representative of 2-­4
experiments. D. Representative facs plots of IFNg vs PD-­1 gated on CD8+ CD44hi
splenocytes in an adult infected with LCMV Armstrong at day 9 post infection and a
neonate infected with 500 PFU of LCMV Armstrong at day 9 and 14 post infection. Data
are representative of 2-­4 experiemnts.
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data would collectively suggest that neonatal CD8 T cells were not undergoing 
partial clonal exhaustion due to high antigen load.  
As clonal exhaustion is a mechanism for protection from potentially lethal 
infections (Chapter 4) we questioned if neonates were unable to clonally exhaust. 
Neonates were infected with an adult dose of high dose of LCMV clone 13 ip and 
monitored for death. These pups all survived until day 14 post infection and 
examination of CD8 T cell responses showed complete clonal exhaustion by loss 
of IFNγ and TNFα production (Figure 5.5). These data suggest that at very high 
infecting doses with a virus known to induce clonal exhaustion, LCMV clone 13, 
neonates can exhaust, and as in adult mice this does not happen at low doses of 
LCMV Armstrong.  
 
C. Neonates had protracted viral load and delayed LCMV-­‐specific CD8 T cell
responses
Since neonatal mice infected with low doses of virus were not becoming 
partially clonally exhausted like the medium dose LCMV clone 13 adult model, 
we questioned when they cleared virus and how this compared to adult mice. In 
adult mice infected with LCMV Armstrong, although virus replicates 
predominantly in the spleen and lymph nodes it has been reported to infect other 
organs including the liver, kidney and fat pads (Wherry et al., 2003a) (data not 
shown). In these studies in adult mice in the kidneys LCMV replicated to low 
levels and peaked with ~4 logs of virus on day 4 post infection after which 
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viral load decreased and was cleared by day 15. Virus is cleared from spleen and 
liver by day 8 with a peak in viral load at day 4 (Wherry et al., 2003a). In neonatal 
mice infected with either 5 or 50 PFU of LCMV the clearance of virus was 
protracted compared to adults (Figure 5.6 A&B). In neonatal mice LCMV 
replicated in all organs examined: the kidney, spleen, fat pads, lung and liver 
peaking at ~5 logs, one log higher than reported in adult mice (Figure 5.6 A&B 
and data not shown). In the kidney of neonates infected with 5 or 50 PFU of 
LCMV the viral load peaked days 5-9, rather than on day 4 as seen in adult mice, 
after which viral loads decreased. The majority of neonates infected with 5 PFU 
cleared virus in the kidney by day 14 post infection, but neonates infected with 50 
PFU, even though viral load was decreased, still had ~3 logs of virus at day 14 
post infection (Figure 5.6A). In the liver the viral load peaked at day 6-7 post 
infection, rather than day 4, and declined thereafter, but was not cleared by day 8 
as in adults (Figure 5.6B). By day 14 post infection, virus was cleared in all 
organs in the majority of neonates infected with either 5 or 50 PFU of LCMV 
(Figure 5.6B). These data show that viral load was protracted in neonatal mice, 
even during infection with very low doses of LCMV Armstrong.  
 In adult mice the peak of the CD8 T cell response, which is at day 9 post 
infection, correlated with the clearance of virus on days 7-8 (Wherry et al., 
2003a). We questioned if the peak of the CD8 T cell response in neonates would 
be delayed due to their protracted viral clearance. The frequency of LCMV- 
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specific CD8 T cells peaked later in neonates than in adults during LCMV 
infection (Figure 5.6C). In adults the frequency of LCMV-specific CD8 T cells 
increased between days 5-9 to make up more than 30% of the CD8 T cell 
response (Figure 5.6C). In neonates the LCMV-specific cells expanded to a 
similar frequency, but this did not occur until after day 9, with the peak of the 
response being at day 14. By total number the LCMV-specific CD8 T cell 
response in adult mice peaked at day 8 instead of day 9, and this may be due to 
the contraction phase initiating on day 9 post infection (Figure 5.6D). In neonates 
there were significantly lower numbers of LCMV-specific CD8 T cells throughout 
infection compared with adult mice (Figure 5.6D). In neonates there was an 
increase in the number of LCMV-specific cells between day 9 to 14 post infection, 
but the number of cells did not contract after this time point. The number of 
LCMV-specific CD8 T cells was still high at day 20 post infection (Figure 5.6D). 
This may be due to residual virus in some mice or contraction may occur 
differently in a maturing mouse. These data show that the kinetics of both viral 
clearance and LCMV-specific CD8 T cells are delayed in neonates.   
 
D. Neonates had replicating virus and LCMV-specific CD8 T cells in 
their brains and mortality was perforin-mediated 
 
Since neonatal mice infected with LCMV Armstrong were not undergoing 
partial clonal exhaustion like the intermediate dose adult mice infected with 
LCMV clone 13, I looked for other models of LCMV that induced mortality. 
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Studies from mice infected with LCMV intracranially found adult mice succumb to 
T cell-mediated death starting at day 6 post infection (Cole et al., 1971; 1972; 
Gilden et al., 1972b; Hotchin, 1962) I questioned whether virus was replicating in 
the brains of neonates and infiltrating T cells were inducing immunopathology 
leading to death. Low levels of virus were found in the brain on day 5 post 
infection of neonates, by day 7 viral load had increased and by day 9 post 
infection there were 4 logs of virus in the brain (Figure 5.7A). LCMV Armstrong 
infection in adult mice do not normally gain access to the mature CNS. However, 
one study did report that very minimal virus could be found in the brain of some 
LCMV Armstrong-infected adult mice, but this could be due to contaminating 
peripheral blood (Wherry et al., 2003a). In our study mice were perfused during 
harvest to exclude this possibility. Viral load in the brain was high during the time 
when neonates were dying during infection. Since CD8 T cells were mediating 
the mortality of neonates infected with LCMV we questioned if T cells were 
infiltrating the CNS to clear virus and inducing death. Activated CD8 T cells were 
found in the brain of neonates on day 9 post infection (Figure 5.7B). These CD8 
T cells were found to be antigen specific responding to stimulation in an ICS 
assay with the epitopes NP396 and GP33 with IFNγ production (Figure 5.7B). 
Infiltration of CD8 T cells into the CNS may be playing a major role in the death 
of neonates during LCMV infection. 
In the intracranial model of LCMV infection in adult mice CD8 T cells are 
essential for lethal disease  
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Figure 5.7. Neonates had virus replicating and LCMV-­specific CD8 T cells in their brains and
were dying from a perforin-­dependent mechanism. A. Neonates were infected with 50 PFU of
LCMV Armstrong ip and the viral load in their brain was determined on day 5, 7 and 9 post infec-­
tion. The viral load of adult mice infected with 5x104 PFU of LCMV Armstrong was determined on
day 9 post infection. neonates n=4-­5 mice/group. adult n=2 mice at day 9 only. Data are from two
similar experiments. B. Representative facs plots for IFNg production by CD8 T cells in response
to peptide stimlation was examined in both the spleen and brain on day 9 post infection of neonatal
mice. Representative from two similar experiments. C. wt and perforin ko neonates were infected
with 5 PFU of LCMV armstrong ip and survival was monitored until day 14 post infection. Data are
from two similar experiments. wt mice are also shown in figure 5.1 A.
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(Cole et al., 1972; Doherty and Zinkernagel, 1974; Nansen et al., 1998; Storm et 
al., 2006). However, the direct cytotoxic functions of CD8 T cells have been 
found to not be required for mortality as the release of chemokines can still 
attract monocytes and neutrophils into the CNS and induce death (Kim et al., 
2009). In order to determine which functions of CD8 T cells were required for T 
cells to mediate mortality in neonatal mice we used a number of genetically 
modified mouse models. T cells have several cytokine and cytolytic functions that 
can mediate cell death and thus immunopathology. Fas-Fas ligand (FasL) 
interactions can induce cell death via caspase 8 activation. Pups lacking FasL, 
infected with 5 PFU of LCMV showed no difference in the kinetics of death or the 
development of immunopathology (data not shown). Likewise, when FasL 
deficient pups were treated with anti-IFNγ and soluble TNF receptor (etanercept) 
to block cytokine signaling there were no differences in mortality (data not 
shown) indicating Fas-FasL, IFNγ and soluble TNF do not play a major role in 
mortality in neonates infected with LCMV. CD8 T cells can also lyse virus-
infected cells directly by cytolytic properties. CD8 T cells contain perforin and 
granzymes. These enzymes are released within close proximity to a target cell 
and induce pores in the cellular membrane and activate caspase 3- and 7-
mediated apoptosis. We questioned if T cell-mediated immunopathology would 
be blocked if pups lacked perforin. Perforin KO pups were infected with a low 
dose of 5 PFU of LCMV and had 100% survival (Figure 5.7C). These data 
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suggest that in neonates CD8 T cells mediated severe immunopathology that 
resulted in death in the majority of pups through perforin-mediated lysis of cells.  
D. Maternal antibody protected neonates from death by mediating 
faster viral clearance 
 
Previous studies have found that neonates from LCMV-immune mothers 
can mediate protection from lethal infections (Baldridge and Buchmeier, 1992). 
LCMV-immune mothers could protect day 10 of age pups from a lethal 
intracranial infection. We questioned if passive immunity would also be a method 
to increase survival of day 7 neonates infected with LCMV Armstrong. Female 
mice were immunized with LCMV Armstrong between 6-8 weeks of age 
considered immune 6 weeks post infection, after which they were used for 
breeding. Neonates infected with 50 or 500 PFU of LCMV Armstrong were 
completely protected from death when mice were followed until day 14 post 
infection (Figure 5.8A) and had minimal lung and liver infiltrates (Figure 5.8B). 
Neonates from LCMV-immune mothers cleared virus from the kidneys by day 9 
post infection, while neonates from naïve mothers still had ~3 logs of virus at day 
14 post infection (Figure 5.8C &D). These data suggest that passive immunity 
could control viral replication early in infection, possibly compensating for the 
immature innate immune system, allowing the neonatal CD8 T cell response to 
control infection without inducing massive collateral damage.  
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Figure 5.8 Passive immunity protected neonates by mediating faster viral clearance. Neonates from
naïve or LCMV-­immune mothers were infected with 50 or 500 PFU of LCMV Armstrong ip. A. Mortality was
monitored until day 14 post infection. Data are from two similar experiments. B. Lung (i & ii) and liver (iii & iv)
sections were stained with H&E on day 14 post infection from neonates infected with 500 PFU of LCMV Arm-­
strong ip from naïve (i & iii) and LCMV-­immune (ii & iv) mothers. Sections are representative of two similar
experiments. C. Viral load was determined in the kidney on various days post infection from neonates with
naïve or LCMV-­immune mothers infected with 50 PFU of LCMV. n=4-­5 mice/group. Data are from 2 similar
experiments. D. CD8 T cell immunodominance hierarchies were examined by IFNg production after peptide
stimulation on day 14 post infection with 50 PFU LCMV from neonates with naïve or LCMV-­immune mothers.
n=3-­9 mice/group. Neonates from naive mothers are also shown in figure 5.4B. Data are representative of 3
similar experiments.
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Studies have found that maternal antibody blocked the development of cellular 
and humoral responses to the live-attenuated measles vaccine (Premenko-
Lanier et al., 2006). Normally, the measles vaccine is administered at 9 months 
of age. However, Peter Aaby’s group showed that an additional earlier 
vaccination at 4.5 months, during the presence of maternal antibody, enhanced 
survival (Martins et al., 2008). We questioned if LCMV was cleared in neonates 
from LCMV-immune mothers too quickly and not allowing for the development of 
a CD8 T cell response. At day 14 post infection CD8 T cell immunodominance 
hierarchies were similar in the neonates from LCMV-immune mothers and naïve 
mothers both in frequency of responses and both had the low NP396-specific 
CD8 T cell response shown earlier (Figure 5.8D).    
 
E. Neonates had altered naïve Vβ repertoires and highly variable 
antigen-specific Vβ usage  
We questioned at what age does the LCMV-specific immunodominance 
hierarchy of a young mouse resemble that of an adult. To compare to the day 7 
neonate, mice were infected at day 12, 18, 20 and 22 of age and 
immunodominance hierarchies were examined at day 9 post infection. 
Interestingly, mortality was only found in mice infected at day 7 of age (data not 
shown). The decreased NP396-specific population was found in mice infected at 
day 12, 18 and 20, but at day 22 there was a shift in dominance and the NP396-
specific response is greater than the GP33-specific response by both frequency  
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and proportion (Figure 5.9A&B).  These data would suggest there is a change 
that occurs in the immune responses of mice at three weeks of age that leads to 
an increased NP396-specific response. I questioned if there was any evidence 
that the limited TCR repertoire, due to delayed expression of TdT, at day 7 of age 
may be mediating this change over time in the NP396-specific response. I found 
that there were significant differences in both CD4 and CD8 T cell Vβ repertoires 
in B6 neonates. In neonatal uninfected mice in CD8 T cells there were 
significantly decreased frequencies of Vβ 5.1/2, 8.1/2, 8.3, 9 and 10 families and 
increased frequencies of Vβ 11 and 13 (Figure 5.10A). The CD4 T cell repertoire 
of neonates also had decreases in the frequency of Vβ 8.1/2, 8.3 and 10 families 
and increases in the Vβ 11 suggesting that there were major differences in these 
Vβ families between neonates and adults (Figure 5.10B). There were also 
increases in the Vβ 6 and 12 CD4 T cell populations in neonates (Figure 5.10B). 
These numerous differences in Vβ repertoire distribution in neonates suggest 
that neonates would also show different Vβ responses for antigen-specific 
populations.     
In adult mice infected with LCMV Armstrong the Vβ repertoire of the 
NP396-specific population includes a dominant public Vβ 8.1/2 usage in all mice 
followed by subdominant usage of Vβ 6, 9, 12 and 13 (Figure 5.10C) (Blattman 
et al., 2000). There is variation, or private specificity, between individuals on the 
subdominant Vβ responses (Blattman et al., 2000). The Vβ repertoire of NP396-
specific cells was found to be significantly different than in adults, and there was  
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a high degree of variability, or private specificity, between individual neonates, a 
finding which did not occur in adults (Figure 5.10C). For example, one pup had 
co-dominance of Vβ usage of 4, 10 and 12, whereas another pup had a more 
monoclonal response with only a Vβ 9 usage (Figure 5.10C). This variability 
between individuals demonstrates increased private specificity of the T cell 
repertoires in neonatal mice compared to adults. Even though neonates are 
genetically identical they have different random insertions in the CDR3 region, 
thereby causing unique TCR repertoires in each mouse, known as private 
specificity.  
The variability in the TCR repertoire is due in part to the enzyme TdT, 
which introduces random nucleotides into the CDR3 region during T cell 
development. In mice TdT expression in the thymus occurs between days 4 to 5 
with longer CDR3 regions being detected in single positive thymocytes by day 8 
of age (Bogue et al., 1991). I found that naïve adult TdT ko B6 mice had an 
altered CD8 T cell Vβ repertoire distribution (Figure 5.11A). TdT ko mice had an 
increased usage of Vβ 8.1/2 and 8.3 and an decreased usage of Vβ5.1/2. The 
decreased usage of Vβ5.1/2 was also found in naïve day 7 neonates, but 
neonates had a reduction in the Vβ usage for Vβ 8.1/2 and 8.3 (Figure 5.10A). 
After LCMV infection adult TdT ko mice developed altered immunodominance 
hierarchies as measured by both frequency and proportional data (Figure 
5.11B&C). Compared to wildtype adult mice, TdT ko adult mice had a significant 
reduction in the frequency of not only NP396-specific cells, but also GP33-  
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specific cells. There were no differences in GP276- or NP205-specific cells 
(Figure 5.11B). By proportion, TdT ko mice had a significant reduction in NP396-
specific T cells with no difference in the GP33-specific population (Figure 5.11C). 
Interestingly, the subdominant epitopes, GP276 and NP205, made up a greater 
proportion of the response in TdT ko mice compared with wildtype adult mice 
(Figure 5.11C). The reduction in the NP396-specific response in TdT ko adult 
mice was similar to that found in wildtype neonatal mice infected with LCMV 
(Figure 5.4B), but there was also a reduction in the GP33-specific response that 
was not found in day 7 neonates. Interestingly, TdT ko adult mice had an 
increased usage of Vβ 8.1/2, which is the dominant Vβ found in the NP396-
specific population of LCMV-infected mice, and still had a decreased response to 
this epitope. These data suggest that the CDR3 region may be playing a greater 
role in antigen-specific responses than just the Vβ repertoire. However, these 
data collectively show that there were differences in the repertoire of neonates, 
both in the naïve populations and the antigen-specific responses.   
 
F. Neonates have decreased type I IFN responses  
 
 In addition to the differences found in the neonatal TCR repertoire we 
questioned if differences in the innate responses of neonates could be 
responsible for the altered immunodominance hierarchies. A reduction in the 
NP396-specific CD8 T cell population has also been found in IRF7 KO adult mice.  
119
  
!" "# $!
%
&'
&%
()*+, .),/ 01234/0)1
13)15/3 % 678
59*:/ %3" 678
:)
; !
54
/0<
3
/=
.3
>>
7?
!"#$%& ()*+
70;*+3 %@&! ?3)15/3, (59 93:5=39 /=.3 > >7? +3,.)1,3, 52/3+ ABCD 01234E
/0)1@ ,-.& / /!0 123 4&23$%&5 "6 78& 3&%$4 9: 6&9627&3 265 25$;7 4"<& 27 +=>
=? 265 @+ 89$%3 .937 "6:&<7"96 A- 7-.& / /!0 A"92332-) 6BCD@ 4"<&E#%9$.) F272
2%& :%94 78%&& 3"4";2% &G.&%"4&673)
**** ***
120
IRF7 is a key transcription factor in the induction of type I IFN after LCMV 
infection (Zhou et al., 2012). Since type I IFN is required for CD8 T cell 
proliferation and differentiation during LCMV infection (Welsh et al., 2012), we 
measured type I IFN by bioassay after LCMV infection in neonates compared to 
adults. We found that at 24 hours post infection type I IFN levels were below the 
limit of detection in our assay (Figure 5.12). At 48 hours type I IFN was detected, 
but at significantly lower levels in neonates. By day 3 post infection neonatal type 
I IFN levels were similar to adults. Delayed type I IFN induction is not surprising 
and is known to occur in neonates (Kollmann et al., 2012). Type I IFN controls 
anti-viral responses, and delayed expression would allow unchecked viral 
replication in neonates and could be contributing to the generation of altered 
immunodominance hierarchies by a yet unknown mechanism.  
   
G. Female pups are protected from death but only on the Balb/c 
background  
 
Different strains of mice are known to have different susceptibilities viral 
infection. Balb/c mice are known to be more sensitive to Th1-inducing viruses. 
Balb/c mice have a higher affinity IL-4 receptor that skews immune responses to 
Th2 (Schulte et al., 1997). We questioned if Balb/c mice would be more resistant 
to neonatal LCMV infection, as they may not develop such a strong Th1/CTL 
immune response. We found that Balb/c infected neonates died at a similar rate 
as B6 neonates (Figure 5.12A). However, on the Balb/c background  
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all female mice survived and only males succumbed to infection. Hormonal 
differences that exist between males and females have long been known to alter 
immune responses. In B6 neonates there was no difference between males and 
females.  
Chapter Summary 
 
The data in this chapter show that day 7 neonates were highly susceptible to T 
cell-mediated perforin-dependent immunopathology and death after LCMV  
infection. Death was not due to viral load alone, as mice lacking both CD4 and 
CD8 T cells had high viral loads in several organs, but retained a 100% survival 
rate. Passive immunity through LCMV-immune mothers could mediate faster viral 
control in neonates and also result in 100% survival. LCMV-specific CD8 T cell 
responses in neonates were similar to adults in frequency, but significantly 
reduced in total number. CD8 T cell immunodominance hierarchies in neonates 
resembled adults infected with an intermediate dose of LCMV clone 13, in that 
neonates had decreased NP396-specific populations. However, neonates 
differed from LCMV clone 13-infected adults as they did not develop partial clonal 
exhaustion. Analysis of the Vβ distribution of the CD4 and CD8 T cell populations 
in uninfected neonates showed significant differences in the frequency of several 
Vβ including those that are commonly used in the NP396-specific Vβ repertoire 
of adult mice. Examination of the NP396-specific Vβ repertoire of neonates 
showed that they were both significantly different from the adult repertoire, but 
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there was also a high degree of variability between individuals, which is not seen 
in adults. TdT ko adults also had a reduction in the NP396-specific response, 
further supporting the role of the narrowed repertoire in the altered 
immunodominance hierarchies of neonates.  In addition to the altered CD8 T cell 
response we showed that there was a severely delayed type I IFN response in 
neonates.      
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Chapter 6: Heterologous immunity is a mechanism for 
protection in neonatal mice 
 
 Human newborns and infants receive multiple vaccines to protect them 
against infection. Previously, vaccinations have been given with the thought of 
protecting against specific pathogens. However, several non-specific effects of 
immunization have been observed. Children that receive the BCG or measles 
vaccine, which are live attenuated vaccines, are non-specifically protected from 
death from other pathogens besides tuberculosis or measles virus (Aaby et al., 
1995; Roth et al., 2005). Furthermore, this protection is lost and children are 
actually more susceptible to death if they are subsequently given the combination 
diphtheria, tetanus and pertussis (DTP) vaccine (Aaby et al., 2007). 
Heterologous adaptive and innate immunity may be mediating these “non-
specific” effects of vaccines.  
 One model of protective heterologous immunity is LCMV-immune mice 
challenged with VV. Previous immunization with LCMV can protect mice from a 
lethal challenge with VV (Chen et al., 2001; Cornberg et al., 2007; Selin et al., 
1998). Adoptive transfer of LCMV-immune splenocytes into naïve mice protects 
during a VV challenge (Selin et al., 1998). However, if the LCMV-immune 
splenocytes are depleted of either CD4 or CD8 T cells, protection is lost (Selin et 
al., 1998). Crossreactive CD8 T cell lines, that were generated by stimulating 
LCMV-immune splenocytes with VV epitopes, can protect naïve mice from VV 
challenge (Cornberg et al., 2007; 2010). During VV challenge of LCMV-immune 
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mice there is an expansion of several different LCMV epitope specific 
populations. Some individual LCMV-immune mice show an expansion of LCMV-
NP205-specific CD8 T cells, while others have a crossreactive LCMV NP118- or 
GP34-specific response (Figure 1.5) (Kim et al., 2005). Private specificity, or the 
unique TCR repertoire of individual mice, mediates which crossreactive response 
will expand during VV challenge (Kim et al., 2005). The TCR repertoires of 
neonatal mice are less diverse than that of adults (Figure 5.10) (Adkins, 2005). 
We questioned if this altered T cell repertoire would result in altered protection in 
this model of beneficial heterologous immunity if mice were immunized with 
LCMV as neonates. Furthermore we questioned if the altered neonatal 
repertoires may impact the crossreactive patterns that are found when these 
same mice are infected with VV as young adults 6 weeks later.  
 
A. Mice immunized with LCMV as neonates show immune protection 
after VV challenge 
 
Since neonates from naïve mothers have ~80% mortality after LCMV 
infection (Figure 5.1) I decided to use neonates from LCMV-immune mother 
which are protected from death (Figure 5.8). Neonates were immunized with 50 
PFU of LCMV ip at day 7 of age and allowed to mature to 7 weeks of age, after 
which they were challenged with VV. On day 6 post VV challenge mice were 
harvested, and the viral load in the fat pads was determined by plaque  
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assay (Figure 6.1A). Similar to adult mouse studies, there were significantly 
lower viral loads in both males and females that were immunized with LCMV at 
day 7 of age. These data suggest that heterologous immunity is also a 
mechanism of protection when mice are immunized as neonates.   
 
B. Males immunized as neonates develop enhanced panniculitis 
during VV challenge 
 
Adult male LCMV-immune mice challenged with VV develop 
immunopathology of the fat pads called AFN. The IFNγ and TNFα produced by 
crossreactive memory cells recruited to the fat pad causes the upregulation Fas 
on adipose tissue (Siwei Nie, unpublished data). Fas expression on the surface 
of adipocytes interactions with FasL on CD8 T cells and results in patches of 
necrosis on the fat pads. AFN can vary in severity from mild to moribund. The 
severity of pathology is also determined by the private specificity of the 
crossreactive memory T cell population, as demonstrated in adoptive transfer 
experiments (Nie et al., 2010). At the dose of VV used for these experiments 
AFN is not directly induced by viral lysis of cells. Uninfected adult and neonatal 
male mice challenged with VV have mild levels of AFN (score 0-3) (Figure 6.1B). 
With previous immunization with LCMV, AFN levels are increased to moderate 
(score 4-6) and severe (score 7-8). Interestingly, LCMV-immune female mice do 
not develop AFN after VV challenge (Figure 6.1B). The mechanism for this sex  
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difference is currently unknown. When both males and females were immunized 
with LCMV as neonates and challenged with VV, AFN was only found in males, 
similar to that found in adults. Uninfected male neonatal mice developed mild 
AFN with a significant increase in LCMV-immune mice (Figure 6.1B). These 
data suggest that the mechanisms for AFN are maintained in mice immunized as 
neonates.  
 
C. VV responses are similar in mice immunized with LCMV as 
neonates and adults 
 
 After infection with VV, mice develop CD8 T cell responses to several VV-
specific antigens. These responses are predictable and consistent between 
individual mice. Naïve mice infected with VV produced a dominant response to 
B8R with subdominant A47L-, E7R- and A11R-specific responses (Figure 6.2).  
The A11R-specific response is known to be crossreactive between LCMV and 
VV as LCMV-immune splenocytes can expand in culture to A11R stimulation and 
produce IFNγ and TNFα and stain with both tetramers (Cornberg et al., 2007; 
2010). We questioned if mice were immunized with LCMV as neonates would 
this alter their crossreactive CD8 T cell responses to VV compared with mice 
immunized as adults. There were no differences in the VV-specific 
immunodominance hierarchies between mice immunized with LCMV as 
neonates or adults (Figure 6.2). The only significant difference that was  
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observed was a decreased response to the dominant B8R epitope in both male 
and female mice immunized as adults, and female, but not male mice immunized 
as neonates. (Figure 6.2). This reduction may be due to the more rapid 
clearance of VV by the memory CD8 T cell responses.  
 
D. Mice immunized as neonates have similar numbers of LCMV-
specific memory, but altered immunodominance hierarchies 
 
The size of the CD8 T cell memory population has been found to 
determine the level of protective immunity in homologous challenge models 
(Cerwenka et al., 1999; Hamada et al., 2009). Because neonates have reduced 
T cell numbers (Ridge et al., 1996) (Figure 5.3) I questioned if mice immunized 
as neonates would have fewer LCMV-specific CD8 T cells compared to mice 
immunized as adults. Surprisingly, we found that there was no difference in the 
number of memory LCMV-specific CD8 T cells in the spleens between these 
groups six weeks post LCMV infection (Figure 6.3A). The increase in the LCMV 
memory frequency and the later dominance of NP396 most likely relates to the 
slow clearance of LCMV over more than 14 days as compared to adults.  
 In LCMV-immune mice challenged with VV there are multiple LCMV-
specific memory populations that can recognize VV antigens and expand. Most 
commonly these are GP33/34-, NP205- and GP118-specific populations (Kim et 
al., 2005). We compared immunodominance hierarchies in mice immunized as 
neonates to adults and found that there were several differences even before VV   
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Figure 6.3. Mice immunized with LCMV as neonates had similar number of
LCMV-­specific CD8 T cells, but altered immunodominance hierarchies and
skewing after VV challenge. At 6 weeks post LCMV-­immunization the A. total
number of LCMV-­specific CD8 T cells and B. LCMV CD8 T cell immunodominance
hierarchies were determined in the blood or spleen mice immunized as a neonate or
an adult. Data is from three similar experiments. n=25-­29 mice/group C. To determine
skewing of the immunodominance hierarchies due to crossreactivity LCMV-­immune
mice were bleed before VV challenge and immunodominance hierarchies from this
time point were compared to immunodominance hierarchies from day 6 post VV
challenge. These show the frequency of mice skewing to each LCMV epitope. Data
are representative of three similar experiments. n=26 adults n=39 neonates. NS= not
significant, **p<0.01, ***p<0.001, ****p<0.0001
B.
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challenge (Figure 6.3B). There was a higher proportion of NP396-specific cells 
in mice immunized as neonates that was surprising because this population was 
decreased at day 9 and 14 post LCMV-infection (Figure 5.4). There was no 
difference in the proportion of GP33/34-specific cells between neonates and 
adults. However, there was a reduced proportion of the crossreactive, NP205- 
and GP118-specific cells (Figure 6.3B). Therefore, the LCMV memory of mice 
immunized as neonates is altered in the epitope-specific hierarchy as compared 
to mice immunized as adults. We questioned if this could influence the pattern of 
crossreactive LCMV responses, which expand during VV infection. 
In mice immunized with LCMV as an adult and challenged with VV the 
most common crossreactivity that arises is NP205 (Kim et al., 2005). Expansion 
of NP205-specific memory cells is found in about 50% of LCMV-immune mice 
after VV challenge, with 27% of mice skewing towards GP33/34-specific cells 
and 15% towards GP118-specific cells (Kim et al., 2005).  By assessing 
immunodominance hierarchies before and after VV challenge we can determine 
which crossreactive response expanded in individual mice. Mice immunized as 
neonates showed a different skewing pattern than mice immunized as adults 
(Figure 6.3C). The most common crossreactivity was GP33/34, which occurred 
in 61% of mice with 10% expanding NP205- and 6% expanding GP118-specific 
responses. The decreased usage of NP205- and GP118-specific memory 
responses during VV challenge may be due to their decreased frequency and 
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perhaps altered TCR repertoire since NP205- and GP118-specific populations 
were diminished compared to mice immunized as adults.  
 
Chapter Summary 
 
In this chapter we show that the age of immunization does not alter the 
immune protection and immunopathology that can occur in the beneficial 
LCMV+VV model of heterologous immunity. Mice immunized as neonates with 
LCMV have lower viral loads and some male mice develop panniculitis. The VV-
specific CD8 T cell response that develops in these mice is unchanged by the 
age of LCMV infection, suggesting no dramatic alterations in the immune 
systems functionality. Considering the differences in neonatal and adult LCMV-
specific responses it was not surprising to find that the LCMV-specific 
crossreactive responses utilized by mice immunized as neonates differed from 
mice immunized as adults. This may be due to precursor frequency as there was 
a significant decrease in the NP205-specific memory proportion in mice 
immunized as neonates even before VV challenge, or it may be due to TCR 
repertoires as neonatal mice develop different TCR repertoires to adults. These 
data demonstrate that even though there are altered crossreactivities in mice 
immunized as neonates, the principles of heterologous immunity are maintained 
in the immature neonatal immune system, and most likely contribute to the 
beneficial “non-specific” effects of vaccines.   
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Chapter 7: CD8 T cell immunity and heterologous 
immunity in neonatal mice infected with PICV 
 
Neonatal mice are sensitive to infection in general, but also to infection 
with nonlytic viruses, like LCMV, that can quickly replicate within a host (chapter 
5). PICV is distantly related to LCMV, and they share 48% sequence homology 
(see methods for sequence analysis), but PICV does not replicate as well in adult 
B6 mice.  To obtain an optimum CD8 T cell response adult mice need to be 
infected with 2x107 PFU of PICV ip, which is 400-fold higher than the optimum 
dose of LCMV Armstrong. PICV provides protective heterologous immunity to 
both LCMV and VV infections (Brehm et al., 2002; Chen et al., 2012; Selin et al., 
1998). Expanded populations of the crossreactive NP205-specific cells induce 
faster clearance of heterologous viruses but also cause a skewing of both the 
LCMV- and PICV-specific CD8 T cell immunodominance hierarchies, with most 
mice developing a dominant or co-dominant NP205-specific response. We 
questioned whether neonatal mice, which succumb to LCMV infection, would be 
able to clear PICV. Furthermore, we questioned if mice immunized with PICV as 
neonates would show expansion of the crossreactive NP205-specific population 
thus altering the  PICV-specific immunodominance hierarchy after LCMV 
challenge due to crossreactivity.  
 
A. Neonatal mice control PICV infection without mortality  
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I questioned if neonatal mice that are highly sensitive to LCMV would be 
able clear PICV without mortality. Day 7 neonatal mice were infected with 4x104 
PFU of PICV ip, and 100% of mice survived. The dose of PICV was increased to 
4x105 and 4x106 PFU, and still 100% of pups survived (data not shown), 
suggesting that PICV can not replicate to as high levels in neonates, as was 
found with LCMV infections, allowing the CD8 T cell response to clear virus 
without inducing severe immunopathology. To determine the kinetics of viral 
clearance in neonatal mice compared to adults PICV titers were determined in 
multiple organs over time. In the fat pads of adult mice PICV replicated well, 
reaching ~3 logs during the early phase of infection, day 2, after which viral load 
declined and was cleared by day 7. In neonatal mice viral load in the fat pad 
remained high at ~3-4 logs until day 7 post infection after which it declined and 
virus was cleared between day 8-11 (Figure 7.1A). In adult mice PICV does not 
grow well in the kidney. Low levels of replicating virus can be detected in the 
kidney between days 3-5. Interestingly, in neonatal mice virus replicated to over 
three logs of virus in the kidney and followed a similar kinetics of clearance as 
the fat pad (Figure 7.1A). These data show that even though neonatal mice do 
not die from PICV infection, nor do they achieve the same levels of virus as 
LCMV, they still have protracted viral clearance, a hallmark of infection in 
neonates. 
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B. Neonatal mice are capable of producing adult-like CD8 T cell 
responses 
 
Since CD8 T cells mediate PICV clearance, we examined how the CD8 T 
cell responses in neonates compared to that of adult mice after PICV infection. 
The overall size of the PICV-specific response was significantly reduced in 
neonatal mice infected with 4x104 PFU, but by increasing the infecting dose to 
4x105 and 4x106 PFU neonatal mice produced PICV-specific responses that 
were similar in frequency to adults (Figure 7.2A). The total number of responding 
CD8 T cells in neonates was still significantly lower than adult mice (Figure 7.2B).  
To more closely examine the PICV-specific CD8 T cell response, 
immunodominance hierarchies were examined for three epitopes. At day 8 post 
infection in adult mice the NP38-specific response dominated, followed by an 
intermediate NP122-specific response and a very subdominant NP205-specific 
response (Figure 7.2C). At low dose there was a significant reduction in the 
frequency of NP38-specific cells compared to adult mice but, by increasing the 
infecting dose to 4x105 and 4x106 PFU, the NP38-specific response could reach 
adult levels (Figure 7.2C). Similar to the CD8 T cell responses in LCMV-infected 
neonates, there was a difference in PICV-specific immunodominance hierarchy 
with a loss of NP122-specific T cell response (Figure 7.2C). Even with increased 
doses this response did not develop (Figure 7.2C).  
These experiments were performed on day 8 post infection because this is 
the known peak of the CD8 T cell response in adult mice after PICV infection.  
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However, based on the viral load data we know that it takes longer for neonates 
to clear PICV infection. We questioned if the peak of the CD8 T cell response 
would be delayed in neonates, similar to that found in LCMV-infected neonates. 
Examining the frequency of PICV-specific CD8 T cells through the course of 
infection we observed that in adult mice the peak of the response was at day 8 
after which the response declined into memory (Figure 7.2D). In neonates we 
found that the highest frequency of PICV-specific cells was found at day 11 post 
infection, suggesting there was a delay in the response (Figure 7.2D). These 
results show that neonates can produce adult-like responses to PICV infection, 
but still have the hallmarks of delayed viral clearance and reduced number of 
CD8 T cells and altered immunodominance hierarchies.     
 
C. Neonates immunized with PICV show adult-like expansion of the 
crossreactive NP205 response leading to altered immunodominance 
hierarchy after LCMV challenge 
 
After immunization with PICV adult mice develop a subdominant response 
to the crossreactive epitope, NP205 (Brehm et al., 2002). This small epitope-
specific response, usually less than 1% of the memory CD8 T cell pool, can 
expand after LCMV challenge and cause faster viral clearance, narrowing of the 
NP205-specific TCR repertoire, alteration in the immunodominance hierarchy 
and can allow for viral escape (Brehm et al., 2002; Cornberg et al., 2006; Selin et 
al., 1998). In a preliminary experiment we questioned could the crossreactive 
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NP205 response expand upon subsequent challenge with LCMV and alter the 
immunodominance hierarchies of mice immunized with PICV as neonates. Mice 
immunized as neonates developed strong responses to the dominant NP38 
epitope, a lower NP122-specific response than adults and a similarly low 
frequency of the NP205-specific response in memory (Figure 7.3). After 
challenge with LCMV there was an expansion of the NP205-specific memory 
response and at day 7-8 this response dominated in all of the mice (Figure 7.3). 
These data demonstrate that, like adult cells, crossreactive CD8 T cells produced 
during a neonatal infection can expand during a subsequent heterologous 
infection and altered immunodominance hierarchies.  
 
Chapter Summary 
 
This chapter summarizes preliminary data on a model of neonatal 
infection with a second less virulent arenavirus, PICV. After infection of day 7 
neonates with PICV there was no mortality even at a high dose of 4x106 PFU. 
Even at this high dose, PICV did not replicate to the same levels as LCMV 
Armstrong or remain as protracted. Neonates could successfully clear PICV, but 
with delayed kinetics compared to adult mice. The CD8 T cell responses in 
neonates were adult-like in frequency, but not total number, and peaked later 
than adults. The immunodominance hierarchies in neonates were altered with a 
loss of the NP122-specific response. When mice immunized with PICV as  
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Figure 7.3. Mice immunized with PICV as neonates and challenged with LCMV
demonstrate skewing of the immunodominance hierarchy and expansion of the
crossreactive response. Mice immunized with 4x104 PFU of PICV at day 7 of age
were challenged with 5x104 PFU of LCMV Armstrong six weeks later. Immunodomi-­
nance hierarchies were determined on day 7-­8 post challenge. Data is from two
similar experiments with 6-­13 mice/group.
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neonates were challenged with LCMV there was a skewing of the 
immunodominance hierarchy such that the crossreactive NP205-specific 
response expanded, similar to that found in mice immunized with PICV as adults. 
Whether this mediates protective heterologous immunity still needs to be tested.  
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Chapter 8: Discussion 
 
The induction of T cell-mediated immunopathology is one of the 
consequences of the host’s immune system attempting to clear a viral infection. 
Immunopathology can be induced during the reactivation of memory cells or 
during a new naïve response. T cells employ several mechanisms to induce 
immunopathology, such as the production of cytokines like IFNγ and TNFα, 
which activate and recruit other immune cells to the site of infection or the 
production of cytotoxic factors such as FasL, perforin and granzymes. My major 
hypothesis is that the difference between an immune response that causes 
severe pathology versus one that induces minimal pathology is the efficiency at 
which the immune response can clear antigen and quickly shut down. If a 
pathogen is cleared quickly there is limited cellular damage, but an infection that 
is allowed to replicate, for a prolonged period, requires lysis of a greater number 
cells to clear infection and a longer amount of time for T cells to amplify an 
immune response. This thesis used four different models, each defining a 
different mechanism to study the balance between viral load and the efficiency of 
the immune response and their subsequent affect on disease outcome. 
 In the first model we studied the effect of competition between immune 
responses to two viruses, LCMV and PICV, which contained a crossreactive 
epitope, NP205 (Chapter 3) (Figure 8.1). Co-infection caused the LCMV-specific 
CD8 T cell response to become smaller in size. Specifically there was a  
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reduction in the LCMV-specific effector, but not the central, memory pool (Figure 
3.5-3.6). Upon rechallenge with LCMV clone 13, co-immunized mice had 
enhanced immunopathology, as measured by increased ALT levels and greater 
weight loss, with higher viral loads compared to mice immunized with LCMV 
alone (Figure 3.1). Co-infection also led to an increase in the crossreactive 
memory pool, in some mice. The frequency of which directly correlated with fat 
pad pathology and weight loss during PICV rechallenge. Ablation of the NP205-
specific response using a mutant virus resulted in minimal immunopathology 
(Figure 3.2-3.4). By administering two viruses simultaneously, the competition 
between the immune responses to these viruses decreased the efficiency of the 
memory CD8 T cell immune response to both, such that during a rechallenge 
with either virus, replicating virus was not cleared as effectively as from a LCMV- 
or PICV-immune mouse and increased the chance of developing 
immunopathology in some mice (Figure 8.2).  
 In a second model, by using three different doses of the highly virulent 
LCMV clone 13, a virus known to replicate to such high levels it can result in 
clonal exhaustion, we shifted this balance (Figure 8.3). During a low dose 
infection with LCMV clone 13, mice developed a strong, functional CD8 T cell 
response that cleared virus after approximately one week, causing minimal 
immunopathology. During a high dose infection LCMV clone 13 induced clonal 
exhaustion of the LCMV-specific CD8 T cell response, with a loss of IFNγ and  
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TNFα production by the NP396-specific population, and TNFα from the other 
epitopes (Figure 4.2B). In this instance clonal exhaustion or loss of a functional 
T cell response in the presence of an overwhelming viral load was beneficial to 
the host as there is little immunopathology. The price, however, was viral 
persistence. However, an intermediate dose of LCMV clone 13 was found to 
cause severe immunopathology of the lung and liver and death in up to 75% of 
mice (Figure 4.1, 4.3 & 4.4). Upon examination of the T cell response in mice 
infected with an intermediate dose of LCMV clone 13 we found partial clonal 
exhaustion, where the NP396-specific response was not lost, but the TNFα:IFNγ 
ratio shifted had so these cells are less effective. (Figure 4.2). This partial 
exhaustion caused a moderate reduction in the efficiency of the T cell response, 
but not to the level of complete exhaustion as found during high dose LCMV 
clone 13 infection, resulting in severe T cell-mediated immunopathology as they 
were unable to clear the virus (Figure 8.3). 
 In a third model, we used neonatal mice known to have an immature, less 
efficient immune system to examine the balance between viral load and 
efficiency of the T cell response and its effect on disease outcome. Using the 
LCMV Armstrong system, where adult mice have minimal immunopathology and 
a functional CD8 T cell response that clears virus quickly, we infected day 7 
neonatal mice and found severe immunopathology and ~80% mortality (Figure 
5.1 & 8.4). Our data would suggest that delayed immune responses, particularly 
early production of type I IFN, which directly control viral replication, allowed  
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LCMV to disseminate into the immature CNS in neonatal mice (Figure 5.7). In 
adult mice, LCMV Armstrong does not normally replicate in the CNS during an ip 
infection. In neonates the high viral load did not cause clonal exhaustion, 
allowing cytotoxic CD8 T cells to enter the immature CNS and induce perforin-
mediated immunopathology  and death (Figure 5.7). Neonatal mice were 
capable of undergoing clonal exhaustion under the right circumstances, such as 
a high dose LCMV clone 13 infection which replicates very rapidly early to high 
levels (Figure 5.5). We further perturbed the balance by infecting neonates of 
LCMV-immune mothers, which were able to clear virus faster than neonates from 
naïve mothers and had 100% survival rate with minimal lung and liver pathology 
(Figure 5.8). When early viral load was controlled, such as in adult mice infected 
with LCMV Armstrong or neonates from LCMV-immune mothers, an efficient 
CD8 T cell response cleared virus quickly with little resulting immunopathology 
(Figure 8.5). When clonal exhaustion occurred, either in neonates or adults 
infected with a high dose of LCMV clone 13, there was also minimal 
immunopathology due to the lack of a cytotoxic T cell response that could induce 
cellular damage (Figure 8.5). Using a second less virulent arenavirus, PICV, we 
found an adult-like T cell response that did not induce mortality or 
immunopathology due to the slower replication of PICV and relatively normal rate 
of clearance. Without widespread, high viral loads T cells did not induce severe 
immunopathology in neonates infected with PICV (Figure 8.5).  
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 To further understand the role of memory development and 
immunopathology in neonatal mice we used a fourth model examining beneficial 
heterologous immunity. During a VV challenge, LCMV-immune mice immunized 
as neonates were compared to mice that were immunized as adults. Mice 
previously immunized to VV have been shown to have sterilizing immunity during 
VV rechallenge due to the high efficiency of their VV-specific memory responses 
resulting in very limited immunopathology (Figure 8.6). Naïve mice challenged 
with VV have no immunological protective immunity, resulting in high viral load. 
However, naïve mice developed VV-specific CD8 T cell responses that cleared 
virus within ~1 week, and those mice developed little T cell-mediated 
immunopathology. LCMV-immune mice, immunized as either neonates or adults, 
have crossreactive memory responses that aid in clearing virus faster than a 
naïve response, but slower than a VV-specific memory response during VV 
challenge. However, due to the slower rate of VV clearance, the less efficient 
crossreactive memory cells have time to amplify the immune response in the fat 
pads, where VV grows preferentially to high doses. This increased IFNγ and 
TNFα produced by the memory cells leads to increased Fas expression on 
adipocytes and Fas-FasL dependent necrosis (Nie et al., 2010). This model of 
heterologous immunity illustrates the balance of memory T cell responses, either 
homologous (VV+VV), crossreactive (LCMV+VV) or primary (naïve+VV) in the 
development of immunopathology.  
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Model 1: Co-infection reduced effector memory and enhanced 
crossreactivity  
 
 Co-infection with two viruses containing a cross-reactive epitope can lead 
to increased disease severity and delayed viral clearance upon re-exposure to 
either of the immunizing viruses. Furthermore, this could be correlated with at 
least two different mechanisms, one mechanism for each of the two virus 
rechallenges. During PICV rechallenge, an increased inefficient crossreactive 
CD8 T cell response contributed to enhancement of immunopathology in co-
infected mice, while protection against LCMV clone 13 rechallenge was reduced 
in co-infected mice coincident with a reduction in the number of LCMV-
specific effector-memory cells. In both viral rechallenge models, an ineffective 
memory T cell response in co-infected mice facilitated increased viral replication 
for a longer period of time, possibly leading to enhanced and prolonged 
accumulation of secondary effector T cells in the tissues. This may in turn be 
associated with increased collateral damage in the form of immunopathology. 
Crossreactive responses have been shown to mediate severity of 
immunopathology in models of heterologous immunity. In IAV-immune mice 
challenged with LCMV, there is significant lung pathology induced by the 
crossreactive IAV-specific memory responses to PB1 and PA224 (Wlodarczyk et 
al., 2013). These responses are crossreactive with the LCMV epitopes GP34 and 
GP276, respectively. IAV-immune mice with the greatest magnitude of 
crossreactive responses developed the most severe lung pathology after LCMV 
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challenge. In fact, there was a direct correlation between the severity of 
pathology and the frequency of the crossreactive responses prior to LCMV 
challenge. Ablation of the crossreactive responses by either peptide tolerization 
or use of viral mutants resulted in decreased lung pathology (Wlodarczyk et al., 
2013). We found a similar reduction of the fat pad immunopathology when we co-
infected mice using the mutant LCMV (L212A), which lacks the crossreactive 
NP205 epitope. Homologous memory responses can result in protective 
immunity and quickly clear virus before immunopathology can develop. 
Crossreactive memory responses are more likely to clear virus slower and less 
efficiently. Slower viral clearance allows for greater viral replication allowing for 
greater recruitment and amplification of the crossreactive memory responses 
leading to greater production of IFNγ, TNFα and cytotoxic factors resulting in the 
enhanced immunopathology observed in some instances of heterologous 
immunity.  
The crossreactive NP205-specific response is responsible for both 
protection and the induction of immunopathology during sequential infections 
with LCMV and PICV. PICV-immune mice challenged with LCMV clear virus 
more quickly than naïve mice acutely infected with LCMV due to the rapid 
expansion of PICV-NP205-specific memory CD8 T cells that are not present in 
naïve mice (Brehm et al., 2002; Cornberg et al., 2006; Selin et al., 1998). PICV-
NP205-specific memory cells are at a higher precursor frequency and lower 
activation threshold than naïve LCMV-specific T cells and are localized within the 
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periphery. However, when PICV-immune mice are rechallenged with PICV after 
an intervening LCMV infection (PICV+LCMV+PICV), a NP205-specific memory T 
cell response of higher affinity to LCMV will most likely be selected for. This is not 
ideal for PICV protection. Consequently, this crossreactive T cell response is no 
longer beneficial to the host during a subsequent PICV rechallenge, but 
contributes to the development of severe panniculitis in 60% of the mice (Chen et 
al., 2012). During simultaneous co-infection with LCMV and PICV, NP205 
epitopes from both viruses were most likely presented. Since there is no 
difference in the proportion of NP205-specific cells within the LCMV-specific 
immunodominance hierarchy in co-infected mice, we believe that the increase in 
NP205 in the PICV-specific immunodominance hierarchy is due to the addition of 
the LCMV-NP205-specific cells. Therefore, the NP205-specific response in co-
infected mice may have a repertoire where an inappropriate crossreactive 
response dominated during the PICV rechallenge and caused severe 
immunopathology in some mice similar to the pervious study in heterologous 
immunity.  
During LCMV clone 13 challenge of co-infected-immune mice, no 
correlation between immunopathology and the crossreactive NP205-specific 
response was found. This would be consistent with the NP205 response in co-
infected mice being predominantly directed against the LCMV-NP205 epitope, 
which represents an appropriate NP205-specific response for control of a LCMV 
clone 13 challenge (Chen et al., 2012). It has previously been shown that the 
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number of virus-specific memory cells positively correlates with protection from 
lethal infection (Cerwenka et al., 1999; Hamada et al., 2009). We believe that the 
smaller LCMV-specific memory population in co-infected mice was an important 
contributor to enhanced immunopathology. Co-immunized mice may take longer 
to control viral replication in peripheral organs, such as the liver, allowing for 
increased infiltration of activated T cells and enhanced immunopathology. 
Interestingly, memory CD8 T cells with heightened expression of CD62L have 
previously been shown to mediate protection during systemic infections of high 
dose LCMV clone 13 in adoptive transfer experiments (Nolz and Harty, 2011). 
Effector memory cells are purportedly activated quickly after re-infection and 
contribute to early control of viral replication (Bachmann et al., 1997).  In a VV 
skin infection model, effector memory cells were found to be the major protective 
memory cell subtype (Jiang et al., 2012).  In the current study, there was no 
difference in the number of central memory cells between LCMV- and co-infected 
mice, but co-infected mice had significantly fewer effector memory cells. These 
data suggest that, if there is no difference in the number of central memory cells, 
an increased number of effector memory cells can enhance protection during a 
LCMV rechallenge. 
T cell differentiation and proliferation are shaped by several factors, 
including antigen load and cytokine milieu (Cui and Kaech, 2010; Curtsinger and 
Mescher, 2010). LCMV- and co-infected mice were infected with the same dose 
of LCMV Armstrong and exhibited similar kinetics of viral clearance. In contrast, 
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there were differences in type I IFN, MCP-1 and IL-6 between LCMV- and co-
infected mice, while co-infected mice mirrored PICV-infected mice. The infection 
environment has been altered in other studies by use of recombinant viruses. For 
example, one group found that an IAV expressing LCMV-GP33 mediated a 
smaller GP33-specific response than wildtype LCMV, which had a reduced 
KLRG1 expression (Mueller et al., 2010). This suggests that the PICV-induced 
early innate inflammatory environment is altering the differentiation and 
proliferation of the LCMV-specific CD8 T cell response. More specifically, type I 
IFN has been found to play a major role in the proliferation and survival of CD8 T 
cells during an LCMV-infection. The levels of type I IFN were similar between 
LCMV- and co-infected mice, but followed different kinetics. In LCMV-infected 
mice type I IFN peaks between 48 and 72 hours post infection, while in co-
infected mice the peak is expedited to 24 hours post infection. Pre-exposure of 
virus-specific CD8 T cells to type I IFN can result in poor proliferative responses 
of CD8 T cells upon encounter with cognate ligand (Marshall et al., 2011). Thus, 
the early bath of type I IFN that the LCMV-specific cells receive in co-infected 
mice may be altering the normal LCMV-specific differentiation and proliferation.  
Another possible explanation for the decreased size of the LCMV-specific 
memory response in co-infected-immune mice may be an unknown factor that 
controls the size of the T cell compartment during primary infections. In memory, 
co-infected-immune mice have smaller LCMV- and PICV-specific responses than 
LCMV- and PICV-immune mice, respectively.  However, the total virus-specific 
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response (LCMV+PICV response) in co-infected-immune mice is similar to the 
LCMV-specific response in LCMV-immune mice, suggesting that LCMV alone 
induces a strong T cell response that fills up the available space in a naïve 
mouse. When co-administered with PICV, there is a reduction in the LCMV-
specific response to make room for the PICV-specific response, resulting in a 
smaller memory pool in co-infected-immune mice. Several labs have studied the 
changes in the size of the memory T cell pool over sequential infections 
(Masopust et al., 2007; Selin et al., 1996; 1999). However, in the current study 
the decreased LCMV-specific memory population in co-infected-immune mice 
was generated during a primary infection and was not a product of sequential 
infection induced attrition.   
There are several alterations in both the early innate and adaptive immune 
responses during a co-infection, which may not be predicted from studying 
individual virus infections. These alterations resulted in a less efficient CD8 T cell 
response and led to enhanced disease severity upon rechallenge. This strongly 
suggests that it would be important to have a better understanding of human T 
cell responses to vaccines that are given concurrently, such as the live-
attenuated measles, mumps, rubella vaccine, to optimize vaccine strategies.  
With the increase in the number of vaccines available, use of combination 
vaccines and simultaneous administration of vaccines has become necessary to 
accommodate all the required immunizations into routine doctor visits and 
maintain vaccination rates. Similarly, the reuse of intradermal needles and bites 
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from insect vectors can also result in a co-infection. As antibody responses 
generally correlate with protection, the majority of the time antibody titers are 
used to determine vaccine efficacy. However, live-attenuated vaccines will also 
induce T cell responses, and their impact on subsequent immunity either 
beneficial or detrimental, has largely been neglected. The T cell epitopes for the 
majority of vaccines are currently unknown, severely limiting the understanding of 
human T cell responses to vaccines. These data suggest that a better 
understanding of human T cell responses to vaccines is necessary to optimize 
immunization strategies. Furthermore, diagnosis and treatment of co-infections 
are more difficult than single virus infections, so studying how the immune 
system responds to multiple pathogens simultaneously may aid in design of the 
treatments for HIV/HCV co-infected patients.  
 
Model 2: Clonal exhaustion protected mice from T cell mediated 
mortality during viral infection 
 
Altering the infection dose with a rapidly replicating virus that can cause 
clonal exhaustion, such as LCMV clone 13, can also shift the balance and result 
in enhanced immunopathology. When a mouse is infected with a high dose of 
LCMV clone 13 the viral load becomes so high that there is a complete clonal 
exhaustion of the CD8 T cell response. During clonal exhaustion there is a 
stepwise loss of function in CD8 T cells, where cytotoxic function is lost then 
cytokine production and finally these cells die by apoptosis (Wherry, 2011). 
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Clonal exhaustion of the LCMV-specific CD8 T cell response results in viral 
persistence with very limited pathology (Ahmed et al., 1984; Welsh and McNally, 
1999; Zajac et al., 1998; Zhou et al., 2004). Likewise, mice infected with a low 
dose of LCMV clone 13 developed minimal pathology, as virus was cleared 
quickly by a fully functional CD8 T cell response. However, when mice were 
infected with an intermediate dose of LCMV clone 13 we found extensive lung 
and liver pathology that resulted in death of up to 75% of the animals. This 
pathology was found to be T cell-mediated. Compared to the low dose infection, 
the CD8 T cell response after the intermediate dose infection is less efficient at 
clearing virus due to its partial clonal exhaustion, where the majority of the 
LCMV-specific CD8 T cells are no longer cytotoxic and produce limited amounts 
of TNF. With this less efficient CD8 T cell response, LCMV clone 13 is allowed to 
replicate to higher levels in essential organs. The balance between the T cells 
inducing immunopathology and the rate at which the remaining T cell response 
undergoes complete clonal exhaustion determines the survival of the individual 
mouse (Figure 8.2).  
The limited pathology that occurred after high dose infection suggests that 
extensive clonal exhaustion may be a beneficial immune mechanism that 
prevents death from an overwhelming CD8 T cell response. The medium dose 
mice that survived eventually underwent complete clonal exhaustion of their 
immune response and became persistently infected, much like the high dose-
infected mice. Persistent LCMV clone 13 infection is ultimately cleared in B6 
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mice by day 60, and epitope-specific CD8 T cells return, except for the high 
affinity NP396 T cells, which have been completely eliminated by 
apoptosis,(Wherry, 2011; Zajac et al., 1998; Fuller and Zajac, 2003) in the 
presence of functional LCMV-specific CD4 T cells (Fuller et al., 2004; Yi et al., 
2010).  
Clonal exhaustion is predicted to be an evolutionary mechanism for 
survival during infection with fast replicating viruses (Wherry, 2011). Clonal 
exhaustion is found to occur in some patients infected with HIV, HCV and HBV, 
but the mechanism for this is not clear. Furthermore, patients that are infected 
with HBV displayed a range of disease severity ranging from an acute resolving 
infection to a chronic persistent infection or fulminant hepatitis (Kondo et al., 
2004) and PD1 expression on virus-specific CD8 T cells has been correlated with 
the outcome of HBV (Zhang et al., 2011). PD1 expression increased on HBV-
specific CD8 T cells early after infection and HBV clearance correlated with loss 
of PD1 expression (Zhang et al., 2011). Similar to these human studies, PD1 
expression correlates with viral clearance in mice acutely infected with LCMV 
Armstrong (Barber et al., 2006). PD-1 expression on LCMV-GP276-specific CD8 
T cells is high at day 6, but by day 8 when the virus has been cleared from most 
organs PD1 expression has returned to naïve-like levels (Barber et al., 2006). 
During high dose clone 13 infection PD-1 expression is induced early, but is 
sustained (Barber et al., 2006). In HBV patients, delayed PD1 expression on 
HBV-specific CD8 T cells was associated with delayed exhaustion of the CD8 T 
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cell response and subsequent acute liver failure. These data suggest that in mice 
infected with an intermediate dose of LCMV clone 13 there may be a delay in 
upregulation of PD1 on the surface of virus-specific cells.   
Another study examined different dose inoculations with LCMV clone 13 
and found that different doses induced different levels of weight loss (Stamm 
2012). Similar to this study, they found that an intermediate dose of virus caused 
the most severe pathology (Stamm 2012). This group proposed that CD4 T cells 
were inducing this wasting phenotype found in mice infected with the 
intermediate dose (Stamm 2012). These results are similar to ours in that we 
found TCRβ KO mice, which lack both CD4 and CD8 αβ T cells, have decreased 
pathology. However, it has previously been shown that CD4 help is required for 
CD8 T cell function, and without it cells are more likely to undergo clonal 
exhaustion and be unavailable to mediate pathology (Matloubian 1994 and 
Bettegay M 1994). A deeper look into this model has shown that NK cells act as 
a rheostat and control CD8 T cell exhaustion. (Waggoner 2012). NK cells can kill 
activated CD4 T cells, resulting in the loss of CD4-help and exhaustion of CD8 T 
cells. Therefore, depletion of NK cells from mice infected with the intermediate 
dose of LCMV results in a fully functional CD8 T cell response, that does not 
develop the partially exhausted phenotype, leading to viral clearance with limited 
pathology. When mice infected with a high dose of LCMV clone 13 were depleted 
of NK cells they shifted down in the paradigm and did not undergo complete 
clonal exhaustion, but only a partial exhaustion and developed severe pathology 
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similar to untreated mice infected with the intermediate dose of LCMV clone 13 
(Waggoner et al., 2012).  
These studies suggest a counter intuitive treatment strategy for other 
lethal arenaviruses, such as Lassa virus. Perhaps patients infected with fast 
replicating viruses should be treated short-term with anti-CD3 (Keymeulen et al., 
2005; Chatenoud, 2009) or anti-CD8, as their immunopathology and death may 
be T cell mediated and preventable. Generalized immunosuppressive therapy 
such as corticosteroids may have been tried in the past and are being used 
during acute IAV H1N1 infection in patients with severe lung disease, but these 
treatments would lead to suppression of all aspects of the immune response, 
leaving the host helpless. Just focusing on the CD8 T cell responses or even 
particular CD8 functions such as blocking FasL or INFγ may improve outcome 
without disabling the complete immune system. 
 
Model 3: Neonatal susceptibility to LCMV infection is mediated by 
perforin-dependent CNS pathology 
 
Our data show that neonatal mice infected with LCMV at day 7 of age 
were highly susceptible to perforin-mediated T cell-dependent death. 
Furthermore, the presence of replicating virus and virus-specific CD8 T cells in 
the CNS during the days of greatest mortality suggests that neuropathology is a 
major mechanism of death. The age of infection is important in understanding the 
disease outcome as 12 day old infant mice did not die from low dose LCMV 
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Armstrong infection (data not shown). Alternatively, the day 7 neonates could be 
protected by passive maternal antibody, which would be able to mediate viral 
control early after infection. Our data from this study suggests that the limited or 
delayed innate immune response of day 7 neonates allows for enhanced viral 
replication and results in greater immunopathology from CD8 T cells clearing 
wide spread viral infection.  
It is well documented in humans that newborns are more susceptible to 
viral infections, such as herpes simplex virus (HSV), due to their reduced ability 
to induce a type I IFN response (Kollmann et al., 2012). Newborns to infants 2 
months in age are at the highest risk of severe HSV infection and susceptibility 
correlates with low TLR-mediated type I IFN production (Kollmann et al., 2012). 
In our study we found that type I IFN production was delayed in neonates after 
LCMV infection (Figure 5.12). Neonates had undetectable type I IFN levels at 24 
hours post infection and reduced levels at 48 hours post infection. It was not until 
72 hours post infection that adult-like levels were detected in neonates (Figure 
5.12). This delayed response may have allowed dissemination of virus into 
organs where LCMV Armstrong is not normally found in adults, such as the CNS 
(Figure 5.7A) (Wherry et al., 2003a) and led to T cell-mediated death.   
The intracranial model of LCMV infection has been extensively studied in 
both adults and day 1 neonatal mice (Evans et al., 2002). After intracranial 
infection of adult mice, LCMV replicates in the chorioid plexus, ependymal and 
meninges of adult mice, with 90% of the virus leaving the CNS and replicating in 
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the periphery (Storm et al., 2006). In the spleen CD8 T cells are primed to 
develop into effector cells. After infection cells of the CNS release low levels of 
chemokines, such as CCL5 (RANTES) and CXCL10 (IP10), that draw in T cells 
to the brain (Asensio and Campbell, 1997). Likewise, astrocytes within the CNS 
can release growth factors, such as VEGF, that cause vascular permeability of 
the blood brain barrier (BBB) (Argaw et al., 2009). The BBB is composed of 
endothelial cells connected by tight junctions and separates circulating blood 
from the central nervous system. Historically, the BBB was thought to be 
immature in neonates and allowed for the passage of dyes from the blood stream 
into the brain (Behnsen G 1927). However, several studies have reexamined the 
concentration of dyes, such as Evan’s blue and trypan blue used to examine 
BBB permeability, in humans, rats, rabbits and mice and showed that there was 
no passage of dye into the brain of neonates suggesting that the BBB is fully 
formed at this stage of development (Grontoft, 1954; Millen and Hess, 1958; 
Moos and Møllgård, 1993). However, the sensitivity to permeabilization in 
neonates may be different than that found in adults, making them more prone to 
CNS T cell-mediated immunopathology.  
 Immunocompetent adult mice infected intracranially with LCMV undergo 
100% T cell-dependent mortality between day 6-8 post infection (Cole et al., 
1972; Doherty and Zinkernagel, 1974; Nansen et al., 1998; Storm et al., 2006). 
The mechanism for death in this model is complex as blocking CD8 T cell 
function using several different knock out mice, including mice lacking perforin or 
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granzymes, still resulted in death due to the chemokine recruitment of monocytes 
and macrophages to the CNS (Kim et al., 2009). We found 80% mortality of 
neonates infected with LCMV ip (Figure 5.1A). However, by blocking cytolytic 
function of CD8 T cells, 100% of neonates survived the end of the experiment at 
day 14 post infection (Figure 5.7C). In adult mice infected intracranially with 
LCMV Armstrong perforin deficient mice survived 3-5 days longer than wildtype 
controls, but this was attributed to delayed recruitment of cells to the CNS (Storm 
et al., 2006). It is currently unknown if perforin is required for CD8 T cells to enter 
the CNS during LCMV infection of neonates. Furthermore, the requirement of 
monocytes and neutrophils that occurs in adults may not occur in neonates due 
to altered chemokine production or chemokine receptor expression.  
 Generally, LCMV Armstrong when administered ip is not thought to 
replicate in the CNS. However, one study has reported very low levels of virus 
can be found in the brains of some mice infected with LCMV Armstrong ip at day 
5 post infection and the presence of small populations of GP33-tetramer positive 
CD8 T cells (Wherry et al., 2003a). After iv infection with LCMV clone 13 over 6 
logs of virus can be found in the brain until one month after infection and ~10% of 
the CD8 T cells isolated from the brain were GP33-tetramer positive, but the 
function of these T cells was not assessed (Wherry et al., 2003a). Since during 
persistent infection with LCMV clone 13 the CD8 T cell response undergoes 
clonal exhaustion, with a loss of cytotoxcity, this may prevent CD8 T cell-
mediated CNS pathology. In neonatal mice even though viral load was very high 
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clonal exhaustion did not occur during low dose LCMV Armstrong infection, and 
this allowed for a fully functional T cell response to attack the CNS and induce 
death (Figure 5.4). It is currently unknown if viral replication in the CNS and CD8 
T cell infiltration are playing a role in the enhanced immunopathology found in 
adult mice infected with an intermediate dose of LCMV clone 13, but this is a 
strong possibility. 
Clonal exhaustion of CD8 T cell responses is due to over activation of the 
cells through extensive exposure to antigen during some fast replicating viral 
infections. Neonatal mice infected with 500 PFU of LCMV Armstrong do not lose 
production of TNFα or retain PD-1 expression giving no indications of exhaustion 
(Figure 5.4). When neonates are infected with a high dose of LCMV clone 13 ip 
there is complete clonal exhaustion of the LCMV-specific CD8 T cell response 
and 100% survival (Figure 5.5). Whether low doses of LCMV clone 13 infection 
result in clonal exhaustion or mortality of neonates is unknown at this time. 
Furthermore, it is also unknown if neonates given a higher dose of LCMV 
Armstrong would undergo clonal exhaustion and survive. There may be other 
factors besides initial viral dose that are playing a role. LCMV clone 13 has a 
higher affinity for the alpha-dystroglycan receptor and a point mutation in the 
RNA polymerase that result in infection of a greater number of cell types and 
faster viral replication (Matloubian et al., 1990; Salvato et al., 1991). Furthermore 
the induction of type I IFN has recently been linked with the clonal exhaustion 
found during LCMV clone 13 infection (Teijaro et al., 2013; Wilson et al., 2013). 
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Infection with high dose LCMV clone 13 induces strong IFNβ responses within 
the first 24 hours post infection, which is not found during LCMV Armstrong 
infection (Teijaro et al., 2013; Wilson et al., 2013). Neonates had poor type I IFN 
responses during the first 48 hours of LCMV Armstrong infection (Figure 5.12), 
and this may be part of the explanation for why neonates do not undergo clonal 
exhaustion and survive. It is unknown if day 7 neonates produce stronger type I 
IFN responses after high dose clone 13 infection, where they did clonally 
exhaustion.  
Tissue-dependent restrictions on viral replication promote LCMV 
Armstrong replication in neuronal cells over LCMV clone 13 (Dockter et al., 1996). 
Isolation of viral clones, from either the brain or spleen, of mice infected as day 1 
newborns with LCMV Armstrong revealed different tropisms (Ahmed et al., 1984). 
Virus isolated from the brain and used to infect adults caused an acute infection 
with a strong induction of a CD8 T cell response, while a splenic viral isolate 
caused persistent infection and clonal exhaustion (Ahmed et al., 1984). Day 1 
newborns infected with LCMV clone 13 have replication of LCMV clone 13-like 
clones in their brain (Dockter et al., 1996). However, if clone 13 was mixed with 
LCMV Armstrong prior to infection, LCMV Armstrong preferentially grows in the 
CNS, out-competing LCMV clone 13 (Dockter et al., 1996). If the differential 
tissue-specific preferences of LCMV clone 13 and Armstrong affects the T cell 
mediated death of neonates is unknown at this time. 
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Model 4: Neonatal repertoire alters immunodominance hierarchies 
and crossreactivities 
 
After infection with either LCMV or PICV, neonatal mice developed CD8 T 
cell immunodominance hierarchies that are altered from hierarchies that develop 
in adult mice infected with either of these viruses. LCMV-infected neonates have 
decreased frequencies of NP396-specific CD8 T cells, while after PICV infection 
neonates do not mount a response to the NP122 epitope. These alterations 
between adults and neonates could be from a combination of several factors 
including TCR repertoire, Tregs suppression of immune responses, or the ability 
of APC in neonates to process and present the same epitopes as adults.  
The TCR repertoire in newborn mice is limited to the VDJ segments 
encoded in the germline. Between days 4 and 5 of age the enzyme TdT is 
expressed in the thymus of mice (Bogue et al., 1991). This enzyme introduces 
non-coding-nucleotides into the junctions between the VDJ segments and 
exponentially increases the diversity of the TCR repertoire in an individual. By 
day 8 of age elongated CDR3 regions, which contain the junctions between the D 
and J segments, are found in single positive thymocytes (Bogue et al., 1991). We 
found that mice that were infected at day 7 of age had altered immunodominance 
hierarchies at day 9 post infection with either LCMV or PICV (Figure 5.4 & 7.2). 
At this age the TCR repertoire of mice is more diverse than a newborn, but is still 
significantly different compared to adults, as shown by the differences in Vβ 
repertoire (Figure 5.10). Specifically, we found that the Vβ repertoire in the 
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NP396-specific population of neonatal mice was highly variable both from the 
predictable Vβ usage of adult mice and between individual mice, with each 
individual neonatal mouse having a different Vβ repertoire in their NP396-specific 
CD8 T cell population. This variability between neonates indicates the 
development of private specificity, or unique repertoires that are actively 
developing in individual neonates. In adult mice the NP396-specific response has 
a very high affinity response to the peptide MHC complex compared to other 
responses such as GP33 (van der Most et al., 1998; Wherry et al., 2003a). Naïve 
neonates have a significant reduction in the Vβ 8.1/2-specific CD8 T cell 
population at day 7 of age. This is the dominant Vβ that appears in the NP396-
specific population in adult mice (Figure 5.10C) (Blattman et al., 2000). This 
suggests that the high affinity Vβ 8.1/2 response does not develop in mice until 
later. Adult TdT ko mice had a similar reduction in the NP396-specific response 
as neonates, further suggesting that the limited TCR repertoire of neonates may 
be playing a role in the decreased NP396-specific responses (Figure 5.11). 
However, since uninfected TdT ko adult mice actually had an increase in their 
Vβ8.1/2 usage (Figure 5.11) and still had a loss in their NP396-specific response 
after LCMV infection, it may also suggest that the Vβ usage has less of an impact 
on the hierarchy development, and it may be more mediated by the specific 
CDR3 region generating high affinity clones.  
Besides the intrinsic properties of the TCR, other factors such as antigen 
processing and presentation may be mediating the reduced NP396-specific 
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response found in LCMV-infected neonates. It has been reported that the 
NP396-specific response is dependent on cross presentation (Alatery et al., 
2010). Cross presentation is the process of antigen presentation where antigen is 
taken up by the APC through pinocytosis or phagocytosis of dying cells and 
loaded into MHC class I molecules in the endosome. One study used in vitro 
stimulation of T cell lines with L929 that were incubated with UV-treated LCMV-
infected HEK293 cells to test the cross presentation of LCMV epitopes (Alatery et 
al., 2010). HEK293 cells cannot directly present antigen to the CD8 T cell lines 
and the UV-treatment killed all replicating LCMV. Therefore, LCMV peptides 
must be picked up by the L929 cells and cross presented to the CD8 T cell lines. 
In this study NP396 was cross presented at higher levels than GP33 (Alatery et 
al., 2010). Studies have found that CD8α+ DC are the major subset of APC that 
cross present antigen to CD8 T cells in several different viral infections, including 
LCMV (Belz et al., 2005). The inability of neonatal mice to cross present NP396 
may be another possible explanation for the decreased NP396-specific response 
after LCMV infection. By day 7 of age neonatal mice have adult-like splenic 
architecture and ratio of DC: T cells (Sun et al., 2003). However, it is unknown if 
they have the same ability to cross present during viral infection as the 
inflammatory environment plays a big role in DC maturation and neonates have 
poor innate responses.  Altering the inflammatory environment by the addition of 
the TLR 2 and 3 agonists, Pam3CysSerLys4 and polyinosinic polycytidine acid 
(poly IC), to LCMV infection in adult mice also resulted in a decrease in only the 
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NP396-specific response (Siddiqui and Basta, 2011). The concurrent 
administration of both TLR agonists with LCMV decreased the ability of APC to 
cross present antigen (Siddiqui and Basta, 2011). Since cross presentation may 
play a greater role in the immunodominance of the NP396-specific response it 
was reduced compared to mice infected with LCMV alone.  
There may also be T cell-intrinsic differences between neonates and 
adults that lead to altered immunodominance hierarchies. One study found that 
RSV infection in day 7 neonates led to a similar reduction in an immunodominant 
epitope (Ruckwardt et al., 2011). In this study it did not appear to relate to TCR 
repertoire suggested by the fact that TdT ko mice did not show the same 
reduction in the immunodominant epitope. To examine if the priming environment 
of the neonate was responsible for the decreased immunodominant response, 
adult CD8 T cells were transferred into neonates and their immunodominance 
was examined after infection. Adult cells that responded to infection within the 
neonatal host could develop the normal adult hierarchy. The conclusion of this 
study was that there were additional CD8 T cell-intrinsic defects in neonatal T 
cells that caused the loss of the immunodominant epitope-specific response. 
Therefore, besides TCR repertoire and antigen presentation, there could be other 
unknown defects that contribute to the decreased NP396- and NP122-specific 
responses in neonatal mice after LCMV or PICV infection.  
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Model 4: Heterologous Immunity, crossreactivity and neonatal T cells 
 
 Mice immunized as neonates with LCMV and challenged with VV or 
immunized with PICV and challenged with LCMV showed similar traits of 
crossreactivity and heterologous immunity. In both of these models of protective 
heterologous immunity memory cells can crossreact with antigens from the 
challenging virus and mediate faster viral clearance of a heterologous virus. 
Compared to mice immunized with LCMV as adults, mice immunized as 
neonates showed altered crossreactivities when challenged with VV. In mice 
immunized as adults with LCMV and then challenged with VV the most 
commonly used crossreactive response is NP205. However, GP33/34 
crossreactivity was found in the majority of mice immunized as neonates. 
Possible reasons for this difference are the TCR repertoire of NP205-specific 
cells in neonates is less crossreactive to VV or the higher precursor frequency of 
memory GP33/34-specific cells in mice immunized as neonates gives that 
population an advantage during VV challenge. 
 The TCR repertoire, specifically the Vβ repertoire of crossreactive CD8 T 
cells is associated with disease outcome in heterologous infections (Cornberg et 
al., 2007; 2010). This was demonstrated using adoptive transfer of CD8 T cell 
lines derived from different LCMV-immune mice stimulated with the VV epitope 
A11R into naïve hosts. Most of these crossreactive CD8 T cell lines mediated 
faster viral clearance and decreased weight loss after VV challenge, but some 
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did not (Cornberg et al., 2010). Protection was associated with higher avidity to 
VV-A11R and a less diverse, more oligoclonal Vβ repertoire (Cornberg et al., 
2010). It is unknown if protective crossreactive responses between LCMV and 
VV are due to specific high affinity Vβ populations, but this is a likely possibility. 
This would then suggest that the limited TCR repertoire of the neonate may not 
allow for these high avidity crossreactive responses in the NP205-specific 
memory pool that occurs commonly in adult mice. 
 T cells from mice deficient in TdT, similar to newborn mice, have been 
reported to have increased crossreactivity or promiscuity of their TCR allowing 
them to respond to a greater number of antigens than wildtype T cells (Gavin and 
Bevan, 1995). T cell clones isolated from TdT deficient and wildtype mice specific 
to the IAV epitope NP366 were screened against a library of random peptides 
coated targets and TdT ko clones were able to recognize a greater number of 
peptides (Gavin and Bevan, 1995). The role of TdT is to insert non-template 
encoded nucleotides into the CDR3 region. As TdT expression increases in 
newborn mice the CDR3 region becomes longer (Bogue et al., 1991). However, 
increased crossreactivity did not correlate with length of the CDR3 region in this 
study (Gavin and Bevan, 1995). One possible explanation for this increased 
promiscuity of the TdT ko TCR is that it makes more interactions with the α-
helices of the MHC molecule instead of the epitope (Gavin and Bevan, 1995). 
This is supported by a study that found positive thymic selection, where T cells 
interacting with self peptide-MHC complexes are promoted to survive, was 
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increased in TdT ko mice (Gilfillan et al., 1994). This increased crossreactivity 
may allow the limited TCR repertoire in the periphery of neonates to respond to a 
wide range of pathogens. This type of crossreactivity that may be less dependent 
on TCR-epitope interactions is not found in middle-aged humans (Naumov et al., 
2008) (Anna Gil, unpublished data). In HLA-A2 individuals the IAV M1-specific 
response is found to be more crossreactive if the CDR3 region contains multiple 
glycines/alanine runs, as this would allow the TCR to be more flexible to interact 
with a greater range of epitopes. In elderly individuals, who are more reliant on 
their crossreactive memory pools, there is an increase in the CDR3 length of 
their M1-specific CD8 T cell response (Anna Gil, unpublished data). In contrast to 
the neonatal T cell response, which contains no memory T cells, the majority of 
the middle-aged and elderly human T cell pool is composed of memory cells. 
Both of these situations benefit from increased crossreactive responses to 
recognize pathogens, but with age and numerous sequential infections with 
unrelated pathogens there is a selection for the longer CDR3 regions containing 
glycine runs that may provide a more flexible, higher affinity response to common 
pathogens that we are frequently exposed to, such as IAV. 
 Mice immunized with LCMV as neonates had altered immunodominance 
hierarchies as compared with mice immunized with LCMV as adults (Figure 6.3) 
with reduced the memory precursor frequency to GP276, NP205 and GP118. In 
mice immunized as adults NP205 was the most common crossreactive response 
followed by GP34 and GP118, but in neonates GP34 was more often 
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crossreactive. The lower memory precursor frequency of NP205- and GP118-
specific cells in mice immunized as neonates may be playing a role in the altered 
crossreactivities during VV challenge. This reduction in the size of the NP205- 
and GP118-specific cell populations may be promoting the GP34 crossreactivity 
as the smaller populations may not be able to compete.  
 
Sex differences mediate altered immunopathology in Balb/c mice, but 
not B6 
 
Immunological sex differences arise due to differential hormonal regulation 
between males and females (Klein, 2012). In B6 neonatal mice infected with 
LCMV Armstrong there was no difference in mortality between males and 
females (Figure 5.13C). However, in Balb/c neonates, females had 100% 
survival after infection with 5 PFU of LCMV, while the vast majority of males 
succumb to infection (Figure 5.13B).  
Sex differences are also found in the Balb/c model for myocarditis after 
Coxsackie virus infections (Huber et al., 1982). This model recapitulates human 
sex differences found in myocarditis as it affects mostly males or pregnant 
females in the 3rd trimester or postpartum time period (Woodruff, 1980). In the 
mouse model the protective effects found in females are attributed to higher 
estrogen levels. Estrogen receptors are expressed on numerous immune cells 
including NK cells, T and B cells, macrophages and dendritic cells (Robinson and 
Klein, 2012). T cells express the estrogen receptor and the effects of estrogen 
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signaling are concentration dependent. Low to normal levels of estrogen result in 
Th1 priming of T cells, while higher doses result in Th2 skewing of the T cell 
response and humoral responses. Generally, males have lower levels of 
estrogen and produce cellular immune response, while females have higher 
levels of estrogen and better humoral immunity (Grossman et al., 1983; Styrt and 
Sugarman, 1991). In Balb/c mice infected with Coxsackie virus males had Th1 
skewed immune responses with CD4 T cells producing IFNγ and IL-2 and IgG2a 
antibody responses. Females in the same study developed CD4 T cells 
producing IL-4 and IL-5 and IgG1 antibody responses (Huber and Pfaeffle, 1994). 
These results were hormone dependent as the addition of testosterone to 
females or estrogen to males could invert the skewing of the immune response. 
Estrogen can directly alter IFNγ expression because there is an enhancer 
element in the IFNγ gene (Robinson and Klein, 2012). Low doses of estrogen 
produce IFNγ production in T cells along with increased MAP kinase signaling 
and Tbet expression (Robinson and Klein, 2012).  
 Coxsackie virus-induced myocarditis is T cell-dependent 
immunopathology (Huber and Lodge, 1984), similar to what we found in 
neonates infected with LCMV. Ablation of T cell responses decreases disease 
severity in both models. It is currently unknown if increasing the estrogen levels 
in B6 neonatal mice play a protective role and result in decreased 
immunopathology after LCMV infection or the treatment of Balb/c female 
neonates with androgens would induce increased immunopathology and death.  
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 Strain-specific differences between B6 and Balb/c mice were also playing 
a role in immunopathology induced by LCMV in neonates. In B6 neonates males 
and females both died with the same kinetics and developed the same pathology, 
but Balb/c females survived, while the males did not (Figure 5.13). The Balb/c 
strain of mice is known to be more Th2-prone due to the increased affinity of the 
IL-4 receptor alpha chain for IL-4 (Schulte et al., 1997). The characteristics of 
Balb/c females to be more Th2-skewed based upon strain differences and 
enhanced estrogen levels may be the deciding factor in the survival of female 
Balb/c mice during LCMV infection.  
 
Summary 
 Understanding how the dynamics of the T cell response are changed by 
the context of the infection and how this changes the resulting immunopathology 
is important in developing protective immunological memory. In this thesis I 
utilized several models to change the efficiency of the immune response and 
induced T cell mediated immunopathology. Co-infections are commonly acquired 
from multiple mosquito bites or combination vaccines with several live-attenuated 
viruses. This thesis shows that co-infections are drastically different than single 
virus infections in the early innate, effector and memory phase of the infection 
and understanding how different viruses impact each other is critical to vaccine 
design and treatment of co-infected patients. Several human pathogens can 
cause clonal exhaustion. Using a murine model of clonal exhaustion we showed 
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how dose, or antigen load, can change the functionality of the T cell response 
and the developing immunopathology. This study has implications for 
understanding why some patients develop severe immunopathology and others 
do not. Understanding neonatal immunity is important for vaccine design and 
treatment of early childhood infections. We showed that for some quickly 
replicating viruses, such as LCMV, the lack of early viral control can lead to 
widespread infection and severe T cell-mediated immunopathology. Maternal 
immunizations to provide passive immunity or type I IFN treatments may provide 
the support the neonatal immune system needs to control infections or enhance 
vaccination. Furthermore, the benefits of heterologous immunity were found to be 
maintained in mice immunized as neonates. Understanding how beneficial 
crossreactivity, or “non-specific immunity”, can protect against unrelated 
pathogens may be an additional mechanism used to guard neonates against 
lethal infections.   
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